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Introduction: Molecules, Machines 
and Men  
 
The research described in this thesis focused on “interactive evolutionary algorithms 
and data mining for drug design”. That may sound impressive, but what does it mean? 
The purpose of this introduction is to ensure that people who do not know much about 
interactive evolutionary algorithms and data mining will have a pretty good idea what 
those are after reading the next few pages, and that people who are already familiar 
with the field will get a more intimate acquaintance with the problems we are trying to 
solve, and the perspective that we have. Interactive evolution and data mining are 
really just formal names and procedures for activities all of us already do in daily life: 
whenever you redecorate your room, you're performing a kind of interactive evolution, 
by asking yourself whether the room would look better if you painted it blue or soft 
yellow or added a large portrait of Barack Obama. Whenever you are browsing the 
newspaper, looking for interesting articles, you are doing a form of data mining. 
Science is often just common sense formalized. This thesis will discuss interactive 
evolutionary algorithms for drug design, as well as data mining, but these are merely 
sophisticated tools to achieve our goal: to find new or better drug molecules. 
 The research I have done was a collaboration between the department of 
Medicinal Chemistry, which focuses on developing biologically active molecules, and 
the Algorithms group of computer science, which investigates the use of computer 
methods to solve real-world problems. The subject of my research was therefore how 
to use computers (machines) to design drugs (molecules), which are discussed in the 
next two sections of this introduction. However, while creating the computer programs, 
we found out that by merely focusing on software and molecular structures we were 
neglecting something crucial: the scientists themselves. Creating a computer program 
that should be used by people required us to pay attention to how people think, and 
how a computer program can be made intuitive and easy to use. We also found that it 
was extremely useful to complement the molecule-generating capabilities of the 
computer with the experience and pattern-recognition ability of people. We therefore 
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also dedicated a section to the third factor in this research, the “interactive” in 
interactive evolution. After these sections on molecules, machines and man, there will 
be an introduction to some of the terms used in this thesis. Finally, we will discuss the 
aims of this thesis and give an outline of the chapters to follow. 
 
 
Molecules, machines and man 
 
Molecules 
The human body viewed at normal scale already seems complex. However, when one 
zooms in to the microscopic level of cells and proteins, it becomes even more 
fascinating, for only on that scale the true complexity of our existence is revealed. The 
human body contains about one hundred trillion cells of over 200 distinct cell types, 
with 20,000 genes, which can produce at least as many proteins. It also contains a large 
variety of hormones, fatty acids, and other small organic compounds which help the 
cells and organs communicate and cooperate with each other in many ways, adjusting 
the activity of the body to whatever is needed in the circumstances in which we live. 
 Next to admiring the beauty and complexity of the workings of life, and satisfying 
our curiosity on how things work, there is also a very practical reason to strive to 
understand the human body: fighting disease. If we know how the human body works 
when it is healthy, and what happens when it falls ill, it should be easier to find a 
proper remedy for a disease. And in the end, it is not the understanding, but the action, 
the resulting medicine, that is important. However, even if one knows what is wrong in 
the body, the problem may still not be easy to correct. 
 Except from some cases in which the “diseased part” of the body can simply be 
removed (surgery), the most effective way to treat diseases is by administering drugs, 
which contain many billions of molecules of a specific compound. These drug 
molecules bind to biological molecules (usually proteins), either activating them or 
inhibiting them. This changes the behaviour of the protein, and thereby the behaviour 
of the cell, ultimately affecting the organ or even the whole body. For example, aspirin 
works by inhibiting cyclooxygenase, an enzyme which produces prostaglandins, 
compounds that cause pain. When someone takes aspirin, aspirin molecules diffuse 
through the gastro-intestinal wall and enter the bloodstream, where they block 
cyclooxygenase. With a reduced number of active cyclooxygenase enzymes which 
create pain-causing prostaglandins, less prostaglandins are produced, and so the pain is 
alleviated. By targeting the right step in biological processes, drugs can “reset” the 
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body to a healthier state, or at least alleviate the symptoms of a disease. 
 There are however still many diseases which cannot be treated well with current 
medicine, for example AIDS, many forms of cancer, and Alzheimer’s disease. Finding 
drugs for these and other diseases is difficult for several reasons. First of all, the 
mechanism of a disease is often not clear, so it is not always known which protein to 
target. The second problem is that even if a good target protein is found, a molecule 
must be developed which binds to it effectively. Also, these molecules must be able to 
get to the right place in the body and not be metabolized or excreted before they can 
reach the diseased area. And finally, the molecules should not interact strongly with 
other biological molecules, which would cause harmful side effects. Finding a 
molecule that both interacts effectively with the target and has favourable “ADME-tox” 
properties (absorption, distribution, metabolism, elimination, toxicity) is a very 
difficult and time-consuming process: it costs on average over 800 million dollars and 
12 years of development time to bring a drug to the market1. 
 Our goal in this project was therefore to investigate how we could help drug 
discovery become faster or better.  
 
Machines 
Finding new drugs for diseases is the 'why' of this project; let us now turn to the 'how': 
how can we improve the drug discovery process? In the past three decades, various 
methods have been developed to improve or speed up the drug design process: so-
called “rational design”, high-throughput screening, combinatorial chemistry, and, 
more recently, systems biology and bioinformatics. These methods, diverse as they are, 
have one striking common denominator: they all use computers. 
 Even while computers often only do “simple things fast”, they can increase 
efficiency in scientific research tremendously. For example, when I was a MSc student, 
if I wanted to find information on a certain compound, I needed to manually search 
multiple annual editions of the chemical abstracts service (thick books), before I could 
jot down the numbers of the abstracts, which had to be looked up in another series of 
heavy books. Of course, if the abstract suggested that the article would be useful, I still 
had to locate the attic section and/or shelf where that specific edition of the journal was 
located, and then go to the copier to make a copy for myself. The process could take 
hours. Nowadays, using internet and search machines, one can find and print articles 
about a particular compound or topic in seconds or minutes. Next to doing fast 
calculations (allowing for example fast elucidation and visualisations of protein 
structure), and controlling complicated machinery (such as in high-throughput 
screening), information storage and distribution is probably the greatest benefit of IT. 
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For example, electronic lab journals allow companies to find out about already 
performed experiments much more easily than the “classical” method of finding a 
synthesis in a stack of paper lab journals.  
 However, what could we add to the already impressive array of computational 
techniques for aiding drug discovery? In this research we have focused on the 
possibilities of two fields of computer science: evolutionary algorithms and data 
mining.  
 Evolutionary algorithms address one of the traditional problems of computers: 
computers can be programmed to do anything that involves any sequence of fixed 
actions – but sometimes it is not known which actions are necessary to achieve the 
desired result. Finding a molecule that binds to a certain protein is a problem of this 
type: the goal is known, but there is no “procedure” that will systematically and 
unambiguously lead to the desired molecule. In practice, intelligent trial and error is 
needed. Evolution works this way too. First, it produces a large number of solutions 
(animals/plants) to certain problems (environments). Then, the best of these solutions 
procreate (are copied, changed/adapted and combined) to produce even better solutions 
in the next generation. Inventions and machines change over the generations just like 
organisms, and computer programs can simulate this by changing and combining the 
best designs of a collection of designs. In our case, those designs are molecules. 
 Data mining is another powerful technique, useful in cases where the programmer 
does not yet know what the “rules” of a system are, for example which factors in one’s 
diet increase or decrease the risk of heart disease. By statistically analysing large 
amounts of data, data mining can unravel patterns in masses of data which may be 
hidden for the human eye. For example, software has been developed that correctly 
picked out the 10 known fraudsters (and about a dozen new suspects) in a database of 
the online auction site eBay – totalling one million transactions and 66000 users, far 
too much data for a human to analyze.2,3 Likewise, data mining could give insights in 
hidden patterns in databases of molecules or drugs. 
 Looking for ways to help drug design, we therefore wondered how we could use 
data mining and evolutionary algorithms to our advantage. 
 
Man 
When one develops software that will also be used by others, a third factor needs to be 
taken into account, next to problem knowledge and computer knowledge: people. In 
my research this is more important than in day-to-day science, where for many 
scientists and programmers the existence of people almost seems an afterthought. 
Scientific papers are usually written in the passive voice, ranging from the standard “10 
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ml NaOH (1M) was added to the mixture” to the slightly deceptive “it was 
hypothesized that…”, as if a hypothesis objectively and unambiguously follows from 
certain facts or experimental results. While perhaps scientists should behave 
objectively and perfectly rational, scientists are people, and people are not completely 
objective or rational, even though they may try. Therefore, if something needs to be 
used by humans, even if those humans are scientists, it is not sufficient that it is 
objectively and scientifically functional. And this is also true for software. Even a 
potentially useful computer program may not be used if people can’t find the time or 
courage to read 500-page manuals to learn how to navigate through cumbersome, 
illogical menus. It was therefore important for us to pay attention to how people think, 
and how we could adapt the software to make it easier to use. 
 On the positive side, it would be wrong to see humans merely as imperfect 
reasoning machines. Humans have evolved in nature, where there is usually lack of 
useful information combined with a huge amount of useless information that obscures 
the useful information there might be, where there are urgent problems with not 
enough time to calculate all odds and all possible ways out, and where an incredible 
amount of knowledge is required to achieve even the most modest results – even 
walking up stairs is something most programmers dread to program robots for. Humans 
are far superior to computers in detecting new patterns, making connections between 
pieces of information, and thinking “out of the box” to solve a problem. Humans can 
easily solve many problems which baffle the most advanced computers, for example, 
recognizing a face even if it is seen from the side, understanding words even if they’re 
spoken in dialect, or walking through a house without bumping against walls or 
furniture. 
 It would therefore be ideal if we could not only use the capabilities of the 
computer, but let the talents of the human/scientist complement these. However, 
combining humans and computers is not easy to do right. The first main problem is that 
to be of any kind of use, software must be user-friendly – software that cannot be 
understood by the user will not be used, even if it has tremendous capacities. Second, 
what things can or should we delegate to the computer, and what things can we ask of a 
human user? And can we close the gap so that there can be useful collaboration? 
 The third issue we had to pay attention to in this research was therefore how to 
effectively make use of human-computer collaboration. Computers can make 
calculations of molecule properties quickly, while chemists have lots of experience and 
intuition on which molecules are drug-like and which molecules can and cannot be 
synthesized. Yet any cooperation between man and computer can only occur if the 
software is sufficiently intuitive and user-friendly. The first word processor I used, 
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Symphony, required the user to remember the key combination of <ALT>-<F1>-
<B><A><B> to put anything in boldface, but such an interface would nowadays only 
discourage use. The last of the three questions is therefore how to design our chemical 




Introduction to some of the terms and concepts used in our 
research 
 
A number of computer science and cheminformatics terms will occur throughout this 
thesis, and while most of them will be explained in more formal terms in the following 
chapters, it may be useful for reader comprehension to clarify some of the most 
important concepts here. 
 
Interactive Evolutionary Algorithm 
One of the main aspects of evolution is selection, sometimes called “survival of the 
fittest”. In evolutionary algorithms we also want the best solutions to survive and 
procreate, but to do that we have to determine what we mean by “best” or “fittest”. 
Does “fittest” mean the strongest construction? The smallest molecule? The circuit 
board that gets the job done with least components? Or the circuit board that consumes 
least energy? Sometimes the fitness of a design can be calculated easily and objectively 
by a so-called “fitness function” which takes the organism/solution as input and returns 
a number that indicates its quality. Other times, though, the quality of a solution is 
difficult to calculate. For example, the ideal interior design of a room will depend on 
the taste of the human occupant.  
 Cases in which there is no objective way to calculate fitness are however not 
impossible to solve. Evolutionary algorithms can work if there exists any method to 
assign relative quality to solutions, and it is perfectly possible to have a human being as 
the “fitness function”. That means that a human scores solutions or selects the ones he 
or she considers best. An evolutionary algorithm that uses a human to evaluate 
solutions is called an interactive evolutionary algorithm or interactive evolutionary 
computation (IEC). IECs have been used in many applications, varying from face 
image generation to help an eye-witness reconstruct the face of her attacker,4 
geophysics in which experts can distinguish realistic from unrealistic earth layer 
patterns, to helping people find better settings for their hearing aid.5 Since interactive 
evolutionary algorithms can use both explicit and implicit/subconscious knowledge of 
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drug design present in human medicinal chemists, it also seemed a promising approach 
for our research. 
 
Data mining 
Governments, companies, universities and many other organizations nowadays have 
large databases which house enormous amounts of data. Such data is useful in its own 
right (for example, checking how much money your bank account contains), but these 
databases also bring the promise that one can discover patterns and laws in the data, 
much like Kepler discovered the laws of planetary motion from his astronomical data. 
However, most databases are so vast that it would be hard or impossible for a human to 
find laws and patterns. For that reason, many scientists are working on techniques 
collectively called “data mining”, which means that they develop software that can 
automatically find relationships between data or parameters. Usually data mining is 
performed on database tables, for example, whether there is a correlation between the 
education and the income of a person, and if yes, what it is and how strong it is, but it 
can be applied to any collection of data. For example, data mining also can handle a 
“shopping basket” problem in which a supermarket wants to find out whether people 
usually buy product X with product Y (such as bread and peanut butter). In this thesis, 
our main investigation of data mining is described in chapter 3, while chapter 4 and 




Docking is a term used for computer simulations of the interaction between small 
molecules and proteins. Small molecules such as drugs influence the behaviour of 
proteins by crawling into a “sensitive” place in the interior of the protein, much like a 
key enters a lock or a hand fits into a glove. Similar to the docking of ships in a 
harbour, a “docking program” will attempt to find the best fit of a small molecule into 
an enzyme or receptor. However, docking is a difficult problem, and many different 
docking programs have been developed, such as GOLD, FlexX, DOCK and Glide,6 
each having its own strengths and weaknesses. For drug design, the ideal is to predict 
how well a drug candidate would bind to a receptor, so one could select the most 
promising leads from a large library of compounds without having to perform 
expensive syntheses and biological testing. However, docking programs are yet far 
from reliable for finding such quantitative binding strengths, since the exact strengths 
of electrostatic interactions and hydrogen bonds between ligand atoms and the amino 
acids in a protein are unknown, and most docking programs cannot simulate how a 
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protein can mould itself around a ligand to improve binding. However, docking 
programs can often indicate how a molecule would fit into a protein, and despite their 
flaws they are currently the most reliable methods to theoretically compare binding 
affinities of a wide variety of small molecules. We used docking for the research in 
chapter 6, as despite its imperfections, docking is the best simulation of a `protein 
like`-system currently available. 
 
 
Aims of this thesis 
 
The aim of the research described in this thesis is to use evolutionary algorithms and 
data mining to help find new drugs. 
For this purpose, we have: 
-developed an internal representation of molecules and a set of mutations aimed to 
reach all possible molecules in chemical space. 
-created a user interface that allows chemists to give input and feedback to the 
evolutionary algorithm efficiently and easily. 
-mined large molecule databases to find frequent and infrequent substructures that can 
be used to design new molecules. 
 
We also tested out the resulting interactive evolutionary algorithm in collaboration with 
the medicinal chemists at our laboratory. A set of compounds generated by the 
evolutionary algorithm was examined by the chemists, who selected the molecules they 
deemed most interesting and adjusted them for ease of synthesis. Subsequently, these 
compounds were synthesized to assess whether the methods we developed could 
indeed be used to find new biologically active molecules. 
 
 
Outline of this thesis 
 
This thesis will open with a review on the applications of evolutionary algorithms in 
drug design (chapter 2). Chapter 3 focuses on the question on how well current 
chemistry covers total chemical space –what is the real diversity of compounds? The 
answer is perhaps somewhat sobering (the term “chemical clichés” in the title of this 
chapter was coined for a reason), however we also indicate ways to use the data 
gathered to create more novel molecule scaffolds. Chapter 4 will discuss the Molecule 
Evoluator, a computer program we developed that uses an interactive evolutionary 
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algorithm to create novel chemical compounds by using both computing power and 
chemist's intuition. In chapter 5, we show that the results of the Molecule Evoluator 
can be improved by combining the evolutionary algorithm with the technique of data 
mining, and show how the parameters of the evolutionary algorithm can be set to 
reflect the results of our data mining – which is not as straightforward as it may seem! 
Chapter 6 tackles the question whether atom- or fragment-based approaches are 
preferable for evolutionary algorithms in molecule design, by using docking to 
approximate the fitness of the compounds generated by the Molecule Evoluator. The 
part dedicated to our investigations closes with chapter 7, which looks into some real-
world results: creating novel biologically active compounds which have been 
discovered by collaboration between medicinal chemists and the Molecule Evoluator. 
Finally, chapter 8 closes this thesis with the conclusions and my perspectives on the 
future of computers in drug design. 
 
 
 "We have so much time and so little to do. Strike that, reverse it." 
 - Willy Wonka, Charlie and the Chocolate Factory (Roald Dahl) 
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Designing a drug is the process of finding or creating a molecule which has a specific 
activity on a biological organism. Drug design is difficult since there are only few 
molecules that are both effective against a certain disease and exhibit other necessary 
physiological properties, such as absorption by the body and safety of use. The main 
problem of drug design is therefore how to explore the chemical space of many 
possible molecules to find the few suitable ones. Computational methods are 
increasingly being used for this purpose, among them evolutionary algorithms. This 
review will focus on the applications of evolutionary algorithms in drug design, in 
which evolutionary algorithms are used both to create new molecules and to construct 
methods for predicting the properties of real or yet unexisting molecules. We will also 
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discuss the progress and problems of application of evolutionary algorithms in this 






Being healthy is usually taken for granted, but the importance of health becomes very 
clear when it is not present: the various illnesses can greatly diminish the quality and 
quantity of life, and are usually fought with all means available. One of the primary 
means of conserving health or improving quality of life is the administration of small 
molecules called drugs. These molecules can bind to specific critical components 
(generally proteins) of the target cells, and activating or deactivating these components 
leads to a change in behaviour of the entire cell. Cells of disease-causing organisms or 
of the patients themselves can be targeted1, leading to destruction of the cells or 
modification of their behaviour. This can help to cure or at least alleviate the disease. 
Modern medicine has access to a large variety of compounds to fight diseases ranging 
from AIDS to high blood pressure, from cancer to headache, and from bacterial 
infection to depression. 
 Drugs, together with improved nutrition and hygiene, have led to a large increase 
in life expectancy in Western society (in 1900, life expectancy in the USA at birth was 
47.3 years, which had increased to 77.0 years in 2000). However, there still exists a 
great need for new and better therapeutics. Current drugs can in most cases only slow 
cancer, not cure it. The remarkably effective treatment of HIV infection with 
combination therapy prevents the progression of AIDS, but the treatment itself is quite 
harmful to the body. And some illnesses, like Alzheimer’s disease, are still untreatable. 
 Unfortunately, developing a novel drug is not easy. The pharmaceutical industry is 
spending enormous amounts of time and effort to develop drugs that improve on 
existing ones or treat previously untreatable maladies. On average, development of a 
new drug takes 10 to 15 years and costs 400-800 million US dollars (DiMasi et al., 
2003). A large part of this money is spent on investigating compounds that eventually 
turn out to be unsuitable as drugs. Many molecules fail to become drugs because of 
“low bioavailability”, which means that they do not succeed in reaching the site of 
                                                 
1 In the case of viruses, which have no cells themselves, the viral proteins which are 
present in the infected human cells are targeted, preventing or reducing proliferation of 
the virus.  
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action due to poor solubility in water/blood (Lipinski et al., 1997), bad penetration of 
the gut wall, or being broken down by the body before they can exert their effect.  
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Additionally, the biological targets of the drug candidates may turn out not to have a 
significant influence on the disease, or the adverse effects outweigh the health benefits.  
 Due to these many independent factors that can make a drug candidate fail, it is 
hardly surprising that only one out of about 5000 screened drug candidates reaches the 
market (Rees, 2003). The drug development process (Figure 2.1) is largely an elaborate 
and expensive filter to eliminate the unsuitable compounds. 
 The largest part of time and effort of drug development is spent on trials to 
determine whether the drug candidate meets these criteria of bioavailability, efficacy 
and safety. Since it is better that a drug candidate should fail early in this process 
instead of late, the pharmaceutical industry generally strives for the “fail fast, fail cheap” 
ideal.  
 To fail fast and cheaply, it is essential to have fast, cheap methods of determining 
whether the drug candidate does or does not have suitable properties to be a drug. 
Computational methods are ideal for this goal, since they could replace expensive 
biological tests and do not even need the synthesis of the drug candidate. Additionally, 
computers are also applied to increase the input of the pipeline by suggesting 
alternative drug candidates.  
 One of the classes of methods used in the pharmaceutical industry for these 
purposes is evolutionary algorithms, which seems especially appropriate since drug 
design is largely survival of the fittest compound. This review will focus on the diverse 
evolutionary algorithms applied to the problems of drug design. We will first introduce 
the concept of evolutionary algorithms. 
 
Evolutionary algorithms 
Evolutionary Computation is the term for a subfield of Natural Computing that has 
emerged already in the 1960s from the idea to use principles of natural evolution as a 
paradigm for solving search and optimization problems in high-dimensional 
combinatorial or continuous search spaces. The algorithms within this field are 
commonly called evolutionary algorithms, the most widely known instances being 
genetic algorithms (Holland 1975, Goldberg 1989, Goldberg 2002) 2 , genetic 
programming (Koza 1992, Koza et al., 2003), evolution strategies (Rechenberg 1973, 
                                                 
2  It should be noted that many evolutionary algorithms described in this review are 
called “genetic algorithms” by their authors, even though they do not follow Holland’s 
original scheme at all. This misleading nomenclature might decrease in the future, 
however meanwhile the reader is advised when searching literature on evolutionary 
algorithms in the area of drug design to supplement his database queries regarding 
“evolutionary algorithms” with searches for “genetic algorithms.”  
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Rechenberg 1994, Schwefel 1977, Schwefel 1995), and evolutionary programming 
(Fogel et al. 1966, Fogel 1995). A detailed introduction to all these algorithms can be 
found e.g. in the Handbook of Evolutionary Computation (Bäck et al., 2000). 
 Evolutionary Computation today is a very active field involving fundamental 
research as well as a variety of applications in areas ranging from data analysis and 
machine learning to business processes, logistics and scheduling, technical engineering, 
and of course drug design, the topic of this article. Across all these fields, evolutionary 
algorithms have convinced practicians by their results on hard optimization problems, 
and thus became quite popular today. This introductory section on evolutionary 
algorithms aims at giving the reader a first impression of their fundamental working 
principles, without going into details of the variety of implementations available today. 
The interested reader is referred to the literature for in-depth information. 
 The general working principle of all instances of evolutionary algorithms is based 
on a program loop that involves implementations of the operators mutation, 
recombination, selection, and fitness evaluation on a set of candidate solutions (often 
called a population P(t) of individuals at generation t) for a given problem. This general 
evolutionary loop is shown in the following algorithm.  
 
 
Algorithm 2.1: Simplified abstract evolutionary algorithm. 
 
  t := 0; 
  initialize P(t);  
  evaluate P(t); 
  while not terminate(P(t)) do 
   P’(t)  := select_I(P(t)); 
   P’’(t) := recombine(P’(t)); 
   P’’’(t) := mutate(P’’(t)); 
   Evaluate(P’’’(t)); 
   P(t+1) := select_II(P’’’(t) ∪ P(t)); 
   t := t+1; 
  od; 






In this general setting, mutation corresponds to a modification of a single candidate 
solution, typically with a preference for small variations over large variations. 
Recombination (called “crossover” by some investigators) corresponds to an exchange 
of components between two or more candidate solutions. Selection drives the 
evolutionary process towards populations of increasing average fitness by preferring 
better candidate solutions to proliferate with higher probability to the next generation 
than worse candidate solutions (this can be done probabilistically like in genetic 
algorithms, or deterministically like in evolution strategies). Selection can be used 
either before recombination as a kind of sexual selection operator preffering better 
individuals to generate more copies before recombination occurs, or as an 
environmental selection operator after fitness evaluation to reduce population sizes by 
removing worse individuals from the population. This second selection operator can 
also take the original population P(t) into account, thus allowing the algorithm to 
always keep the best individuals in the population (which is called an elitist strategy 
assuring that fitness values do not get worse from one generation to the next). By 
evaluation, often called more specifically fitness evaluation, the calculation of a 
measure of goodness associated with candidate solutions is meant, i.e., the fitness 
function corresponds to the objective function of the optimization problem Y = 
f(x1,…,xn) → min (max) at hand (minimization and maximization are equivalent 
problems), where f: M → R maps candidate solutions defined over a search space M 
into real-valued (usually scalar) measures of goodness.  
 Evolutionary algorithms offer several advantages over conventional optimization 
methods, as they can deal with various sets of structures for the search space M, they 
are direct optimization methods which do not require additional information except the 
objective function value f(x1,…,xn) (i.e., no first or second order derivatives in 
continuous search spaces), they can deal with multimodal optimization problems (i.e., 
problems where many local optima exist where the search can get trapped into a 
suboptimal solution), and they can also deal with additional problems such as 
discontinuities of the search space, noisy objective function values or dynamically 
changing problem characteristics. 
 The candidate solutions (elements of the search space M) to an optimization 
problem can have arbitrary datastructures. However, certain kinds of candidate solution 
structures are popular, such as binary or discrete valued vectors, as often associated 
with the concept of a genetic algorithm, real-valued vectors, as often associated with 
evolution strategies or evolutionary programming, or parse trees in a functional 
language such as LISP, as often associated with genetic programming. The differences 
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between these representational instances of evolutionary algorithms have become 
blurred since 1990, however, such that state-of-the-art evolutionary algorithms often 
use concepts from several of the pure historical instances together in an implementation 
that is tailor-made for a particular application problem. Also, many mixed 
representations are used to solve challenging problems defined in more complex search 
spaces, e.g., mixed-integer nonlinear optimization problems. Expansions to new search 
spaces including graph-based representations naturally imply the potential application 
of evolutionary algorithms to drug design or molecule optimization problems. 
 
Scope and limitations of this review 
This review focuses on the stage of drug design in which the drug molecule is designed. 
Therefore applications of evolutionary algorithms that are also important but 
preliminary to this stage, such as protein folding prediction and elucidation of protein 
structure, are not discussed here. The interested reader is referred to other literature, 
such as the compilation of reviews edited by Clark (2000). 
 The articles discussed in this review were published in the period from 1993 to 
2004. Our primary criterion for selection was diversity in application and method, not 
recency. However, most of the articles (44 of 54) are from the period 1998 to 2004, 
since the application of evolutionary algorithms in drug design only started to bloom in 
the mid-nineties. 
 Due to our focus on design of drug molecules, the distribution of literature 
references is skewed towards chemical literature. The three major journals discussing 
cheminformatics and computational chemistry contributed 38 articles, journals in 
medicinal chemistry and general chemistry 13 articles, and computer science-based 
conference proceedings only 3 articles. This is however not an exhaustive compilation 
of existing literature, and the interested reader will be able to find more relevant 
articles in the (medicinal) chemical and computer science literature.  
 We hope that this review will help the reader gain insight in the problems of drug 
design and the diverse kinds of evolutionary algorithms applied so far, and enable him 
or her to read or perform additional research in this area with a wider perspective and 
more understanding. We hope that in this way the review can contribute to the further 
development of computational methods that help solve the problems of drug design, 
and enable researchers to apply the power and processing capabilities of the computer 





2. Evolutionary algorithms in the design of molecule 
libraries 
 
To find a lead compound for further drug design a set of compounds (called a library) 
can be tested for the desired biological activity. A good library should have good 
efficiency and good effectiveness: it should be so small that the cost of testing it is as 
low as possible, yet be so large that the chances of finding a suitable lead compound 
are sufficiently high.  
 Choosing the contents of the library rationally instead of randomly can enhance 
the efficiency and effectiveness: since compounds with similar structures usually have 
similar activities, a library consisting of compounds that are very dissimilar to each 
other will require fewer compounds to cover as much of the “biological activity” space. 
 Another criterion is drug-likeness: drug molecules must have certain properties to 
work (for example, have a weight of under 500 atomic mass units to be taken up by the 
body (Lipinski et al., 1997)), so such constraints can also be enforced during the design 
of the library. 
 More advanced criteria can also be applied, if more information is available: if the 
structure of either a ligand (a compound that binds to the receptor) or of the target 
receptor itself is known, one could select those compounds which look like the ligand 
or fit into the receptor, instead of the most diverse ones; this is called targeting.  
 The most popular method of creating the compounds of the molecule libraries is 
combinatorial chemistry: a number of compounds of group A, which all have a certain 
common reactive group, is combined with a number of compounds of group B, which 
have another common reactive group that can react with the reactive group of A 
(Figure 2.2). 
 In this way, N+M reactants are converted into N*M products. Higher dimensions 
of synthesis (N+M+P reagents give N*M*P products) can also be applied. Since there 
are many available reactants and multiple reaction steps can be applied, the number of 
potential compounds is much larger than the number that is practically and 
economically feasible to make and test. For this reason, selection of the reagents to be 
used or of the products to be made is very important. This has turned out to be a 
promising application for evolutionary algorithms. We will now discuss a number of 
these applications. 
 The first application we would like to discuss is the program SELECT (Gillet et 
al., 1999). SELECT has the objective to construct a general library, the compounds of 
which should both be diverse and druglike. Testing this idea on virtual amide 
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(100x100) and thiazoline-2-imide (12x99x54) libraries, the goal is to choose that 
sublibrary which has highest diversity, and whose molecules have a similar property 
distribution as known drugs (so if 15% of drug molecules have 3 rotatable bonds, 15% 
of library molecules should have 3 rotatable bonds too). The desired sizes of the 
























Figure 2.2: A simple combinatorial library. 
 
The data structures representing the candidate solutions (these data structures are 
commonly called “chromosomes” in the field of evolutionary algorithms, see also the 
glossary) were vectors with as length the number of reagents for the target library, 
consisting of the identification numbers of the reagents used. Each set of reagents was 
assigned to a separate partition of the chromosome. Single point mutation and single 
point crossover (crossover only occurred in one randomly chosen partition) were 
applied. The population size was 50.  
 The diversity of the library was determined by first calculating a chemical 
fingerprint of each molecule, a vector of bits, and summing the differences between all 




In the case of the amide library, with diversity as fitness criterion, convergence was 
reached after about 1000 iterations, with a very reproducible optimum (mean 0.595, 
standard deviation 0.001)- a clear improvement over the diversity of randomly 
constructed libraries (mean 0.508, standard deviation 0.015). However, it turned out 
that taking drug-likeness as additional criterion decreased the diversity, and that 
depending on the relative weights of the criteria, different solutions were found. This 
task of minimizing diversity while maximizing drug-likeness could be viewed as a 
multiple criteria decision making task. 
 Since manually adjusting the weights to create different solutions is inelegant and 
impractical, the authors subsequently developed an extension of SELECT, called 
MoSELECT (Gillet et al., 2002). The goal of this program is to find a set of solutions, 
each solution so that no other solution in the set is equal or superior to it in all respects 
(the solution is nondominated, or “Pareto optimal”; see Figure 2.3).  
Figure 2.3: Pareto optimality. In this example, both fitness criteria are to be 
maximized. A solution is dominated if there exists another solution that has 
equal or better scores on all criteria. for example (0.5 , 0.6) dominates (0.4 , 
0.5) because 0.5>0.4 and 0.6>0.5. However, (0.5 , 0.6) does not dominate 
(0.4 , 0.65) because 0.5>0.4 but 0.6<0.65. 
 
 
This algorithm can perform multi-objective optimization by Pareto-ranking the 
chromosomes: nondominated chromosomes get rank 0, chromosomes which are 
dominated by one other chromosome get rank 1, etcetera, after which roulette wheel 


























Information about the mechanism of this selection method can be found in the glossary. 
This Pareto-ranking approach results in many nondominating solutions found; using 2 
fitness criteria resulted in 31 nondominated solutions (in a population of 50), while 
increasing the number of criteria to 5 and the population size to 200 gave 188 
nondominated solutions. However, speciation was observed so niching (forbidding the 
algorithm to create new solutions which are similar to already found solutions) was 
applied to ensure diversity. This reduced the number of solutions to 24, but made them 
more different. (Evolutionary algorithms have also been used for finding sets of Pareto-
optimal solutions in other contexts, in which they turned out to be quite efficient, one 
advantage of the evolutionary algorithms being that they can find a set within a single 
run – see Deb (2001) for an in-depth coverage of the topic). 
 While diversity is a very desirable characteristic in a general purpose library, 
libraries can also be designed to discover a lead to a specific target. Sheridan et al. 
(2000) designed a combinatorial library of molecules built out of three fragments. 
There were 5321 fragments possible for the first part of the molecule, 1030 fragments 
for the middle of the molecule and 2851 available fragments for the third part of the 
molecule. Since synthesizing 15 billion compounds would be prohibitively expensive 
and time consuming, the authors desired to design small libraries (100-125 
compounds) of molecules that looked most promising. They wanted to create libraries 
of compounds that look like angiotensin-II antagonists (a “2D-criterion”, which only 
uses information on which atoms are connected to which other atoms) as well as 
libraries of compounds that fit in the active site of the protein stromelysin-1 (a “3D-
criterion”, which must know and manipulate the three-dimensional structure of the 
molecule).  
 Furthermore, Sheridan tested whether evolving a 5x5x5-library yielded results as 
good as evolving a library of one hundred separate molecules, addressing in this way 
the question whether the benefit of needing fewer different reagents by the 5x5x5 
library is offset by a decrease in library quality. In the experiments the 2D-criteria were 
as well achieved, on average, by the library-based as by the molecule-based runs, be it 
at much more computational cost (molecule based: <20 minutes; library based: about 
120 h). 3D-Fitness evaluation took over 120 times as long as 2D evaluation, so library-
based runs could not be performed using 3D-fitness criteria. However, the library 
created of the 5+5+5 most frequent fragments in the molecule-based optimization had a 
considerably lower score than the original library. While for “2D”-criteria the whole is 
approximately “the sum of its parts”, in the more realistic 3D fitness function this 
approximation no longer holds. The fitness landscape is probably much more rugged, 
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i.e. contains many more local optima in which a solution can become trapped. It is 
interesting to note, however, that despite this ruggedness the number of generations 
needed for convergence was approximately the same for 2D and 3D, namely 10-20 
generations. 
 A method that combines targeting and diversity is to use a known molecule as a 
template structure. Liu et al. (1998) generated two sets of compounds, the first set 
based on a benzodiazepine template (see figure 2.4) and the second on a template 
derived from the (-)-huperzine A molecule. 
 
 











Figure 2.4: Template-based (virtual) library design. 
 
A library of 73 fragments was used to fill the open positions on the template. A 
population of one hundred molecules was generated by attaching randomly chosen 
groups to the template molecule. After this, the diversity of the population was 
determined by converting the 3D-structure of the electronic field around the molecules 
into sets of vectors, and measuring the dissimilarity between the vectors of the different 
molecules. Crossover was implemented by exchanging groups of two molecules at the 
same template position, mutation by having fragments exchange template positions or 
by replacing one of the fragments. After a short run (10 generations) convergence was 
reached. No data were provided on the reproducibility of the run. 
 The (-)-huperzine A library was generated in the same way as that of the 
benzodiazepine analogs. Subsequently some of the proposed structures were 
synthesized. One of them was found to have a higher binding affinity to the target than 
the lead itself, showing that the method is effective. 
 From the foregoing it is clear that evolutionary algorithms can optimize the 
diversity and other properties of combinatorial libraries. However, related experiments 
by Bravi et al. (2000) have given some interesting insights into the structure of the 
search space. Bravi et al. investigated if one could not only determine the optimal 
library composition, but also the optimal library size. Filters were used to select the 
most druglike compounds from a virtual library of 13x41x59 (of which 16% turned out 
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to be good). To synthesize all druglike molecules using a combinatorial library would 
require a library of 12x39x49; using this in combinatorial chemistry would however 
generate about 23000 compounds, of which 78% would be non-druglike. How to find a 
balance between efficiency (how large a part of the combinatorial library consists of 
desirable structures) and effectiveness (how large a part of all good structures are 
contained by the sublibrary)? Bravi’s program PLUMS used an algorithm that evenly 
weighed these two factors and designed a library that still contained 86% of all good 
molecules, with only 37% undesirable products. 
 The method Bravi used was based on iterative removal of the component whose 
removal produced a library with an optimum score. His results were as good as those 
of the GA to which he compared it, as long as PLUMS followed alternative parallel 
paths if there was no preference for removal. This suggests that the fitness landscape is 
not very rugged for this problem, and that an iterative method might replace a GA in 
such cases. However, a simpler method (monomer frequency analysis (MFA), which 
assumes that the best library is built from the fragments that are most frequent in the 
good compounds) failed to find this optimum. Analysis of the results showed that how 
often a fragment occurs in a good library is less important than how often it occurs 
with other good fragments. However, a subsequently designed dynamic version of 
MFA that iteratively chooses the best compounds of each set of reactants until 
convergence is reached, did find the global optimum. 
 Does this mean that evolutionary algorithms are not needed in library design? This 
is not very likely, since using more advanced 3D-fitness functions seems to make the 
fitness landscape more rugged. A simple method like PLUMS will get stuck in a local 
optimum more easily, especially if the building blocks of the library must be selected 
among thousands instead of dozens of reactants. However, iterative methods like 




Several experiments have been performed using evolutionary algorithms in library 
design, to create libraries to satisfy many different objectives such as diversity, 
targeting and drug-likeness. While improvement of the libraries with respect to the 
fitness criteria is clearly seen in these experiments, and reproducibility seems fair 
enough, the major current challenges lie in refining the fitness criteria to accurately 




The diversity in the diversity criteria themselves suggests that more systematic 
attention to this problem might be worthwhile, and the great computational cost of 
more advanced (docking) criteria of target selection are still troublesome in more 
refined applications. Also the drug-likeness criterion might need revision. 
 Libraries are designed to find lead molecules, which usually grow in size during 
drug development to satisfy additional criteria. In many cases this may generate 
molecules that are too large to be drug-like. Screening the “drug-like” larger molecules 
for biological activity has a lower chance of success than screening smaller molecules, 
since large molecules have a smaller probability to fit in the space of the active site 
than small molecules (Hann et al., 2001). Therefore, it would be more valuable to 
evolve libraries with the criterion of lead-likeness. However, libraries of leads are 
currently not available, while libraries of drugs are. Unless calculations correct for the 
too high molecular weight and lipophilicity of drug-like compounds, “drug like” 
library design will probably produce suboptimal compounds.  
 A second development is the use of several conflicting criteria simultaneously in 
library design, of which the Pareto optimality by Gillet et al. (2002) and the prefiltering 
by Bravi et al. (2000) are examples. While certainly interesting, the problem of 
choosing the right weights by the user is now shifted to selecting the right nondominant 
set. Weighing must be done sooner or later. It is a good beginning, but further 
measures (probably based on existing knowledge of drug development and probability 
theory) are needed to find a better way of weighing the weights. 
 An application which has not been discussed in these articles is selecting 
compounds from a non-combinatorial library. This will become more important as 
proprietary compound collections of pharmaceutical companies grow and more 
compounds are made available by external suppliers. The disadvantages of 
combinatorial chemistry (generally too large and lipophilic molecules, failing reactions, 
etc.) could prompt using evolutionary algorithms to select a targeted or diverse test set 
out of tens of thousands of compounds that are available. This will be an interesting 
and important challenge. 
 Computationally, the different evolutionary algorithms can doubtlessly be 
improved by incorporating more domain knowledge. However, since the computational 
cost of most applications discussed is acceptable and performance is good, the 
relatively simple current algorithms may be preferred over more advanced versions. 
Comparisons with deterministic methods (Bravi et al., 2000) indicate that evolutionary 
algorithms can be applied quite well to the problem of library design. Although 
competing methods can also satisfy the designer’s needs (Agrafiotis, 2002), 
25 
 
evolutionary algorithms, perhaps with some small modifications, are very likely to 
become the standard method in library design. 
 
 
3. Evolutionary algorithms in conformational analysis 
 
A molecule is a three-dimensional entity consisting of atoms connected by bonds. 
Though the movement of the individual atoms is restricted by the bonds, most 
molecules can assume different shapes by bond stretching, by angle bending and, most 
importantly, by rotating parts of the molecule around single bonds (see Figure 2.5). 
The amount by which a bond is rotated (varying between 0 and 360 degrees) is called 
its torsion angle. 
  
 
Figure 2.5: Change in conformation by rotation around a bond. 
 
Conformational analysis, the generation and comparison of different conformations of 
a molecule, is an important part of medicinal chemistry. This is because the properties 
of a molecule are partially determined by the shape or range of shapes it can assume. 
Conformational analysis usually has two goals. The first and most common goal is to 
find the conformation of minimal energy, the “global minimum”. The energies of all 
other conformations (which correspond to their chance of occurring in nature) should 
be taken relative to the energy of this global minimum. This is especially important 
when a molecule is docked as a ligand into the active site of a receptor (see section 6). 
The increase in energy of the docked molecule relative to its minimum gives 
information on the true binding energy and therefore the likeliness that the docking is 
correct. The second goal of conformational analysis is to obtain a group of diverse yet 
energetically feasible conformations for virtual screening to address the issue whether 
the molecule or one of its good conformations fits a certain required pattern, a so-called 
pharmacophore. 
 Since bonds can be rotated over the entire range of 360 degrees the number of 
conformations of the molecule is in theory infinite. However, many conformations are 
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so similar that conformational analysis usually takes a minimal step size of 15-30 
degrees. Unfortunately, allowing n different torsion angles for m rotatable bonds each 
will give nm possible conformations; for a flexible drug molecule like orphenadrine 
(which has six rotatable bonds), conformational analysis with a resolution of 15 
degrees would produce 1.9 x 108 conformations. Systematic search is infeasible in 
these cases, and heuristic algorithms, among which evolutionary algorithms, are 
applied. 
 An excellent example of a genetic algorithm applied to finding the conformation 
of minimal energy is the work of Nair and Goodman (1998). Nair and Goodman 
applied the genetic algorithm to linear molecules of carbon atoms (alkanes), and took 
the torsion angles as genes. After random generation of the population, crossover was 
performed followed by mutation. Subsequently the new structures were minimized 
with a local optimizer and their optimized conformations written back into their genes 
(so-called Lamarckian evolution), and the new generation was chosen from the pool of 
parents+children by roulette wheel selection on their energies, which were weighted 
with a Bolzmann factor that determined the penalty for higher energy. This process was 
repeated for a fixed number of generations. 
 The genetic algorithm found several minima for the chains of 6, 18 and 39 carbon 
atoms. The next, most interesting challenge was finding the optimal energy of PM-
toxin A, a long, approximately linear molecule (33 carbon atoms). This was tackled by 
first optimizing a 33-atom alkane, listing the several thousands of low-energy 
conformations found. Subsequently the branching groups were added and the resulting 
structures locally optimized. A minimum of less than -100 kJ/mol was found. A Monte 
Carlo search, using the same amount of structure optimizations, found a minimum of 
only –78 kJ/mol. Furthermore, the GA found 168 conformations with an energy below 
–70 kJ/mol, the Monte Carlo approach only two. 
 It is interesting to note that the more complex and flexible the molecule becomes, 
the more minima of approximately equal energy can be found. Since the energy of the 
global optimum is much more important than the conformation of the global optimum 
and dozens of conformations give the approximately good result, knowing the “best” 
answer is relatively unimportant. This makes stochastic algorithms like evolutionary 
algorithms even more useful in this situation. 
 Jin et al. (1999) analysed the pentapeptide [Met]-enkephalin, which has 24 torsion 
angles. Three different versions of their program GAP were used: GAP 1.0, GAP 2.0 
and GAP 3.0. In GAP 1.0 a uniform crossover was used together with a diversity 
operator that mutated a child structure if more than half of its angles differed by less 
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than 5 degrees from its parent structures. GAP 2.0 included a three-parent crossover 
(two parents are crossed, their product is crossed with the third parent), and GAP 3.0 
has a “population splitting scheme”, which only allows crossover of individuals in 
different populations. The offspring was generated by crossover and subsequent 
mutation. After these steps, parents and offspring were taken together, the lowest half 
(50 conformations) was selected as the next generation, and after 1000 generations the 
runs were stopped. In this case, the minimum found was about 3 kcal/mol higher than 
the one found by a Monte Carlo method. 
 Since other experiences with GA/MC comparisons like those of Nair and 
Goodman (1998) and Tufféry et al. (1993) found the genetic algorithm to be superior 
to Monte Carlo, especially when optimizing large systems like proteins, the authors 
analysed their algorithm. By measuring the search space coverage it was found that, 
surprisingly, higher mutation rates led to lower coverage. This suggests that most 
mutations are so harmful that they are rapidly selected out by the strict fitness criterion 
(best half), and the next generation consists mainly of unmodified “parent” 
conformations, which tends to prevent departure from local minima and restricts the 
search space covered. 
 For certain purposes, not a single low-energy conformation is needed, but a set of 
low-energy conformations that differ as much from each other as possible. These 
conformations can be used for e.g. pharmacophore screening or as starting 
conformations for docking. Mekenyan et al. (1999) designed a GA for optimizing the 
diversity in a population of conformations. The fitness criterion was a diversity 
criterion that measured how bad the best possible superposition of two conformations 
was (in root mean square distance between corresponding atoms). The score of the 
individual was the average dissimilarity to the other members in the population.  
 Next to the traditional torsion angles Mekenyan included the flexibility of rings by 
allowing free ring corners (atoms that were part of only one ring) to flip, and storing 
the flipped/unflipped information in the chromosome too. This may be very valuable 
for complex molecules that often contain flexible rings.  
 Mutation was performed and followed by crossover. If the children were 
energetically inadmissible or too similar to already present conformations, they were 
discarded. If Nc viable children were found within a certain number of tries, the most 
diverse subset of size Np was selected from the total pool of Nc+Np conformations. The 
evolution was stopped if fewer than Nc viable children had been produced within the 




Mekenyan experimented with different settings of the population size and the number 
of children. The runs did not seem very reproducible and in most cases were stuck in 
local optima. The general conclusion was that the ratio between the number of parents 
and the number of children Np/Nc is very important. If Np/Nc is lower, convergence is 
reached faster and more of the search space is covered, but if it is higher, runs are more 
reproducible. 
 Thinking more theoretically about the quality of evolutionary algorithms, Wehrens 
et al. (1998) considered that only taking the value of the best individual to judge an 
evolutionary algorithm is somewhat limited, and proposed additional criteria: 
reproducibility and coverage of the search space. The authors describe the application 
and implementation of these criteria in the case of the conformational analysis of N,N-
dimethyl-N’-4-phenylbutylmalonamide. 
 This compound has 7 rotatable bonds, the torsion angles of which form the genes 
of the chromosome. A population of size 50 was used for a run of 100 generations. 
Tournament selection was performed with tournament sizes varying from 2 to 10. 
Crossover rate was 0.8 with uniform crossover applied. In the experiments, several 
parameters were varied, mainly to investigate the influence of the “sharing” operator. If 
the root mean square difference between the torsion angles of the child and parent 
conformations is less than the sharing distance, a randomly selected torsion angle of 
the child will get a random twist between 0 and a fixed number of degrees called the 
“sharing offset”.  
 Coverage was measured by dividing the search space into hypercubes (hypercube 
size of 90 degrees, so there are 47 hypercubes which can be visited in the search space). 
About 10% of the search space was visited using a GA without sharing, 30% with 
sharing, 77% by random search. So while sharing increases coverage, selection 
pressure decreases it. A tournament size 10 instead of 2 further decreased the coverage, 
be it slightly. 
 The second criterion of coverage was how many clusters of low energy were 
found using different parameter settings. In this case this was 6 to 14 clusters for the 
genetic algorithm, 0 for random search.  
 Another criterion, reproducibility, was measured in two ways: the first way was to 
count the number of clusters in common between two runs, the second was projecting 
all conformations into the 7 dimensional “torsional” space and determine the principal 
components. The ratio of the overlap of the principal components of the different runs 




As the authors note, their criteria may also be used for other applications of genetic 
algorithms. Though some of their ideas seem useful, they have, considering the 
subsequent literature, not yet been widely applied by other researchers. 
 
Conclusions 
Evolutionary algorithms have been applied to conformational analysis with some good 
results. While there are some experiments that indicate that the method of “directed 
tweak” is slightly superior in conformational searches (Clark et al., 1994) evolutionary 
algorithms are more versatile: they can search for sets that are diverse, as well as 
pursue multiple objectives. Next to seeking the most suitable mutations and crossover 
methods and optimizing the parameters, there are some other interesting points that 
could justify further research. The first question is how one could incorporate 
molecular mechanics such as the deformations of rings in the evolutionary algorithm. 
Secondly, almost all energies are now calculated for molecules in a vacuum, yet the 
relevant energies for biological molecules are those in solution. One should carefully 
compare the vacuum results with those calculated using modern force fields that 
include water to check whether and when this approximation is allowed. A third item, 
which is growing in importance, is the application of conformational analysis to larger 
molecules, especially proteins. 
 As our understanding of biology increases, molecular movement and 
conformations will be able to shed light on the dynamic properties of chemical and 
biological systems. Conformation analysis will be important to determine the “4D”-
descriptors, which describe the possible changes of the molecule over space and time. 
Evolutionary algorithms, with their flexibility and possibilities to optimize systems in 
which the elements depend on each other, as is the case in conformations, will 




4. Evolutionary algorithms in molecule superposition and 
pharmacophore detection 
 
If two molecules bind to the same receptor, can one deduce from this information 
which other molecules will bind? The traditional way of solving this problem is by 
comparing the structures of the active molecules: one superimposes the molecules onto 
each other to detect the similarities. If they have the same kinds of atoms in the same 
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relative positions, those may be important. Out of this superposition, features which 
might be important for activity are postulated, and their relative 3D-orientation 



















Figure 2.6: Molecule superposition and pharmacophore detection. “Ar” 
stands for aromatic center, 1 Å is 0.1 nm. 
 
This entire process of superposition and assignment of pharmacophoric points is called 
pharmacophore detection (see figure 2.6). 
There are two fundamental difficulties in molecule superposition and 
pharmacophore detection. The first is the definition of a good superposition. There are 
at least three possible criteria: 
1) In a good superposition both molecules have low energies; their conformations 
have energies at or close to the global minimum. 
2) In a good superposition the volumes of the molecules overlap optimally, which 
means that they fit in the receptor in about the same space of the active site. 
3) In a good superposition, the most important atoms/parts should overlap best, the 
other parts of the molecule are relatively unimportant. 
In fact, all these factors seem to play a role. Ultimately the criteria a molecule has to 
fulfill to be active are determined by the three-dimensional structure of the receptor, 
but unfortunately that structure is generally not known. Nevertheless, a method that 
finds high similarity of whatever kind between various active molecules and does not 
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match inactive molecules would certainly be promising. 
 The second problem in molecule superposition is the combinatorial explosion: 
most molecules can assume thousands of conformations, so searching for the best 
overlap of two molecules or more by a systematic search method quickly becomes 
infeasible. It is no surprise that evolutionary algorithms have been applied in order to 
help to solve this problem.  
 An early example of a genetic algorithm to superpose molecules and detect 
pharmacophores is given by Payne and Glen (1993). The chromosomes representing 
the molecules are bit strings, the first elements give the 3D-coordinates for the location 
and the orientation of the molecule leading to 6 degrees of freedom. They are followed 
by genes for each bond that can be rotated and for each ring corner that can be flipped. 
 In some cases the fitness criterion was how well a molecule obeyed certain 
distance constraints, i.e. selected groups in the molecule or of different molecules 
should be at a certain distance from each other. Overlap constraints, i.e. overlapping 
another molecule as much as possible, and spherical constraints were also used. The 
latter constraint is defined by a sphere drawn around the molecule, the surface points of 
which have values representing the distance from the sphere surface point to the 
molecule’s surface point directly beneath it or the charge on that surface point. The 
total fitness was a weighed sum of the several fitness functions that were appropriate 
for the situation. Chromosomes were represented as bit strings, the mutation was bit-
flip mutation and one-point crossover was used. 
 Several problems were tackled with this algorithm: finding the conformation of a 
molecule which obeyed certain distance restraints, elucidating a pharmacophore, fitting 
a molecule onto itself, and fitting different molecules of a similar biological activity 
onto each other.  
 It turned out that some of the problems were relatively easy to solve using the 
genetic algorithm. If there is a fixed set of constraints or a rigid template molecule like 
morphine the evolution reaches convergence (in runs of 300 generations of 1000 
molecules). If however flexible molecules have to be fitted onto each other, the 
“moving target” makes convergence very awkward. However, when an intermediate 
step was added in which the conformers were rigidly fitted onto each other the time 
spent by the genetic algorithm was reduced from 10 days to 9 minutes! 
 All in all, the program described seemed to do its job fairly well, though greater 
degrees of freedom clearly gave it so much trouble that optimization became difficult. 
A last problem is that when some regions of a molecule are important to receptor 
binding and others are not, a sphere model might not be a very suitable means for 
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finding the part of the molecules that are similar. This is due to the fact that the 
differences in the other parts may drown out the similarities unless one has large data 
sets. Moreover, superpositions of the many molecules of those large data sets 
themselves might lead to poor convergence. 
 Superposition of molecules has often the goal of finding a pharmacophore. 
Holliday and Willett (1997) wanted to use a genetic algorithm to find a group of 
pharmacophore points (in their case: N and O atoms) in a 3D-arrangement present in 
all molecules with a certain biological activity. 
 Their original genetic algorithm proved to be too slow, but the authors found that 
performance could be improved by splitting it into two smaller genetic algorithms: one 
to find sets of corresponding atoms in the different molecules, a second to combine 
these sets into the smallest possible superset. 
 The first genetic algorithm uses chromosomes of length n×m, where n is the 
number of molecules and m a user-defined number of atoms that has to be found per 
molecule. Crossover is performed on the border between molecules, mutation replaces 
an atom by another atom of the same molecule. If the atoms in the chromosome of two 
different molecules have the same types and approximately the same distances to each 
other, the second set of atoms is “fused” with the first. The evolutionary process thus 
results in a chromosome grouped in a few different clusters of molecules, the 
molecules of each cluster containing identical atoms in a common geometric pattern. 
 The second genetic algorithm uses the collection of patterns found by the first 
algorithm and attempts to find a superset which contains all of them. The chromosome 
here is a list of the 3D coordinates of the several points. The second algorithm can add, 
move or remove points in this 3D-arrangement and continues until every molecule in 
the set has at least m points (the value of m specified by the user) in common with the 
superset, within a certain tolerance range. The second genetic algorithm uses clique-
finding algorithms to speed up this process. 
 The program was tested on five data sets of 10-19 biologically active compounds. 
In most cases, 3 or 4 point subsets common to all compounds were found, thus 
indicating the effectiveness of the method. 
 However, the authors add that their program should be developed further. Next to 
the nitrogen and oxygen atoms there may be other important elements in a 
pharmacophore such as a phenyl group (see also Figure 2.6). Additionally, most 
ligands are flexible and their active conformation is not known; therefore the genetic 
algorithm should either work on a good superposition (in which case it would not give 
much useful extra information) or take the flexibility of the molecules into account. 
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This issue of flexibility was addressed by Handschuh et al. (1998) who used a genetic 
algorithm to superpose flexible molecules. This superposition was again based on atom 
superposition, but in this method the superposed atoms did not have to be of the same 
type.  
 The authors recognized that a good superposition of molecules should satisfy 
conflicting demands. Although as many atoms as possible of the two molecules should 
be matched, matching too many atoms will result in a worse fit. For this reason Pareto 
optimization was used to obtain alternative solutions. 
 The computer program fitted only two structures simultaneously; each individual 
consisted of a chromosome containing the information of both molecules. The 
chromosome consisted of two parts, which contained the “match pairs” (which atoms 
of structure one were fitted onto atoms of structure two) and the torsion angles of the 
molecules, respectively.  
 A population of 100 molecule-pairs was created and subsequently evolved. 
Mutation and crossover in the torsional part was straightforward and mutation in the 
match part replaced or deleted atom matches. Crossover in the match part was 
implemented by choosing two match lists of equal length in the parents and appending 
them to the end of the other parent’s match list, removing duplicate atom matches in 
the original parent. Interesting was the inclusion of two “knowledge augmented” 
operators, “creep” and “crunch”, which added atom pairs to or removed them from the 
match list based on their distance in the current superposition. These operators 
improved the final results substantially, since much closer fits of 0.05-0.2Å were 
obtained instead of root mean square scores of 0.6-1.0Å. 
 Another innovation somewhat similar to the speedup described by Payne and Glen 
(1993) was the use of the directed tweak method to adapt the torsion angles of the 
match after each individual was generated. This was however not Lamarckian since the 
genes were not changed and the matching procedure was only used to determine the 
fitness value. Instead restricted tournament selection was used. Here one solution 
competed against the solution most similar to itself from a random subset of the 
population. The winner was copied into the next population. This selection method was 
chosen in order to conserve diversity. 
 Handschuh et al. applied the genetic algorithm to overlaying several angiotensin II 
antagonists, with good results in that overlays of 10-20 atoms were reached with low 
root mean square values (<1Å). Additionally, a known angiotensin II pharmacophore 
was found. These results indicate that the method is quite promising. However, some 
problems of pharmacophore finding remain difficult to solve, even with a method as 
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advanced as this one. A true choice about whether molecules A and B overlap best in 
overlap 1 or 2 can only be made if it can be determined whether the identity of the 
atoms really matters (Figure 2.7). In some cases it will, in others it won’t, such that 




A B 1 2
or ?









There are several different kinds of molecule superposition. Superposing the shape and 
charge fields of two dissimilar molecules, superposing the most important atoms, or 
superposing all atoms are all options, but which one is “correct” or “better”? Probably 
much depends on the protein and the set of ligands. The existence of different criteria 
seems to indicate that superposing molecules is a multi-objective problem, with the 
different weights reflecting the one true objective of how well the superposed 
molecules occupy the “superposed” space when binding to the receptor. Comparison 
with experimental data such as crystal structures would greatly help to test, validate 
and optimize the different methods. Pending that, extra calculations of for example the 
energy of the ligands may help to make a choice between different superpositions. 
 Also, it would be worthwhile to extend the pharmacophore models with known 
inactive compounds that are similar in structure to the active molecules and study if 
these fit or not. This may yield information on criteria for internal energy of the 
superimposed conformation or information about the “excluded volume”, the parts of 
the molecule that the receptor cannot accommodate. 
 Thirdly, there is the problem of superposing larger sets of compounds. The extra 
information gained by including more compounds is probably useful, but an optimal 
multiple superposition is much more difficult to find. Overlaying two molecules is 
quite standard, but what to do if there are more? While Handschuh et al. (1998) found 
that the order of superposition of their four compounds did not influence the results, it 
seems likely that a naive evolutionary algorithm would fail if it would attempt to 
35 
 
overlay more than ten structures simultaneously. Sequential overlap of many 
compounds will probably yield local minima, especially since there may be different 
“best” superpositions according to the Pareto optimality criteria. Handling large 
datasets, especially truly large data sets on which one can apply statistics, seems to 
become possible (Chen et al., 1999). It is still unclear yet whether this will be the final 
answer due to the necessarily limited number of conformations and pharmacophoric 
points used by such methods.  
 Lastly, in several cases there may be more than one active site on the receptor, or 
the binding site is so large that not all molecules will necessarily share the same 
volume. Discovering that there are several different pharmacophores in this case will 
be a challenging test for any superposition method.  
 All in all, evolutionary algorithms have led to valuable software for molecule 
superposition and pharmacophore detection. Still the field of molecule superposition 
does not have the answers yet for handling more than two molecules and choosing 
between different superpositions. While there are also non-evolutionary methods for 
pharmacophore detection (Chen et al., 1999; Ting et al., 2000), it is very likely that 
evolutionary algorithms will continue to be applied. 
 
 
5. Evolutionary algorithms and quantitative structure-
activity relationships 
 
In drug design and development one of the prime views is that the biological activity of 
a given compound is determined by its physico-chemical characteristics. Already in the 
19th century it was postulated by Crum Brown and Fraser (cited in Parascondola, 1980) 
that “there can be no reasonable doubt that a relation exists between the physiological 
action of a substance and its chemical composition and constitution”. In more recent 
days Hansch and coworkers (Parascondola, 1980) were the first to suggest that such a 




This is called a quantitative structure-activity relationship, or QSAR. In the above 
formula the biological activity is a numerical value such as the logarithm of the 
concentration at which a compound exhibits half of its maximal biological activity. The 
descriptors are numerical values of the properties of either the entire molecule (like the 
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molecular weight) or of a specific part of the molecule. In the latter case, the equation 
needs to be derived from a set of highly similar compounds.  
 
The major use of a QSAR formula is the prediction of the biological activity of a 
compound that has not yet been tested or has even not been synthesized yet. This can 
be done with models consisting of descriptors that can be calculated theoretically. In 
essence, the structure of the molecule, which is a graph, is converted into a vector of 
numbers, which can hopefully be related to the biological activity by a (simple) 
function. In theory QSAR can thus greatly increase the speed and reduce the cost of 
drug design by eliminating the synthesis and testing of compounds with low activity.  
 However, the major problem regarding QSAR is that scientists can now choose 
among many hundreds of descriptors, such as experiment-based descriptors, graph-
theoretical descriptors, quantum mechanical descriptors and others. Additionally, 
researchers are more and more realizing that QSAR does not have to be a weighted 
sum of simple descriptors. Cross-products and polynomials (Lučić et al., 2003), splines 
(Rogers and Hopfinger, 1994) and even more exotic functions can be used to forge new 
descriptors out of the old ones, enlarging the set of available descriptors even more. 
Since a specific biological activity is commonly only measured in dozens of 
compounds, the hundreds to thousands of descriptors available will lead to overfitting 
if fitting procedures are used without proper caution. Since there are no ‘golden rules’ 
to govern the choice, selection of the ‘right’ descriptors is probably the most 
problematic step in the whole process. 
 Currently, matrix techniques such as principal component analysis (PCA) 
(Hemmateenejad et al., 2003) and partial least squares (PLS) (Geladi and Kowalski, 
1986) are applied to reduce the number of descriptors used. However, the resulting 
convoluted descriptors are often difficult to interpret, and the design of more active 
compounds is cumbersome for a medicinal chemist if the QSAR formula cannot be 
easily understood. 
 The more straightforward descriptors can lead to a model that is more easily 
interpreted, and are therefore still used by many researchers. The traditional way to 
choose the best descriptors for the model from the wide variety available is called 
forward stepping. This is a local search process, in which first one-descriptor models 
are built, of which the best is chosen. Subsequently, one by one those descriptors are 
added that improve the quality of the model most. Since it is possible however that 
there are descriptors that are separately not very informative but extremely valuable 
when combined, global optimization techniques are increasingly being used, among 
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which evolutionary algorithms.  
 A typical example of an evolutionary algorithm to select the descriptors in QSAR 
analysis is the work of Kimura et al. (1998). In their research, CoMFA (comparative 
molecular field analysis, a technique that compares molecules by looking at their 
shapes and the electrostatic fields created by the charges of the atoms) was applied to a 
set of 20 polychlorinated benzofurans. The molecules were superposed and a grid of 
17x15x5 was laid over the superposition. For each molecule the strength of the electric 
and steric field at each grid point was calculated and used as a descriptor. This resulted 
in 2550 descriptors, which, using conventional CoMFA with partial least squares, gave 
a r2 value of 0.96 and a leave-one-out cross-validated q2 value of 0.89.  
 Subsequently, the authors applied their genetic algorithm, GARGS (GA-based 
region selection). First a coarse grid was defined (8x6x5) that divided the molecules 
into larger regions. The chromosomes were bit-strings, each bit encoding the 
inclusion/exclusion of a specific region in the model; a population of 240-bit 
individuals was created. The fitness of each chromosome was calculated by the q2 
value and the best 90% of the population was selected as basis for the next generation. 
Uniform crossover on 10 pairs of chromosomes and bit-flip mutation on all 
chromosomes was applied. Elitism conserved the chromosomes which had the highest 
q
2 values among the chromosomes which had as many or fewer parameters (Pareto 
optimality, see section 2).  
 The genetic algorithm resulted in a model with only 8 regions (43 parameters) 
which by partial least squares analysis gave a model with r2=0.97 and q2=0.95. Thus 
descriptor selection not only reduced overfitting but also slightly improved the fit of 
the training set, possibly by removing clutter which prevented the partial least squares 
analysis from finding the optimum. External validation on a prediction set showed 
indeed improvement over conventional CoMFA, the root mean square error decreasing 
from 2.63 to 0.99. GARGS was later used by the same authors in a 3D-QSAR study of 
acetylcholinesterase inhibitors (Hasegawa et al., 1999). 
 An addition to conventional parameter selection was presented by Cho and 
Hermsmeyer (2002). Their algorithm GAS (genetic algorithm guided selection) could 
be used for two purposes. Next to the binary vector indicating use/non-use of 
descriptors, each individual also contained a vector of numbers which divided the 
compounds into several classes. The size of each chromosome was thus equal to the 
sum of the number of descriptors and the number of compounds. However, only one 
part of the chromosome was optimized per run, so compound classification was 
separate from descriptor selection. The fitness decreased with increasing size of the 
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errors in the prediction and increasing number of variables, to prevent overfitting. 
Roulette wheel selection was used to select the parents for one-point crossover or 
mutation. In the case of crossover, the offspring replaced the worst parent if it was 
better. 
 The data set of Selwood and coworkers (1990) was used as a test for descriptor 
selection. The set consists of 31 compounds with their biological activity against 
disease-causing nematodes, measured in vitro. GAS selected the same descriptors in its 
best models as other researchers including Selwood et al. (1990) and Rogers and 
Hopfinger (1994). Subset selection was tested on the XLOGP data set, which contained 
1831 compounds. Here each molecule of the test set was assigned to the set which 
contained the molecule most similar to it, where similarity was measured as the 
Euclidian distance between the descriptor vectors of different molecules. Subset 
selection apparently worked, increasing the r2 for the test set from 0.80 to 0.84. 
Remarkable is that in the XLOGP experiments the r2 of the training set was 
systematically lower than that of the external validation set (such as 0.76 vs. 0.80). 
Perhaps this has something to do with the relatively small size or higher homogeneity 
of the external validation set relative to the training set (19 drugs vs 1831 more general 
organic compounds). 
 In conclusion, the authors demonstrated that their genetic algorithm did work for 
both variable and subset selection, though subset selection may be less applicable for 
the smaller data sets that characterize QSAR.  
 Descriptors often do not correlate linearly to the biological activity. Therefore, 
Rogers and Hopfinger (1994) developed an evolutionary algorithm called GFA 
(genetic function approximation). Its main feature is that it creates individuals that are 
lists of descriptors on which diverse functions are applied, like splines, squaring, or 
squared splines. As an example the descriptor HOMO was used to design the novel 
descriptor <-9.545-HOMO>2, which was combined linearly with the other (derived) 
descriptors. A typical individual thus may look like {C4,<2.301-Ut>,(Ut-2.966)
2,<-
9.631-HOMO>2}. One-point crossover is applied, mutations either add a descriptor or 
change the number in the spline function. If a duplicate of the new model does not 
already exist in the population, it replaces the worst individual. The run is completed if 
the score of the models stops improving. 
 The Selwood data set was mined with only basic descriptors (no splines or 
polynomials). GFA indeed found a better descriptor combination than Selwood had 
found (r2=0.72 vs 0.55). In an acetylcholinesterase inhibitor data set of 17 compounds 
and 3 descriptors, linear as well as spline, quadratic and spline quadratic terms were 
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used. The best resulting models had r2-values of 0.85. The population of GFA provides 
the user with multiple models, which are often very similar in quality although they 
contain different descriptors. This allows users to choose the model they intuitively 
regard as the best. This is a very interesting point in QSAR analysis, yet choosing the 
‘right model’ is even more poorly defined than choosing ‘the best descriptors.’ The 
GFA method has been implemented in commercially available software, such as 
Cerius2, and has led to a number of publications by users of that software. Shi and 
coworkers (1998) selected 112 ellipticine analogues from the compound database 
maintained by the National Cancer Institute (NCI). They were able to derive 
meaningful QSAR models with the GFA method after the users had subdivided the 
ellipticine data set manually into structurally homogeneous classes. GFA using splines 
yielded cross-validated r2 values that were consistently about 0.3 units higher than 
those derived by stepwise linear regression.  
 Lučić et al. (2003) used GFA and other approaches for descriptor selection on 4 
different data sets and were somewhat less impressed by the method. This may have to 
do with the fact that they did not allow GFA to use splines, and that they did not use 
stepwise selection but another genetic algorithm to select the descriptors for the 
multiple linear regression, to which they compared GFA. 
 Of course, a QSAR relationship does not have to be the weighed average of a 
number of descriptors. Linear models are commonly preferred due to their simplicity 
and smaller risk of overfitting. However, many investigators are tempted to experiment 
with different types of relationships. After all, many processes in nature are inherently 
nonlinear. Yasri and Hartsough (2001) elaborated on the combination of a genetic 
algorithm and a neural network, which also allows non-linear relationships to be found. 
The authors used a conventional descriptor-selecting genetic algorithm (single point 
crossover, bit flips, offspring replaced the parents if it was better) to select 6 
descriptors out of the 404 available for a data set of 54 benzodiazepine derivatives. 
They found that the q2 was enhanced by the GA/NN combination with respect to 
multiple linear regression with stepwise descriptor selection (0.90 vs 0.80). It is not 
clear in this case whether the improved q2 is due to the incorporation of non-linearity 
by the neural network or due to the superior descriptor selection by the genetic 
algorithm. 
 Neural networks were also used by So and Karplus (1996) who found that the 
evolutionary programming employed gave a more robust optimization of the descriptor 
set than the GFA-based genetic algorithm. The Selwood data set was analyzed and an 
r
2-value of 0.76 was found. Additionally, the authors performed exhaustive 
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enumeration over all three-parameter sets and found that the EP-based algorithm found 
all of the best 100 solutions with the exception of the 95th, the GFA-based one found 
only a few. The most likely reason for this is that the EP only replaced parents if the 
children were better, the GFA replaced all parents regardless of the quality of the 
children. 
 Finally, evolutionary algorithms have also inspired researchers to seek beyond the 
standard descriptor used/not used bit strings. One of these methods is FRED (fast 
random elimination of descriptors) by Waller and Bradley (1999). Data sets were 
preprocessed by eliminating zero variance descriptors and descriptors that were 
collinear to other descriptors. Subsequently FRED started with a population of models 
composed of either a fixed or variable number of randomly selected descriptors. To 
prevent overfitting, the rule of thumb was used that there should be at least five 
compounds per descriptor. The maximum chromosome length was thus set to 6 for the 
Selwood data set. A progeny factor was used to ensure that the population did always 
contain enough individuals to include each descriptor on average “progeny factor” 
times. The user specifies a “kill factor”, which divides the population in a part of 
higher and lower fitness. Those descriptors occurring only in the low-fitness part are 
considered deleterious and are eliminated from the descriptor pool using a tabu-like 
process. After every generation, a new population is generated from the remaining 
descriptors.  
 As mentioned, FRED was tested on the Selwood data set. The original 53 
descriptors were reduced to 23 in the preprocessing step, and FRED was applied with a 
kill-factor of 5% and progeny factor of 30. The authors concluded that their algorithm 
performed efficiently and quite similar to alternative algorithms, yielding the same 
‘optimal’ solutions (r2 of 0.83, q2 of 0.69). 
 A good in-depth review of the somewhat older literature on evolutionary 
algorithms in QSAR is given by So (2000). 
 
Conclusion 
Quantitative structure activity relationships form a terrain in which evolutionary 
algorithms have been applied many times. The most likely reasons for this are that the 
presence and/or absence of descriptors is readily encoded using a standard genetic 
algorithm, and that the fitness of individuals can easily be calculated using available 
statistical techniques. 
 Evolutionary algorithms indeed seem to be valuable to the QSAR process since 
they are able to find better combinations of descriptors than the traditional local search 
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processes, as stepwise addition or elimination, can.  
 Nevertheless, there remain some caveats when applying evolutionary algorithms 
to QSAR. 
 The first of these is that the data sets should be picked carefully. It is encouraging 
that a standard data set seems to have been chosen to enable comparison between the 
different methods, yet this Selwood data set is a somewhat unfortunate choice from a 
biological point of view. It is relatively small, only 31 compounds, yet the measured 
biological activity, the killing of the nematodes, is a complex function of the membrane 
penetration of the compound, its cellular metabolism and its interaction with the target 
receptor. This multitude of biological processes makes it unlikely that the activity of 
the Selwood set can be truly explained by using only six descriptors. Direct 
measurements of receptor or enzyme affinities would be more valuable since these 
would include fewer intervening factors. 
 A second point is that biological measurements tend to have quite large margins of 
error (about 0.5 log units). It therefore remains to be seen how much a slightly 
improved r2 value really means since the inaccuracy of biological data does not allow 
us to choose between models which differ only slightly in performance. 
 From a point of view of a medicinal chemist, it seems that researchers in the 
QSAR-field have been introducing more descriptors, and more complicated, nonlinear, 
methods over the last few years. This development may have been prompted by the 
need to improve the predictiveness of the models. Though these developments offer 
opportunities for improved modeling –and even more opportunities for overfitting- 
there are some practical problems in interpreting and using the results.  
 Neural networks in particular are difficult to interpret and do not readily suggest to 
the chemist how a structure can be improved. Another computational method, like a 
evolutionary algorithm, may be necessary to perform “inverse QSAR” to find better 
structures in such a case. The structures can then be optimized using the predicted 
biological activity as a fitness function. However, the problem remains that results 
researchers do not understand are often used reluctantly, if at all. 
 A striking observation is that most QSAR techniques find a wide range of models 
that differ only minimally in their fitness, yet contain entirely different descriptors. 
This makes one wonder about how the “quality” space looks, and whether the 
descriptor sets do not rather describe similarity between compounds of similar activity 
instead of producing formulas that can be truly extrapolated beyond the measured 
activity range of the tested compounds. For instance, logP, a measure for lipophilicity 
and therefore membrane penetration, is almost always significant in a “Selwood”-
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QSAR. This implies that a factor that is really important in such a system does surface 
consistently; the other descriptors however may be more “classifying”, rather than 
“causing” the activity. 
 Such classification would however not help much in achieving the real purpose of 
QSAR, which is to find a formula which predicts biological activity with such accuracy 
that one can use it to design new compounds with higher biological activity than the 
compounds of the training set. Unfortunately, none of the articles reviewed here 
contains this extrapolation step that would be crucial for validating the usefulness of 
the models. 
 In conclusion, evolutionary algorithms seem to improve the parameter selection of 
quantitative structure-activity relationships, especially since they can be applied to 
other than linear models. The main problem for further application of evolutionary 
algorithms is not so much in improving the quality of the models, but in testing 
whether the models can extrapolate reliably. Leaving the most active compounds out of 
the training set and using them as validation set might provide such a check. This has 
not been done in the articles discussed and is generally neglected in other QSAR 
publications. The reason for this may be that QSAR is known not to be very well suited 
for extrapolation; results such as q2 values are likely to be much worse if the omitted 
data points have to be extrapolated. The failure of QSAR in these cases is rather a 
weakness of the current implementations of the QSAR paradigm than of the 
evolutionary algorithms used to optimize the parameter choice. A second opportunity 
for application of evolutionary algorithms would be to increase the availability of 
models. Next to the traditional linear models and neural networks, genetic 
programming might be applicable to find novel ways to combine existing descriptors. 
Also there is still an avenue less explored by evolutionary algorithms, i.e. to use the 
QSAR models for reverse engineering of compounds. Synthesizing and testing these 
compounds will truly test the validity of the QSAR methods employed and the value of 
evolutionary algorithms therein.  
 
 
6. Evolutionary Algorithms in Ligand Docking 
 
Ligand docking, generally simply called “docking” in the medicinal chemistry 
community, places a small molecule, called the ligand, into a protein in the same way 
that nature does. Docking could be compared to a 3D jigsaw puzzle, in which the 
pieces can be turned in more than four ways and can also change shape.  
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Docking is a very important tool in medicinal chemistry. If one can reliably predict 
how a molecule will bind to a protein, visual inspection of the fit may give information 
to the drug designer at which positions the molecule fits well, at which positions there 
is a worse fit, etc. Based on this information a molecule can be designed that binds 
more strongly. Also, if the original molecule would not be suitable as a drug due to its 
toxicity or other undesirable properties, one can dock other molecules and select those 
that seem to bind well for further testing; this can be much cheaper and faster than 
measuring the binding strengths experimentally. 
 In the ideal case, a docking program would give the medicinal chemist a list of 
alternative docking options of the ligand into the receptor, and assign to each docking 
an energy value indicating the binding strength. If the docking procedure is really 
perfect, there will be a sizeable energy difference between the best and second-best 
conformations, which indicates a large chance that the best docking is also the true 
docking. 
 However, so far no program has reached this ideal. There are two main reasons for 
this: 
1) The energy function is often not very accurate. This means that there may be 
docking options of the molecule that are in reality higher in energy than the real 
docking, but are indicated by the energy function as lower in energy (the lower the 
energy is, the better the docking). Some interactions between the molecule and the 
receptor, such as hydrophobic interactions and entropic effects, are notoriously 
difficult to model. 
2) The search space is often very large. The ligand has three translational and three 
rotational degrees of freedom, as well as one degree of freedom for each rotatable 
bond. Additionally, the hydrogen atoms in the receptor, which are usually not 
visible on the X-ray crystallographic structure, also must be in the right orientation 
for good binding between protein and the ligand. All these degrees of freedom 
result in a search space of about 1020 to 1030 possible docking options, which 
cannot be searched fully.  
Although docking is certainly not easy, much effort has been and still is being spent 
improving existing methods and developing new ones. After all, the structure of the 
protein target itself will give much more information for drug design than any QSAR 
model based on just the ligands can. A perfect docking program would be incredibly 
valuable, one of the holy grails of drug design.  
 Many docking techniques have been developed so far. The following part of the 
review will discuss the role of evolutionary algorithms in the more recent applications.  
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A well known and often used example of evolutionary algorithms in docking is GOLD 
(Genetic Optimisation for Ligand Docking) developed by Jones et al. (1997). This is a 
genetic algorithm that uses chromosomes encoding the internal torsion angles of the 
ligand, as well as two integer strings representing hydrogen bonds between the ligand 
and the receptor. The latter replace the more conventional “location and orientation” 
parameters, since the location and orientation of the ligand is determined by least-
squares fitting of the ligand’s hydrogen donors and acceptors onto those of the protein.  
 Each individual is evaluated by first performing the least-squares fit of the 
hydrogen acceptors and donors of the ligand onto the hydrogen donors and acceptors of 
the protein. Subsequently the internal energy of the ligand and the ligand-protein 
interaction energy are calculated, the sum of which determines the fitness of the 
docking. The population is divided into 5 subpopulations with 100 individuals each. 
The operators are crossover, mutation and migration, which are applied as alternatives 
rather than sequentially. Mutation and crossover differ for the binary (torsional) and the 
integer (matching) part: bit flip mutation and one-point crossover are used for the 
binary string, mutation to a random valid value and two-point crossover is applied on 
the integer string. Additionally, a niching technique is used, which makes new 
individuals replace the worst individual of a similar subgroup instead of the worst 
individual of the entire subpopulation.  
 The genetic algorithm was tested on 100 protein-ligand complexes, and run 20 
times on each. The resulting conformation of lowest energy was compared with the 
corresponding crystal structure. In 71 out of 100 cases GOLD found acceptable 
solutions, in which all or most parts of the ligand bound to the right place in the 
receptor. Also the genetic algorithm generally did not need 20 runs, in 49 out of 100 
cases 2 runs were enough. However, errors in the scoring function found a false 
minimum in at least seven of the 100 cases and regarded it as superior to the crystal 
structure, which is biologically spoken not probable. Other problems encountered 
involved ligands that had too few hydrogen donors and acceptors, which made the least 
squares fitting work poorly, and inaccurate protein structures. If the protein structure 
had a resolution more accurate than 2.5Å, GOLD succeeded in 77% of test cases, else 
it succeeded in only 52%. Finally, in some cases the structure of the ligand was 
distorted by the protein, therefore docking using the normal ligand failed. 
 All in all, GOLD seems an interesting computer program that can dock ligands 
over a wide range of test systems. The authors indicate that incorporating protein 
flexibility in the algorithm would be a useful addition, though probably not necessary 
in all systems. 
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Morris et al. (1998) also used a genetic algorithm, but added Lamarckian evolution 
(Autodock). In every generation 6% of the population was optimized using local search, 
and the improved parameters were written back to the genes. The chromosome here is 
a string of real-valued genes. The first three values are the Cartesian coordinates of the 
ligand, the four following values define the orientation. Usually three are sufficient for 
orientation, but then the so-called “gimbal lock” problem may occur, in which an 
unfortunate rotation can make two rotational axes of the object point into the same 
direction. The last values represent the internal torsion angles. Crossover is two-point 
and always takes place between genes. After crossover the mutation is performed, in 
which the values are mutated using a Cauchy distribution. A population of 50 
individuals was used, and a maximum of 27000 generations or 1.5×106 energy 
evaluations.  
 Seven protein-ligand complexes were docked with the Lamarckian genetic 
algorithm, and for comparison purposes also with simulated annealing and a normal 
(non-Lamarckian) genetic algorithm. Ten runs were performed per method per 
complex. It turned out that the Lamarckian genetic algorithm clearly outperformed 
simulated annealing, which had a large root mean square distance of the fitted relative 
to the crystal docking (>3Å) in 2 out of 7 cases. The root mean square distance 
between fitted and real ligand was quite small in both the Lamarckian genetic 
algorithm and the genetic algorithm (under 1.5Å). The energies in the Lamarckian 
algorithm were slightly lower, though at the cost of more energy evaluations. 
Additionally, the Lamarckian genetic algorithm found the minimum conformation in 
78% of the runs, the genetic algorithm and simulated annealing reaching 40% and 24%, 
respectively. As a validation, the binding energies returned by the fitness functions 
were compared to the experimental binding energies. The prediction error ranged from 
–3.89 to +9.93 kcal/mol, which means that predicted binding affinities vary by a factor 
1000, which is the difference between very good and quite bad ligands. The largest 
deviation, 9.93 kcal/mol for the streptavidin/biotin complex suggests that the protein 
flexibility might be too important to neglect in this case. 
 Several attempts have been made to improve upon this Lamarckian algorithm. 
Hart et al. (2000) performed experiments with different settings of the local search and 
found that improvement was possible by taking another local search algorithm, a 
pattern search method, instead of the previously used Solis-Wets algorithm, and 
increase the number of steps in the local search procedure. Other experiments of the 
same author used self-adaptive evolutionary programs and evolutionary pattern search 
algorithms (Hart et al., 1999). The evolutionary programs could adapt the step size of 
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all search parameters, while the evolutionary pattern search algorithms used only one 
step size which was slowly decreased over the course of the evolution. The 
evolutionary pattern search algorithm was configured in such a way that theory 
guaranteed that it would converge to a stationary point. While both methods performed 
decently, they were still outperformed by the optimized local search method. 
According to the authors, this indicates that the local search had a more extensive 
effect on the evolution than just performing localized step length adaptation. 
 Thormann and Pons (2001) parallellized the Autodock algorithm for use on multi-
processor machines, and called the result EGA/LS (Enhanced Genetic Algorithm with 
Local Search). Dividing the population between the processors resulted in a natural 
island model, which proved to be superior to a single-population model. For the more 
difficult test cases the island model was more effective than a pooled population (the 
minimum found in 76% vs 66% of docking options). Migration between the 
populations was taken care of by one individual called the “king”. The king could be 
overwritten by the fittest individual with a certain chance, and the king itself 
occasionally overwrote some individuals in the subpopulations. In each run, the 
subpopulations were randomly initialized three times, but after the first and second 
round the king was kept, seeding the populations slightly so that convergence could be 
reached faster.  
 Three test cases were taken, which took on average about 9 seconds to dock. 
Unfortunately, no root mean square distance data was given by the authors. Hence one 
cannot know whether the crystal structures were reproduced. One hundred runs were 
made with eight subpopulations of size 25. In general, since docking within one run is 
not assured, the authors advise to use at least three test runs for each complex. The 
main problem encountered was that when many degrees of freedom were taken into 
account (all torsion angles of the ligand and some of the protein as well), the 
optimization got stuck in local minima. However, the local minima that EGA/LS found 
were lower in energy than those discovered by GA/LS, indicating that splitting the 
docking populations at least offers enhanced possibilities to escape from local minima. 
 More recent work based on AutoDock has been described by Thomsen (2003). 
The author did experiments to optimize the evolution parameters of the evolutionary 
algorithm used by AutoDock. The optimal settings were found to be a population size 
of 100, and mutation which was a slowly annealed Gaussian. Arithmetic crossover, 
which creates offspring out of a weighted combination of the genes of the parents with 
in this case a random weight for each gene, was found to be superior to the traditional 
single point, two-point and uniform crossover. Strikingly, the new evolutionary 
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algorithm did not profit from adding the Lamarckian local optimization. While the 
improved evolutionary algorithm showed no significant improvement over the 
Lamarckian genetic algorithm in the three simplest test cases (7-11 dimensional search 
space), it improved upon its predecessor in two of the three more complex test cases 
(12-18 dimensional search space). Ironically, though the docking energies found were 
generally lower, the root mean square distances from the crystal structures were 
slightly increased from those found by the Lamarckian genetic algorithm. The 
efficiency was increased however, the “DockEA” needed only 50,000-150,000 fitness 
evaluations, while the Lamarckian genetic algorithm needed over 250,000 evaluations 
to obtain accurate and reliable results. 
 From these experiments the author concluded that the energy function needs some 
improvement to make the lower docking energies also correspond most closely to the 
crystal structure, but the deterioration of docking quality in one of the more 
complicated test cases relative to the Lamarckian algorithm indicated that the balance 
between exploration and exploitation is sensitive to the protein structure, and testing on 
more complexes would be required to refine the docking algorithm. 
 Among the evolutionary algorithms, genetic algorithms have been most prominent 
in docking. Yang and Kao (2000) however created a docking method called FCEA 
(family competition evolutionary algorithm), which is more similar to evolution 
strategies. Next to the vector of real numbers encoding the location and orientation (6 
numbers) and the torsional angles of the ligand, each individual contains three 
additional vectors. They are of the same size as the data vector, encoding the 
parameters for a decreasing-based Gaussian mutation, self-adapting Gaussian mutation 
and self-adaptive Cauchy mutation, respectively. Thus, each gene in each individual 
has three self-adaptive mutation parameters. The mutation step consists of subsequent 
application of the three mutations (decreasing, Gaussian, Cauchy). In each of these 
submutation steps each member of the population generates l children by mutation or 
recombination with another member of the parent population. The fittest of the children 
survives. In most cases, from each pair of father-child the best survives into the next 
generation, sometimes however from the entire population of n parents and n children 
the n best solutions are selected. For further details on the rather intricate procedures 
and many parameters used in this algorithm the reader is referred to the publication 
itself. 
 The resulting program was subsequently tested on one protein, the enzyme 
dihydrofolate reductase, with three different ligands. Population size was 50, the 
maximal number of generations 250. The results were compared to those of DOCK and 
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other docking programs. While DOCK found the best fit to the crystal structure 
(RMSD 0.6Å vs 0.67Å), the average fit (over 20 runs) by FCEA was better (1.37Å vs 
2.4Å). However, using only one protein structure for comparison seems a bit meager 
for a conclusion on the general competitiveness of this method. 
 Since evolutionary algorithms are by far not the only computational methods used 
for docking, Vieth et al. (1998) made a comparison between three common methods: 
molecular dynamics, Monte Carlo and a genetic algorithm. The genetic algorithm was 
kept relatively simple. The population of 90 individuals was split over five 
subpopulations with an elitism of 2 per subpopulation. In each generation, the 
individuals were modified by using single-point crossover, mutation or migration. In 
migration, two individuals were exchanged between subpopulations. The search was 
performed in two stages for each algorithm, in which the parameters in the second 
stage were adapted to fine-tune the solutions found in the first phase. 
 Five ligand-receptor complexes were used as the test set. It turned out that the 
genetic algorithm worked best for small search spaces in which the ligand was located 
within 3Å of its actual binding site and the molecular dynamics performed best for 
larger search spaces, within 11Å of the binding site. While the genetic algorithm gave 
the highest fraction of runs that found a good docking, the molecular dynamics 
algorithm returned the conformations with the lowest energy and closest fit. 
 Combination of the different computational techniques is also possible. An 
example of this is the Mining Minima optimizer (David et al., 2001), which uses a 
combination of the so-called global underestimator method, genetic algorithms and the 
poling method of Smellie et al. (1995). However, it is possible to regard it as an elitist 
genetic algorithm with some twists. First a large population of individuals is created 
within a certain search region. The individual with the lowest energy is used as the 
center around which the next generation of docking options is created. After each 
generation the width of the search region is narrowed down. To prevent the rediscovery 
of energy minima, exclusion zones are placed around previously found minima. There 
is a crossover-like operator, which combines a newly designed individual by partially 
copying information of a previously found minimum into it. The modified new 
individual is then placed in the next generation.  
 The authors tested their method on 27 complexes and compared their method with 
the genetic algorithm, simulated annealing and tabu search of PRO_LEADS, as well 
with AutoDock, FlexX and MCDOCK. Also nine of the “difficult cases” of GOLD 




The median docking time of the Mining Minima optimizer turned out to be about 1.2 
minutes. The results of the comparison with the other programs indicate that the 
Mining Minima method is comparable to PRO_LEADS and the other programs; 
occasionally it scores higher, sometimes lower. The authors point out that in some 
cases the fit was good, yet the “objective” root mean square distance criterion indicated 
low quality. In some of these cases the solvent accessible parts of the ligand, which are 
relatively free to move, cause the main part of the error. This contribution is however 
not very relevant since these parts do not influence the quality of the docking, which is 
defined by ligand-protein interactions. Six out of nine of the docking options that were 
difficult for GOLD were solved. Three remained problematical: in one case the crystal 
structure itself was suspect, in the other two cases the global minimum was found at 
another place than the binding site. 
 If the elaborate comparisons in this article make one thing clear, it is that the 
different algorithms are more or less suitable for different complexes, since no method 
is superior over all other methods in all investigated complexes. Moreover, some 
complexes seem much more difficult to solve than other complexes, whichever method 
is used. 
 
For a broad overview of the many different methods (genetic, simulated annealing, 
fragment-based methods, etc.) of docking and the many programs using these, the 
review of Taylor et al. (2002) is recommended. 
 
Conclusions 
Several evolutionary algorithms have been developed for docking ligands into the 
active site of proteins, and all obtain reasonable to good results, quite like the other 
heuristic algorithms. It is so far doubtful whether evolutionary algorithms have 
inherent advantages that make them more efficient for docking than for example 
simulated annealing. Since the coordinates of all atoms depend on the location and 
orientation and many of the torsion angles, this high coupling would make it very 
unlikely that there are small simple building blocks that can be recombined with each 
other into larger, high-quality building blocks. This view seems to be supported by 
findings such as that of Thomsen (2003) that arithmetic crossover outperforms the 
more conventional uniform and one- or two-point crossovers. Several promising 
techniques have been found, such as introduction of subpopulations, employing local 
optimization next to the normal genetic algorithm, and using different crossover and 
mutation methods. Further investigation is necessary, however, to conclude whether 
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combining these will further improve docking efficiency and efficacy.  
 In any case, several authors have displayed great ingenuity in introducing novel 
and complex operators, most notably Yang and Kao (2000). Yet the arguments for this 
complexity are lacking, with the possible exception that the other methods do not work 
perfectly. If the complexity of the evolutionary algorithms is enhanced, it should be 
done either carefully and on the basis of solid experimentation, that is, study of many 
complexes, or it should be based on knowledge of the chemical and biological reality. 
Otherwise such methods might “overfit” their docking options due to an overdose of 
adjustable parameters and a paucity of test cases. 
 However, comparison of the diverse methods employed is extremely difficult 
since the three separate components of the docking procedure (fitness function, search 
method and test data) are generally different per article. A desirable development for 
this field would be the introduction of a library of standard search algorithms, fitness 
evaluators and test data sets. Only then a new algorithm can be truly compared to 
existing ones.  
 Another development would be the incorporation of protein flexibility. Proteins 
can dock different small molecules in their active site. Most method developers, 
understandably, have docked the ligands of known complexes and compared those to 
the crystal structures. But is a crystal structure of the protein in which ligand A is 
docked also suitable for docking ligand B? Or would subtle differences in the protein 
conformations prevent finding the real docking? Such extrapolation is of vital 
importance for predicting the binding of series of molecules, and may necessitate 
extending the algorithms with some protein flexibility. 
 Further advances are also needed in the area of fitness functions. Since some 
discovered docking modes have lower energy (according to the computer) than those of 
the crystal structures, the energy evaluation procedures should be improved. Training 
the force fields that evaluate the fits by finding the right parameters and formulas might 
by itself also be an interesting field for applying evolutionary algorithms (an 
application of an evolutionary algorithm in descriptor selection for such a model is the 
work of Deng et al. (2004), see section 8). 
 The ultimate goal of docking algorithms, taking a protein structure and a ligand 
structure and calculating both the position in which the ligand will be bound and the 
affinity of the ligand for the receptor, will probably need the following extensions of 
existing docking algorithms: 
1) Addition of protein flexibility to accommodate the binding of different ligands and 
correct for errors in the crystal structure. 
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2) Addition of water molecules to the active site; these can influence binding as well. 
3) Calculation of the changes of entropy on the protein, the ligand and the water 
molecules during the binding process. 
In conclusion, much remains to be done in the field of ligand docking. It is not certain 
yet whether the docking algorithm of the future is a pure evolutionary algorithm, basic 
simulated annealing, or one of the other methods currently applied. Most likely the 
ultimate docking method will incorporate the most suitable properties of existing 
search methods combined with chemical and biological heuristics. There is still a long 
way to go before ligands can be docked automatically, accurately and with good 




7. Evolutionary algorithms in de novo design 
 
To find molecules with a specific biological activity, compound libraries are 
commonly screened. However, “only” about 1010 structures have been synthesized by 
chemists thus far, while the number of all possible drug-like molecules is estimated to 
be at least 1060 (Gillet, 2000). Clearly, designing new molecules may be required to 
cover more of this “chemical space” and to find a molecule that would be a more 
suitable drug against a certain disease than any currently known molecule. This process 
of designing new molecules is called de novo design. 
 Applying computer programs to design molecules seems an obvious choice, 
especially since computers can create virtual molecules much faster than humans can. 
However, the set of all possible molecules is difficult to search systematically. One of 
the reasons for this is that the number of possible mutations rises with the size of the 
molecule. If one defines a mutation as a single step in chemical space (changing/ 
adding/removing an atom or bond), the number of orthogonal steps/dimensions 
increases with the number of atoms in the molecule. So a “normal” drug molecule, 
which may contain e.g. 20 non-hydrogen atoms, can have over one hundred possible 
one-atom mutations. This results in a very high-dimensional search space, and the 
dimensionality will only increase when larger molecules are allowed. This makes a 
systematic search of all possible molecules to find those with the desired properties 
quite difficult. Also, a molecule is a graph and therefore is difficult to represent by the 
traditional vector notation of a genetic algorithm. Additionally, the rules of chemistry 
limit the number of possible molecules by demanding that e.g. every oxygen atom has 
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two bonds, and every carbon atom four. Therefore, mutation from a carbon atom to an 
oxygen atom will always involve some additional modification of the molecule, like 
removing hydrogen atoms. This is sometimes possible, sometimes not, depending on 
the rest of the molecule. Lastly, developing a proper fitness function is probably the 
most challenging problem of all. Since experimental fitness evaluation is slow and 
expensive, the search goes on for computational methods that predict the properties of 
a molecule reliably.  
 To find promising molecules in the vast chemical space, several different 
evolutionary algorithms have been developed and applied to a variety of de novo 
design problems. A good review on some of the older work has been written by Gillet 
(2000). This review will only briefly discuss the earlier work and mainly cover the 
work performed in the last few years. 
 
One of the first and best known applications of evolutionary algorithms in de novo 
design is the work of Glen and Payne (1995). Since a molecule is a graph that can 
contain cycles, a traditional linear chromosome with bit-flip mutations could not be 
used. Therefore a graph representation of the molecule itself was used as genotype, in 
conjunction with linear chromosomes which indicate the position and orientation of the 
molecule and the torsion angles, similar to ligand docking.  
 Mutation of the orientation, position and torsion angles was performed using an 
approximated Gaussian function. The structure of the molecule could be altered by a 
set of eight mutations, which included adding and deleting atoms or groups of atoms, 
forming and breaking rings, and changing atom types. Crossover could be 1-point or 2-
point between single, non-ring bonds that occupied approximately the same 3D-
coordinates. The fitness function consisted of a weighed combination of scalar 
properties of the molecule such as molecular weight, surface properties and the fit of 
the molecule on a predefined grid. Selection was done by the roulette wheel method. 
 The authors performed two experiments. One experiment was aimed to design 
molecules that resemble ribose, the other to design molecules that fit the active site of 
the bacterial enzyme dihydrofolate reductase (DHFR). Population sizes of 50-100 were 
used, since lower sizes such as 10 were found to be too erratic due to premature 
convergence. Evolution indeed improved the fitness scores from 100 to –30 for the 
ribose analogs. Also, the average score of the best four molecules in the initial 
population of the DHFR experiment was 26.3, but converged after 32 generations  




The authors envisioned two extensions to their program. The addition of metal atoms 
and transition states might be useful to mimic enzymes better. Another important 
improvement would be a fitness function that gives a more biologically relevant value, 
such as binding strength. This would also eliminate the need to set the relative weights 
of the many fitness criteria manually, which is far from objective. Nevertheless, the 
diverse mutations and the 3D-representation of the molecule were designed very well, 
and as of yet few de novo design programs have improved on Glen and Payne’s work 
in these respects. 
 Worth mentioning as another pioneering study of evolutionary algorithms in de 
novo design is the work of Westhead et al. (1995). The authors first generated and 
superposed an initial population of molecules, which formed the input for the 
evolutionary algorithm. Similar to Glen’s work, molecules can be crossed only if they 
have single bonds that lie near each other in the superposition. However, mutation is 
limited to rotation of torsion angles, and the fitness function is less sophisticated than 
Glen’s, being the number of functional groups that overlap the functional groups of a 
known molecule in a superposition. Analogs of the molecules distamycin and 
methothrexate were nevertheless found and scored higher than the initial population of 
molecules.  
 However, though the molecule itself is a graph, the genotype of the molecule does 
not have to be a graph. Other representations might have advantages for an 
evolutionary algorithm. 
 Nachbar (1998) developed a evolutionary algorithm that converted the molecule 
graph into a tree, in which cycles are represented by special ring nodes. Mutation 
involves changing the atom types or bond orders, but crossover is responsible for the 
major part of structural change. The crossovers are very much like those of genetic 
programming, though subtrees containing an open ring bond are not exchangeable. The 
fitness function was a graph descriptor-based QSAR which predicted toxicity of the 
compound in tadpoles. After the population of 50 individuals had been evolved for 50 
generations, 30% of the molecules were in the desired activity range. In this case it is 
somewhat difficult to establish the efficiency of evolution since no data were collected 
on the evolution of the population’s fitness during a run (R.B. Nachbar, personal 
communication). 
 The algorithm did have some small problems, such as that many molecules in the 
final generation were identical, which is not very useful for a chemist who wants as 
many alternative solutions as possible. Checking for duplicates will probably be 
important in any de novo design method. A problem caused by the tree-like 
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representation was that ring manipulation was difficult. The author would have liked to 
be able to expand, contract and break rings at other positions than the ring closure bond, 
but this was not easy to implement. 
 The ring opening problem was solved in subsequent work of the same author 
(Nachbar, 2000) by inverting/re-rooting subtrees. The fitness function changed to 
molecular similarity, and several test molecules were recreated by the evolutionary 
algorithm, with the exception of a large polycyclic molecule, which turned out to be 
difficult to generate due to the surrounding local optima. 
 Douguet et al. (2000) used the chemical SMILES-notation (Weininger, 1988) to 
represent the molecules. SMILES is also tree-like, yet contains fewer brackets since 
hydrogen atoms are not explicitly stated and the superfluous brackets in the linear parts 
of the molecule are omitted. Two crossover operators, one-point and two-point, were 
implemented, as were thirteen mutation operators (though the article, oddly, describes 
only eight). These were quite similar to Glen’s, though ring breaking was absent. This 
may be due to similar problems as Nachbar encountered with tree representations. 
Fitness was calculated as a weighed sum of a few physicochemical criteria, such as the 
solvent accessible surface and the dipole moment of the molecule, which had to be in a 
certain range, and roulette wheel selection was used. As test cases, the target criteria 
were set to the properties of retinal and salicylic acid. The evolutionary algorithm did 
indeed find mimics of these molecules. The structures of some of the molecules were 
adapted by medicinal chemists to make them easier to synthesize. In contrast to the 
work of Nachbar, the authors considered crossover to be very much like a 
macromutation due to the tree-like representation, and it was applied much less 
frequently than mutation.  
 Globus et al. (1999) handled rings more elegantly by using “genetic graphs”. 
These have the advantage that they look very similar to real molecules. A crossover 
operator was implemented which could easily cross over rings, which had not been 
done yet by other authors. However, no mutation operator was used. This had the 
unfortunate result that if a generation happened to contain only rings, no chains could 
be generated, and vice versa. The fitness function was graph similarity to a specific 
molecule. Globus demonstrated that his algorithm can indeed recreate complex 
molecules, even those which have different atom types and a complex structure, like 
the five rings-containing morphine. The authors acknowledge, however, that 
rediscovering known molecules is not very useful, and that a fitness function that gives 




Simplifying the representation of the molecules can work, but tends to restrict the 
possible mutations. This may make an escape from local minima more difficult. 
Another way to apply the evolutionary algorithms more easily is to adapt the problem 
domain and only consider subsets of molecules which have a relatively simple 
structure. 
 Schneider et al. (1998) used experimental data on the biological activity of 
peptides to train a neural network to predict activity from structure. Subsequently an 
evolutionary algorithm was applied that chose the best individual from the initial 
population. Since peptides are linear chains of amino acids, a linear chromosome can 
be used. Mutation can then be performed by picking a position and substituting the 
amino acid there by another amino acid. The best peptide filled the next generation 
together with its mutants, after which the new best peptide was selected. Unfortunately 
the neural network made quite inaccurate predictions, which was aggravated by the 
errors in the biological data used to train it. Nevertheless a peptide with comparable 
activity to the seed peptide but a very different sequence was found.  
 Related work was performed by Patel et al. (1998) who focused on bactericidal 
peptides. A training set of 29 peptides with measured biological activities was used. 
Using this set, 29 multi-layer perceptron neural networks were created, each based on 
28 peptides. The fitness value was taken to be the average of these 29 models. The 
genetic algorithm used was somewhat more conventional than that of Schneider et al., 
having a population of size 100, elitism that conserved the best 25, probability of 
crossover (two-point) 0.6 and probability of mutation 0.033.  
 The genetic algorithm was shown to be much more efficient than Monte Carlo or 
random search in finding peptides with high predicted activity, since only 0.008% of 
randomly generated peptides were in the desired activity range, 0.5% of those 
generated by Monte Carlo but 7.2% of those made by the genetic algorithm. Of the 
more than 400 candidate peptides that were generated by the genetic algorithm, the 5 
most diverse were synthesized and were shown to have high-ranking bactericidal 
activity. 
 With the traditional fixed-size chromosomes the length of the peptide cannot be 
modified; this may however be important for optimizing activity. Kamphausen et al. 
(2002) solved this problem by implementing n×m crossover. This technique selects a 
group of parent peptides and aligns the sequences. It enables the shorter sequences to 
align with the longer sequences by filling the empty space at the end of the shorter 
sequences by repeating the first part of that sequence until the maximum length is 
reached. The length of the child peptide is then determined by averaging the length of 
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the best parent peptide and the average of the other parent peptides. Subsequently, the 
child is assembled by taking one value per column in as many aligned columns 
necessary to reach the target length. The implemented version of this mutation also 
allows the sequence to “shift”, which can lengthen and shorten the sequence at both 
ends. 
 The program was used to find a peptide that optimally inhibited the blood clotting 
protein thrombin. The population contained 123 peptides of lengths 6 to 12, whose 
fitness was determined experimentally. Four cycles of design and testing were 
performed. With each generation the average activity increased, and in the fourth 
generation a very active inhibitor was discovered. It was more potent than known 
peptide inhibitors of thrombin, and this experiment can thus be considered to be 
successful. 
 
Peptides, however, are currently only rarely used as drugs since they generally have 
unfavourable physico-chemical properties. Conventional drugs are much smaller 
molecules, which can be absorbed more easily by the body. Schneider acknowledged 
this and also created a evolutionary algorithm for small molecule design, TOPAS 
(Schneider et al., 2000a,b). This program again uses Schneider’s method in which only 
the fittest individual survives and procreates, but uses molecule fragments instead of 
amino acids. A subset of about 3 of approximately 25,000 fragments is converted by 
the algorithm into a real molecule. The fragments also contain data on the connections 
they can form, which should allow the constructed molecule to be easily synthesized in 
the laboratory. Mutation is implemented by replacing a fragment by a similar fragment 
with the same type of attachment point. The fitness function calculates the similarity of 
the constructed molecule to a known ligand.  
 In the test case, TOPAS identified a ligand chemically not very similar to the 
original molecule, but with receptor affinity, be it a 1000-fold less potent. While one 
could not yet argue that this evolutionary algorithm develops structures that improve 
the affinity of a known ligand, it can find compounds with a similar kind of activity in 
a very different class of chemical structures. 
 The fragment-based approach was also used by Pegg et al. (2001). However, in 
their algorithm runs use far fewer different fragments (in the order of dozens). Acyclic 
graphs containing maximally 16 fragments are constructed. Crossover is performed by 
exchanging subtrees between individuals, mutation by changing one of the fragments 
in an individual or by connecting a fragment to another fragment in the same individual 
as long as this does not introduce a cycle. The fitness is determined by docking the 
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resulting molecule into the active site of the target protein. 
 Three test cases were taken: design of cathepsin analogs, inhibitors of 
dihydrofolate reductase and inhibitors of HIV-1 reverse transcriptase. The results of the 
evolutionary algorithm were compared to the experimental data available. Two major 
problems were discovered. First, fitness evaluations took much time: a run of 100 
generations of a population of 20 molecules took 5 hours of processor time. Second 
and worse, not all good inhibitors were judged as good by the fitness function. So 
while the evolutionary algorithm designed many molecules with higher fitness values 
than the compounds that turned out best in the experiments, it remains to be seen if 
those molecules actually bind better. Like Schneider’s program, the fitness function is 
ill-equipped for optimizing the activity, yet the generated libraries do find general 
trends, i.e. substructures that seem to work. It is likely that the libraries generated by 
Pegg’s program are better than randomly designed libraries in binding to the target site. 
However, since no experimental validation was performed, definitive conclusions on 
the effectiveness of this method cannot be drawn. 
 The SYNOPSIS program by Vinkers and coworkers (2003) can be considered a 
synthesis of the good points of both Pegg and Schneider with some additional clever 
ideas. The database constructed by the authors contains about 32000 molecules, which 
can be transformed and combined using 70 different reactions. A chromosome 
represents a sequence of molecules and reactions, which is transformed by the program 
into the actual molecule. Mutations consist of adding reactions or changing reactants. 
The fitness function is the docking score of the molecule binding to the enzyme HIV-
reverse transcriptase.  
 A good point of this program is that it automatically suggests a synthesis route for 
the molecules. For 8 out of 28 molecules the synthesis route was followed and 
succeeded, while for only 3 molecules the suggested route was tried and failed. In the 
other cases a different method was taken or a compound differing from the original 
suggestion was made. Therefore, depending on the definition of success, 29% to 64% 
of syntheses succeeded.  
 Similar to Pegg, finding good inhibitors proved to be more difficult. The docking 
function was extremely slow (1 processor-hour per compound) which probably only 
allowed small populations and a low number of generations, although the article gives 
no numbers on these. Also the docking function was quite inaccurate. For all suggested 
ligands a high binding strength was calculated, but a low binding strength was found in 
experiments. Similar to Schneider’s approach, the evolutionary algorithm acts not so 
much as an optimizer of biological activity, more as an idea generator of molecules that 
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are on average much more active than one would get from a random library screening. 
In that respect SYNOPSIS is a success.  
 
Conclusion 
A wide variety of evolutionary algorithms has been applied to de novo design. Their 
applications and results highlight both their successes and their current shortcomings. 
 The two main challenges, i.e. representation of the molecular structure and the 
fitness function, have been addressed by the authors with varying success. The many 
applications of evolutionary algorithms in “simplified” chemical domains make it clear 
that representing the molecule remains difficult, and that mutation and crossover are 
not straightforward to implement. However, the work of Glen and Payne (1995) has 
clearly shown that evolutionary algorithms can be applied very well by using the 
molecule as its own representation. Implementing mutations and crossover will remain 
amenable to tweaking and discussion, but basically this problem has been solved.  
 There are currently two major elements in automated de novo design to focus on. 
The first is that the molecules suggested are not always easily synthesized. The 
fragment-based approach by Vinkers et al. (2003) to use available molecules and 
known reactions is promising. However, it also calls attention to the fact that due to 
problems in reaction prediction only few of the thousands of available chemical 
reactions can be used by the program. And even those few “robust reactions” fail quite 
often. Additionally, limiting the reactions and the building blocks will undoubtedly 
confine the parts of chemical space that can be explored by a ‘fragment and reaction’-
based algorithm. Also the fragment-reaction like structure of the chromosomes makes 
mutation awkward: fine-tuning a molecular structure that is almost right is extremely 
complicated and therefore not very likely to happen. On the other hand, atom-based 
mutations like those of Glen and Douguet allow more refined exploration of the 
chemical space and relatively easy fine-tuning of the molecular structures. Yet they 
have the disadvantage that synthetic feasibility of the resulting molecules is doubtful. 
Perhaps the ideal algorithm will use a combination of these two approaches. 
 For the second weak point of current de novo drug design algorithms, i.e. the 
fitness function, good solutions seem even harder to find. Docking, which in principle 
yields the best affinities for a broad diversity of molecules, is extremely slow and 
moreover gives results that are too inaccurate for optimization. This suggests, as in 
section 6, that the most important contributions to this area by evolutionary algorithms 
would be in deriving proper binding functions from quantum mechanical and 
experimental data. Additionally, there is the problem that many important proteins are 
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membrane-bound, and that their crystal structures are therefore extremely difficult to 
determine. This means that docking is currently not applicable to a large portion of 
interesting drug targets. Experimental fitness determinations are for now the only 
alternative, yet it may well be that a evolutionary algorithm used interactively by 
medicinal chemists would need fewer syntheses to achieve optimization than the 
traditional methods. 
 In conclusion, while the quality and applicability of the discussed evolutionary 
algorithms for de novo design varies, they do show promise. Even at this moment the 
applied evolutionary algorithms with their crude fitness functions give inspiration for 
unconventional analogs of known ligands, which opens up alleys otherwise closed off 
by patents or unfavourable physiological properties of the original ligands. As fitness 
functions become faster and more accurate, the future of evolutionary algorithms in de 
novo design looks very bright indeed. 
 
 
8. Other applications of evolutionary algorithms in drug 
design 
 
The scope of application of evolutionary algorithms in drug design is wide. Whereas in 
the previous sections the more prominent uses were discussed, this section will focus 
on some less mainstream work. The publications discussed here may give an 
impression of other areas that have been tentatively trodden, a brief glimpse of areas 
that may become more important in the near future, and inspiration for application of 
evolutionary algorithms to other problems related to drug design. 
  
If a large database of molecules has to be screened for biological activity, most drug 
developers would prefer to test only the most promising compounds. If these have the 
much sought after but ill-defined “drug-likeness” property, they will have a larger 
chance of being a good drug. While one could argue about the merits of selecting for 
drug-likeness versus selecting for lead-likeness (see section 2), the search for drug-
likeness criteria has inspired some interesting research, amongst others that of Gillet et 
al. (1998). Gillet et al. attempted to estimate drug-likeness by taking two databases of 
molecules, the World Drug Index, which contains about 30,000 drug molecules, and 
the SPRESI database, which contains 1.7 million molecules, in vast majority nondrugs. 
Of each molecule in the databases, six simple properties were calculated, such as the 
number of rotatable bonds and the number of hydrogen bond donors. The value range 
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for each property was divided into 20 bins. Using statistics on a subset of 1000 WDI-
molecules and about 17,000 SPRESI-molecules, for each bin the chance was 
determined that a molecule having its property within the value range of the bin was a 
drug molecule. The total database was then sorted to see if the drug molecules indeed 
ranked higher.  
 It turned out that this method gave some information on drug-likeness. For 
example, ranking the molecules by only taking into account the number of hydrogen 
donors resulted in finding 4.6-fold times as many drugs in the top 1000 molecules as 
would be expected by chance. However, combining descriptors worsened this 
enhancement, probably because the descriptors were not truly independent.  
 Subsequently, experiments were performed to see if setting the bin weights by 
using a genetic algorithm instead of statistics would improve the score. The genetic 
algorithm used vectors of length 6x20=120 as chromosomes. Mutation changed the 
value of one bin to a new permitted value, crossover could be one-point, two-point or 
uniform. Two fitness measures were compared: the number of drug molecules in the 
top 1000 and the average rank of drug molecules in the drug-likeness list. The average 
rank resulted in much better scoring over the entire population. The enhancement 
factor here was 3.0; so to find 50% of all drug molecules only the top 17% of all 
compounds had to be considered. Subsequently, experiments were performed to 
distinguish specific classes of drugs from inactive molecules, either by using the 
generic binning weights or weights specifically optimized by comparing the particular 
drug class with SPRESI. The discriminative power of the method depended heavily on 
the therapeutic class. For example, retrieval of anticancer compounds was enhanced 
4.9-fold with the generic binning method and 6.8-fold with specific training, while for 
psychiatric drugs enrichment was only 1.3-fold with the generic method and 2.0 after 
training. The authors suggest that these differences may be due to the fact that there are 
relatively few psychotropics and that the class is structurally quite diverse. 
 The results of this investigation can certainly be considered interesting. Drugs can 
be somewhat discriminated from non-drugs, even by a simple method such as this one, 
and the structure of the chromosomes might yield interesting insights on what makes a 
compound drug-like. However, some problems are not addressed by the authors. The 
SPRESI-database is not 17, but 54 times as large as the WDI. This means that even 
with a factor 3 enhancement, only one in twenty of tested molecules in the first third is 
a drug, which is not a very good score. Additionally, the binning weights are trained on 
structures that already occur in drugs, so compounds which work via diverse 
mechanisms like the psychotropics are not readily found. Therefore using this method 
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to prioritize the lead screening for a novel receptor would probably not be very 
advantageous. 
 In addition to the question of whether a compound has biological activity, another 
important question is which kind of biological activity it possesses. Xue and Bajorath 
(2000) used a descriptor based classification method. By placing the compounds into 
descriptor space, one should be able to discover clusters of compounds with the same 
biological activity and discover which part of descriptor space corresponds to a specific 
biological activity. Since the authors could use over 100 different descriptors, they 
aimed at simplifying descriptor space by using principal components. Dividing the 
principal component space into square boxes, compounds were grouped per box. If the 
compounds in one box had the same biological activity, the set of compounds in the 
box was called a pure class. If the box contained compounds of several biological 
activities, it was counted as a mixed class. Finally, if there was only one compound, the 
box was said to represent a singleton class. 
 The genetic algorithm was designed to solve three optimization problems 
simultaneously: 1) which descriptors should be used, 2) how many principal 
components should be used, and 3) into how many bins should every principal 
component be divided. The chromosome was a vector of 141 bits, 111 bits representing 
the use/non-use of particular descriptors, 15 bits to encode the number of principal 
components used, and 15 further bits to encode the number of boxes into which each 
principal component axis is divided. The fitness function increased with the number of 
pure classes and decreased with the number of mixed classes and singletons. This 
particular fitness measure might have been somewhat disadvantageous, since one 
ideally would want to reward a minimum of classes. It seems more desirable to have 7 
pure classes than 700. 
 The best result had 4 principal components with 5 bins each and found 60 pure 
classes, 27 singletons and 2 mixed classes. The classification method therefore worked, 
though comparison with other classification methods and assessing quality via a 
separate validation set would have been valuable additions to this work. 
 
Whereas ‘drug-likeness’ is a somewhat nebulous concept, there are also more sharply 
defined properties that are important for candidate drugs. One of these is water-
solubility: if a compound does not dissolve in water, it cannot be transported by the 
blood to its desired site of action.  
 Wegner and Zell (2003) derived a quantitative structure-property relationship to 
predict water solubility of a molecule from its structure. The authors calculated 230 
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descriptors from these structures. Since there were 1016 molecules in the training set, 
using all descriptors would probably have led to overfitting. Therefore, the authors 
wanted to reduce the number of descriptors. Principal component analysis was 
regarded to yield non-intuitive results, so a genetic algorithm was created. The initial 
population of this genetic algorithm was seeded with maximally diverse individuals as 
selected by Shannon entropy measures and clique detection algorithms. The genetic 
algorithm for descriptor selection was very similar to the ones used in QSAR (see 
section 5): the chromosome was a vector of bits, each bit indicating the presence of a 
descriptor. The chromosomes could undergo one- and two-point crossover and bit-flip 
mutation. A neural network was trained using the descriptors that were indicated by the 
chromosomes, and the fitness of each chromosome was r2 for the test set. The final best 
model had a validation set r2 value of 0.82, which was comparable to the results of 
other neural networks trained on similar data sets that gave r2 values between 0.79 and 
0.91 for their validation sets. 
 
A third factor to consider when designing drugs is metabolism, the breakdown of drugs 
by the body. Some of these breakdown products are toxic. For example, the drug 
paracetamol itself is harmless, but when taken in huge quantities it is partially 
transformed into a toxic product that causes liver damage. Drug designers therefore 
want to know the possible breakdown products of a compound, preferably before 
synthesis. Rules exist to predict metabolism, and computerized rule bases, like META 
(Klopman et al., 1997) can be applied to automatically predict probable metabolites. 
However, a molecule can often be broken down in many different ways, and it is not 
clear which of those ways are preferred by the body. Assigning priorities to the diverse 
transforms is traditionally done by experts. Klopman et al. however investigated 
whether a genetic algorithm could do this automatically. This would be advantageous 
since it would eliminate the need to manually recalibrate all weights after adding new 
data.  
 The chromosomes contained the priorities of all reactions, coded as a vector of 
binary numbers. Crossover was one-point and only took place between the genes, and 
mutation was performed by flipping bits. Fitness was defined as the number of correct 
predictions minus the number of incorrect predictions, the false positives and false 
negatives. Bolzmann tournament selection outperformed normal tournament selection 
and roulette wheel selection, and was therefore chosen as selection method.  
 For both training and validation sets, the genetic algorithm found a better solution 
than the experts (table 2.1). Clearly, genetic algorithms can combine large amounts of 
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data reliably into a rule-base, an exciting prospect. 
 
 
Table 2.1: Comparison of the results of the genetic algorithm-set priorities 
versus the expert-set priorities. 
 













Expert 103 45 28 66 9 56 
GA 134 14 18 75 0 21 
 
 
Biological activity of a compound can be predicted by computationally docking the 
molecule into the receptor. Often, however, the receptor structure is unknown. The 
common alternative is churning out high numbers of descriptors and using neural 
networks or multiple linear regression to find quantitative structure-activity 
relationships. However, this method does not use any of the knowledge available on 
receptors and their properties. A different possibility is making a model of the active 
site based on the ligand data. Walters and Hinds (1994) used this approach. Their 
computer program GERM (Genetically Evolved Receptor Models) uses a superposition 
of ligands, around which a collection of atoms, typically 50 to 60, is placed. These 
atoms represent the protein atoms of the active site. The interaction energy between the 
proposed active site and the ligands is calculated with a force field. The chromosome is 
the list of the atom types of the atoms in the reconstructed active site. One-point 
crossover and a mutation that randomly changes an atom type into a random other 
atom type were implemented. Crossover was the most important operator but allowing 
some mutation was found to improve the convergence.  
 When populations of 500-2000 chromosomes were allowed to evolve over up to 
10000 generations, models with r2 values of 0.90-0.99 were found. The average error 
for the compounds of the training set was 0.06, but for those in the validation set it was 
0.40. This clearly points to overfitting. However, scrambling the bioactivity values 
indicates that there is also some real relationship behind the numbers: the mean r2 
value of the scrambled sets was only 0.34.  
 GERM has some drawbacks, however. First of all, the ligands of a receptor must 
be superimposed, and as has been discussed in section 4, there is no unambiguous 
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method to do that. Overfitting is quite understandable in this system: after all, there are 
50 to 60 different atoms involved for explaining the bioactivity of about 10 compounds. 
Interestingly, the atoms at some positions had identical types in all of the fittest 
individuals, at other positions there was much more variation. This would suggest 
some biological rationale behind the model, and it would certainly be interesting to 
make runs on superpositions of known ligands docked into the binding sites to see 
whether the conserved residues in the proposed active site correspond to the important 
groups in the real active site. 
 Some other programs used a methodology very similar to that of GERM. An 
example is PARM (Pseudo Atomic Receptor Model) by Chen et al. (1998). The main 
difference with GERM is that heuristics were used to initialize the chromosomes. 
When an atom type had to be assigned to a certain grid point, the heuristics increased 
the chance of choosing a negatively charged atom type if the ligand atoms near the grid 
point were positively charged, and vice versa.. Two training sets, 21 and 12 compounds, 
were used with validation sets whose sizes were about half as large. Crossvalidated r2 
values of 0.83-0.93 were reached. The compounds of the validation set were predicted 
with an average absolute error of 0.52; CoMFA analysis (section 5) yielded 0.61. This 
suggests that PARM can be somewhat better than conventional methods. 
 Vedani et al. (1998a,b) created another pseudoreceptor modeling method. The 
main deviations from Walters’ method were the different and smaller set of pseudo-
receptor atoms and incorporation of receptor flexibility. The latter means that the 
position of each pseudoreceptor atom is adapted for optimal interaction with each 
individual ligand. Therefore, if there are n small molecules in the training set, there are 
also n conformations of the pseudoreceptor. The authors considered this to be 
necessary to allow for changes in receptor conformation upon binding, especially 
regarding the direction of hydrogen bonds. However, movement of the pseudoreceptor 
atoms from their average position is penalized by decreasing the calculated binding 
energy.  
 Six different series of ligands were used, varying from compounds binding to the 
cannabinoid receptor to the β2-adrenergic receptor and the sweet-taste receptor. Each 
series of ligands was split into a training set and a test set. The values of r2 were 
smaller than those of Walters and Hinds (1994), ranging from 0.55 to 0.96. Root mean 
square errors of the training set were approximately 0.4, and for the test set 0.7.  
 The cause of the difference with Walters’ research may be due to the reduced 
number of atom types available, the different force fields, the different test sets, other 
superpositions of the ligand, or receptor flexibility. These multiple changes make direct 
65 
 
comparison between the models difficult. It is therefore unclear whether the 
pseudoreceptor models of the future will follow either of the two methods or will make 
use of new methodology, inspired by advances in superposition procedures and 
improvements in the entropy corrections and force fields of docking.  
 
A final interesting application is the use of evolutionary algorithms to help create a 
good energy function for docking. Deng et al. (2004) used two sets of crystal structures 
of sizes 61 and 105 (of which external validation sets of size 10 resp. 6 were taken), 
and correlated the experimental binding energies with the presence of specific atom 
pairs. Since the authors distinguished 17 atom types and 5 relevant distance bins (1 Å 
wide between 1 and 6 Å) there were 5×17×17=1445 potentially relevant descriptors. In 
a first stage non-changing descriptors, highly correlated descriptors and 4-sigma 
outliers were removed deterministically, subsequently a genetic algorithm was used to 
select the best subset of descriptors. By reducing the number of descriptors used in the 
105 compound data set from 456 to 20, the PLS-regression r2 of the test set was 
increased from 0.43 to 0.60, and the r2 of the prediction of the external test set even 
reached 0.64. 
 These results of Deng et al. can be compared to those of Morris et al. (1998), who 
developed a more traditional empirical free binding energy function using 
physicochemical knowledge, traditional force fields, and linear regression without 
feature selection. Since Morris et al. reached r2 values of about 0.95 versus Deng’s 
0.64, it is clear that Deng’s knowledge-based approach could profit from the physical 
and chemical knowledge that has been collected by experimental scientists. 
Incorporation of free energy loss due to loss of flexibility upon binding and the 
influence of direction upon the binding strength of hydrogen bonds would be obvious 
candidates to test for usefulness. Nevertheless, the increasing availability of crystal 
structures will make “knowledge-based” approaches more and more attractive to help 
refine the standard force field approaches.   
 
Conclusion 
The discussed publications make clear that there are probably many alternative areas in 
drug design in which evolutionary algorithms can be applied. Discovery of new, 
promising applications will most likely depend on the steady spread of knowledge and 
usage of evolutionary algorithms in the community of drug designers. Doubtlessly 
there are still many problems in drug design that can be at least partially solved with 
evolutionary algorithms, and many interesting applications may yet follow.  
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9. Conclusion: Evolutionary algorithms in drug design. 
Considering past, present and future. 
 
Evolutionary algorithms have been applied in the field of drug design for over 10 years. 
In this review we have discussed their role in helping solve some of the problems of 
this field. Let us summarize and consider the findings so far. 
 The most important observation is that evolutionary algorithms are useful for drug 
design. This is, of course, necessarily a biased view since few authors would publish 
methods that do not work for their particular problem. However, the wide range of 
applications in which evolutionary algorithms found optimal or satisfactory solutions 
suggest that evolutionary algorithms are quite suitable for application to a wide range 
of problems in drug design, varying from conformational analysis to finding 
quantitative structure-activity relationships and performing de novo design. 
 This success has led to many applications of evolutionary algorithms, several of 
which have been incorporated into commercial packages. Some of the examples 
mentioned in this review are GFA (Genetic Function Approximation) which is now 
part of the molecular modeling package Cerius2, and the commercialized docking 
program GOLD. However, there is also other software that uses evolutionary 
algorithms, like the computer program Spartan that has procedures for evolutionary 
structure optimization. Doubtlessly there are several other software packages for drug 
design on the market in which evolutionary algorithms are a major or minor component. 
One could say that evolutionary algorithms have proven their worth and either already 
possess or at least approach the status of one of the standard optimization methods in 
drug design. 
 While over time evolutionary algorithms have been applied to more and more 
areas of drug design, one could also ask whether their performance in the diverse areas 
has also improved. 
 Looking at the different areas of application it is not clear whether the more recent 
implementations of evolutionary algorithms are more effective or efficient than the 
older versions. If any trends can be discerned, it is towards more complex evolutionary 
algorithms. Unfortunately it cannot be concluded with confidence that this increased 
complexity leads to improved performance due to the dissimilarity in test data sets, 
fitness functions and quality criteria used by the different authors.  
 The progress in the different fields can be summarized as follows: 
-library design: Multiobjective fitness functions have been introduced. Calculations are 
getting more intricate and biologically relevant (2D/3D). Objective weighing of the 
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conflicting objectives, especially diversity and focusing, remains problematical. 
-conformational analysis: The evolutionary algorithms have largely been superseded 
by the directed tweak algorithm, which is more specialized and seems somewhat more 
efficient than the current evolutionary algorithms.  
-quantitative structure-activity relationships: The evolutionary algorithms seem to 
have grown more complex over the years. While some innovations have been 
introduced, notably the use of more complex functions of the descriptors, the novelty 
of most newer publications that involve evolutionary algorithms lies mainly in novel 
types of descriptors or the addition of other descriptor selection methods, not in the 
evolutionary algorithms themselves.  
-docking: The evolutionary algorithms in this field have grown more elaborate and 
complex, however due to the absence of good test sets it is not clear whether this 
increased complexity has led to true progress. Experiments have indicated that 
Lamarckian evolutionary algorithms and island models are useful. 
-de novo design: Evolutionary algorithms for structure manipulation have not seen 
significant advances since the work of Glen and Payne in 1995, however the fitness 
functions have improved from manually weighted parameters to docking. Also, the 
concept of “ease of synthesis” has been introduced, which is very important to ensure 
that the designed molecules can also be created in the laboratory. 
 
Overviewing the past few years of application of evolutionary algorithms in drug 
discovery, one can conclude that a wide variety of chromosome representations, fitness 
functions and mutation operators have been developed for the different problems. The 
basic principles of evolutionary algorithms, however, still remain at the core of all 
these variants, and have proven themselves to be quite a robust and easily applied base 
of design for a range of optimization problems in this field. As the articles reviewed in 
this paper demonstrate, there are obviously a number of cases where evolutionary 
algorithms do not offer clear benefits over other methods such as Monte Carlo search, 
simulated annealing or deterministic optimization methods. There are also some cases 
where evolutionary algorithms achieve clearly satisfactory results and improvements 
over results that have been available so far. Obviously, a clear general conclusion 
cannot be drawn at this point, as there are no elaborate systematic comparisons of the 
different search methods available yet on the subareas of drug design covered in this 
paper. 
 It is interesting to note that almost all of the applications of evolutionary 
algorithms in drug design today use rather basic genetic algorithms, and thus fail to use 
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self-adaptation capabilities. These are usually associated with evolution strategies and 
evolutionary programming (see e.g. (Bäck, 1996) for an in-depth discussion of this 
topic) but can also be used in genetic algorithms. Other developments in the field of 
evolutionary algorithms, such as estimation of distribution algorithms (used in 
bioinformatics by Saeys et al. (2004)) also have so far found no or only extremely 
sparse application in drug design. It would clearly be an interesting issue for future 
research to check whether these algorithmic techniques can deliver more convincing 
improvements over classical methods. While the success of novel techniques for 
optimization would clearly depend on the particular problem studied, the computer 
programs discussed in this review generally use quite basic algorithms, so chances are 
good that adding advanced techniques can improve their performance. 
 While optimization remains important, the current bottleneck in computational 
methods for drug design seems to be the fitness function, since this is often still either 
somewhat arbitrary, like manually weighing different measures of molecular similarity, 
useless, like rediscovering a known molecule, or inaccurate and too slow for extensive 
optimization, like docking. The biggest problem in current drug design seems to be 
calculating/predicting the relevant properties of a molecule, not finding more efficient 
optimization algorithms. 
 Where does that leave evolutionary algorithms? Should computer scientists be 
content by having added evolutionary algorithms to the standard toolbox of medicinal 
chemistry and move on, or is it still possible to do innovative and useful research in 
this area? 
 One reason to continue applying evolutionary algorithms to medicinal chemistry is 
that the collaboration between computer scientists and medicinal chemists itself can be 
fruitful. Medicinal chemists can profit from the knowledge of optimization methods 
and the experience in validation methods that computer scientists possess. Computer 
scientists may learn from the ideas and paradigms of medicinal chemists, which have 
resulted in diverse and ingenious forms of chromosomes and variation methods. These 
inventions could themselves be interesting concepts to be studied, improved, and 
possibly used for other problems by the computer scientists. 
 However, there are also reasons to believe that continued application and 
development of evolutionary algorithms could also be useful for the development of 
new and better computational methods for drug designers. 
 First, prediction methods in drug design are improving each year, therefore better 
fitness functions will become available. When they do, the existing evolutionary 
algorithms can be reapplied with greater success than before. 
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Second, there is the possibility of finding new application domains. Some of these 
might be known problems in medicinal chemistry or drug development that have not 
been tackled yet with evolutionary algorithms. Others would be the newly emerging 
fields, for example the genomic, proteomic and transcriptomic data which are 
becoming available and have to be processed, combined and modeled. Evolutionary 
algorithms may be useful in this process in some capacity. Though the generic nature 
of evolutionary algorithms makes them vulnerable to later replacement by hybrid 
algorithms or specialized optimization algorithms, like directed tweak, the simplicity 
and wide effectiveness of evolutionary algorithms makes them very suitable for 
pioneering new areas. If optimization yields clear benefits yet takes unacceptable 
amounts of computer power, the evolutionary algorithms may be replaced by more 
specialized methods. 
 Finally, the evolutionary algorithms that are currently used for drug design can be 
improved. Though the fitness functions are more important and time-critical, 
evolutionary algorithms that display more efficient convergence while searching as 
much of the search space would be very valuable. If an evolutionary algorithm needs 
fewer fitness evaluations for a good optimization, one can process and suggest more 
molecules in the same amount of computer time. Even with an inaccurate fitness 
function this collection will still give more “hits” than randomly screening, which 
would be very valuable to drug developers. 
 Yet how to achieve such progress? The key to this would lie in closer 
collaboration between medicinal chemists and computer scientists. Procedures that 
have become quite common in computer science, like having standard test sets on 
which an algorithm should work, should be used much more extensively in medicinal 
chemistry to help compare different methods and improvements in a method more 
objectively. The size and diversity of these sets should be sufficient to draw reliable 
and statistically significant conclusions when comparing different methods, the one to 
three test cases which have been used in some articles probably do not adequately 
reflect the diversity of cases in a particular domain. Publicly available reference fitness 
functions would also be necessary to compare different algorithms in a fair way.  
 
The main contribution of medicinal chemists in this process would be the development 
and testing of heuristics. There are no shapeless, featureless problems in drug design; 
each problem has its own inherent, natural constraints. A generic evolutionary 
algorithm that is applicable in all cases and fails to take the information provided by 
the specific problem into account can be improved by including heuristics which make 
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it less generally applicable, but more powerful for that specific application. Developing 
these heuristics and testing them critically would represent an advance in quality, 
which would be more reliable and systematic than the current independent tweaks of 
poorly compared algorithms which rarely take the biochemical nature of the problem 
space into account. As far as we understand the systems, we can develop heuristics. 
And as for the parts of the system we do not understand, we can observe, make 
hypotheses, test methods and learn from their results. This would result in speciation to 
optimally fill the diverse niches in drug design, and represent a true evolution of 
evolutionary algorithms in this field.  
 Looking over the past and current research, the challenges to create computational 
methods to predict reliably the biological properties of molecules are great indeed, and 
will take much time and intellectual effort to resolve. The current problems in 
developing new drugs indicate that the drug design process as well as the drugs 
themselves can only remain affordable if we can find ways to intelligently combine the 
growing available biological information with the possibilities of quickly and 
effectively searching the huge collection of drug-like molecules. This is a major 




ACTIVE SITE: the part of a protein which binds the messenger molecules or catalyzes the 
biochemical reactions. 
CHROMOSOME: named after the strings of DNA which contain the genetic information of 
biological organisms, chromosomes in evolutionary algorithms are the data structures which 
contain the genetic information/genotype of one individual candidate solution. Often, 
especially in genetic algorithms, a chromosome is a vector of bits or numbers. 
CROSSOVER: another name for the recombine-function of evolutionary algorithms. 
HYDROGEN ACCEPTOR: oxygen or nitrogen atom in a molecule with a free electron pair 
that can bind to a hydrogen atom of a hydrogen donor. 
HYDROGEN BOND: the attractive force between a hydrogen acceptor and the hydrogen 
atom of a hydrogen donor. Is generally the predominant binding force between a ligand and 
its receptor. 
HYDROGEN DONOR: oxygen or nitrogen atom in a molecule that is bonded to a hydrogen 
atom. This hydrogen atom can bind to a free electron pair of a hydrogen acceptor. 
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LAMARCKIAN EVOLUTION: an individual’s phenotype is optimized by a local search. The 
information of the phenotype is subsequently written back to the genotype, which then 
undergoes normal mutation/crossover. 
LEAD (COMPOUND): a compound that seems to have a desirable biological activity and 
may be developed further into a drug. 
LIGAND: a molecule that binds to a large biological molecule (usually a protein). 
MOLECULE: a collection of atoms which are connected by bonds. On a simple level a 
molecule can thus be considered to be a graph in which the nodes are the atoms and the 
edges are the bonds. The specific physical and chemical restrictions on this graph are that 
each atom type has a maximum number of bonds, generally ranging from 1 to 4, and that 
the length of the bonds, the preferences for certain bond angles and finally the interplay of 
the attraction and repulsion between the atoms cause each molecule to assume a distinctive 
range of three-dimensional structures, called conformations. 
POLING: optimization method developed by Smellie et al. (1995) that ensures diversity of 
the individuals in the population by modifying the fitness function in such a way that similarity 
to other individuals is penalized. 
q
2: a measure of statistical significance. It is determined by leaving a subset of the data 
(often of size one) out of the training set, training a model with the remainder of the training 
set, and predicting the dependent variable of the subset. This is done for all items in the 
training set, the r2 value of the resulting predictions is called the q2. It is considered to be 
less sensitive to overfitting than r2 and therefore a better measurement of the quality of a 
statistical model. 
r
2: a measure of the statistical significance of a model. Its values are between 0 (no linear 
correlation between the independent and dependent variables) and 1 (a perfecty linear 
correlation between the independent and dependent variables). It can be calculated by 
comparing the values that a model gives () to the observed values () by the following 
formula:  ≡ 1 − ∑ ( − ) / ∑ ( − )

 , where  is the means of the observed values. 
REAGENT: a molecule that is used in a process in which it will react with another molecule, 






ROULETTE WHEEL SELECTION: A method to select good individuals with higher 
probability than bad individuals as parents of the next generation. All members of the 
population are assigned a segment on a wheel, usually in proportion to their relative fitness. 
Subsequently random points on the wheel are selected and the corresponding population 
members become the parents of the next generation (Parrill, 2000). 
SPECIATION: A large part of the population of individuals is very homogeneous: although 
there are officially many solutions, it is in reality just one solution with small variations. 
Usually one wants to prevent this and develop several solutions which differ significantly. 
SPLINE FUNCTION: commonly written as f(x)=<a-x>. This function returns 0 if x is greater 
than a, and a-x if x is smaller than or equal to a. 
TARGET (RECEPTOR): the biological macromolecule to which a drug or drug candidate 
should bind.  
TORSION ANGLE: Angle indicating how much one end of a single bond is rotated with 
respect to the other end. For four bonded atoms A-B-C-D, the torsion angle of the bond B-C 
is defined as the angle which the C-D bond makes with the plane in which A, B and C lie.  
TOURNAMENT SELECTION: A method to select the parents for the next generation of the 
evolution in an evolutionary algorithm. Tournament selection works by randomly picking a 
certain number of individuals out of the population and letting the best of them become a 
parent, repeating this process as often as is required (Parrill, 2000).  
TRANSITION STATE: When a molecule is broken down by an enzyme, the enzyme first 
twists it into a strained conformation to make the subsequent reaction(s) easier. This 
strained state is called the transition state, since it is the phase a reacting molecule must go 
through in order to form the product.  
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Nowadays millions of different compounds are known, their structures stored in 
electronic databases. Analysis of these data could yield valuable insights into the laws 
of chemistry and the habits of chemists. We have therefore explored the public 
database of the National Cancer Institute (>250,000 compounds) by pattern searching. 
We split the molecules of this database into fragments to find out which fragments 
exist, how frequent they are and whether the occurrence of one fragment in a molecule 
is related to the occurrence of another, non-overlapping fragment. It turns out that some 
fragments and combinations of fragments are so frequent that they can be called 
“chemical clichés”. We believe that the fragment data can give insight into the 
chemical space explored so far by synthesis. The lists of fragments and their (co-) 
occurrences can help create novel chemical compounds by i) systematically listing the 
most popular and therefore most easily used substituents and ring systems for 
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synthesizing new compounds, by ii) being an easily accessible repository for rarer 
fragments suitable for lead compound optimization, and by iii) pointing out some of 
the yet unexplored parts of chemical space. 
 
Introduction 
Over the last two centuries, chemists have synthesized many millions of structures. 
Two of the largest chemical databases, the Beilstein1 and the CAS2, contain over 8 
million and 25 million compounds, respectively. Such large collections of compounds 
could give much insight into chemistry, both into what kinds of compounds can be 
made with current chemical technology, and into which parts of chemical space have 
been extensively investigated or, conversely, barely explored. 
 In most investigations so far, databases have been used for classification of 
compounds: for example, when is a compound drug-like3,4,5? Or which substructures or 
properties correlate with mutagenicity6,7?  
 Relatively unexplored are the possibilities of general databases: collections of 
molecules for which no data other than their structure is available. The only 
investigations known to us which had this purpose8,9 did so to extract a catalogue of 
rings respectively substituents for drug designers. However, it seems desirable to get 
more information out of those general databases than just rings. We could also learn 
much about chemistry and the habits of chemists by studying which substructures and 
substructure combinations occur. 
 In this investigation we want to delve deeper into the knowledge stored in the 
molecular structures. This would not only give us an extensive catalogue of fragments 
to re-use in synthesis of drugs and other compounds, but also insight into “chemical 
habits”. What kinds of compounds are made frequently, and which substructures are 
relatively rarely found together in a molecule? Some of these rare combinations might 
indicate barely explored parts of chemical space, potentially interesting for designing 
new compounds. 
 In this work we will use the name “chemical clichés” for some of the most-
occurring fragments and frequently co-occurring pairs of fragments. The word “cliché” 
originated in the French printing industry where it denoted a stereotype, a kind of 
stamp of for example a picture that was pressed on the paper to produce the same 
image many times. Nowadays the word cliché is mainly used to denote a trite 
expression, such as “missed by a mile” or “top research institute”. However, some 
classes of chemical compounds also seem to be based on the same “stamp” with only 
slight variations, such as benzodiazepines and tricyclic antidepressants. Also, single 
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fragments like the benzene ring can occur extremely often in molecules. We think that 
the word “cliché” is useful to describe this reuse of ideas, while stressing that the 
current templates might not be the only ones that are viable. 
 Then the question remains how to extract knowledge from chemical databases. 
Knowledge is usually found in occurrences and patterns: what occurs in nature, what 
does not occur, and which events occur together? What is correlated with what? 
Looking at the molecular structure as a whole is not very useful, since all chemical 
structures in a database are unique, so on that level they are incomparable. Splitting the 
molecules into the chemically smallest fragments, the atoms, will yield no more 
information than the periodic table. One should therefore look for chemical knowledge 
at a level between these extremes, and that is the level of the molecular fragments. 
 In this paper we first discuss our choice of fragmentation method. Then we will 
describe the method we used to detect whether two different fragments co-occur more 
or less often than expected, and thereafter we will present the results of the fragment 
mining and co-occurrence analysis. We will conclude with a discussion of our findings, 
suggestions for application of the data obtained, and directions for future investigations. 
 
Database 
In this investigation we used the public database of the United States National Cancer 
Institute (NCI). The August 2000 version, which we mined, contains 250251 
structures10. The molecules in this database have been selected to be tested against 
cancer, so were deemed by the database compilers to possibly have biological activity. 
Since many of the compounds are experimental and have not been tested on 
bioavailability and safety in humans, the diversity in structures is quite large, and 
should give a decent cross section of the range and preferences of chemical synthesis. 
 
Fragmentation method 
To find patterns in structures, the first step is to break the molecules into fragments. 
Two categories of fragmentation methods can be distinguished: the “full substructure 
set”, in which all possible 1, 2, 3 …n-atom sized substructures of a molecule are 
detected, and “molecule parts”, in which a molecule is divided into a number of non-
overlapping substructures. 
 While the full substructure set would give all information possible, in practice it 
yields huge numbers of substructures per molecule (several thousands for even a 
medium-sized molecule). This makes such kind of data mining computationally very 
expensive, especially for large collections of compounds. For an exploratory study 
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such as this, a “molecule parts” method would be more suitable, since there are fewer 
parts, they do not overlap, and they correspond to chemically intuitive units. 
 The next question is at which point to “break” the molecules. The two main 
methods here are graph splitting11,12,13 and virtual retrosynthesis14,15,16. Graph splitting 
breaks molecules at topologically interesting points, such as the bond between a 
substituent and a ring, while virtual retrosynthesis uses specific rules based on 
chemical reactions, and breaks for example ester bonds. Both methods yield 
manageable sets of substructures (10,000-100,000 for a medium sized database). From 
a chemical point of view, the retrosynthesis method seems most logical, however it 
does not reflect actual syntheses very well as for example Vinkers et al. found out14. 
The reason is that chemical reactivity depends on steric and electronic factors which 
are for a large part determined outside the three or four atoms of the “breakable bond” 
and its neighbors. Conversely, synthesis can often create bonds (such as alkane C-C 
bonds) which are not considered to be cleavable by most retrosynthesis algorithms, 
because typically only a few dozens of the hundreds of organic reactions are 
incorporated into the software. A last disadvantage is that different retrosynthetic rules 
give different fragment sets. In contrast, graph splitting is quite reproducible, easy to 
implement and divides structures in chemically intuitive units of “ring systems” and 














Figure 3.1: a. A drug molecule (pyrilamine) b. Framework of pyrilamine 
according to Bemis et al.11, consisting of only the ring systems and the 
atoms that directly connect the ring systems. c. Framework of pyrilamine 
according to our definition so without substituents attached to the rings. This 





Deciding to do graph splitting is however not enough, since graph splitting can be done 
in a number of different ways. Bemis et al.11 iteratively cut off all 1-connected atoms, 
so that only “substituents” and frameworks were left, the frameworks being the ring 
systems with the part of the linkers that directly connect them, see Figure 3.1. 
 We decided to go one step further and also split up the frameworks into ring 
systems and linkers. We therefore ended up with splitting molecules into substituents, 
ring systems, and linkers of different orders (linking two ring systems, three ring 
systems, etc.) See Figure 3.2 for an illustration of our fragment classes and the 







Figure 3.2: Our algorithm breaks the bonds between ring systems and the 
rest of the molecule, and thereby splits the molecule (in this example folic 




Figure 3.3: Storage format of ring systems and non-ring systems. While 
ring systems are stored as normal molecules, substituents and linkers 
include one or more “branching atoms” that encode the symbols of the 





The ring structures were stored as normal molecules, only without hydrogen atoms 
(similar to the format of the NCI database itself). For the substituents and linkers we 
considered it useful, like Bemis et al.12, to encode which atoms of the substituent/linker 
bind to the ring systems, as well as to which atom types they bind. We therefore 
encoded the ring attachment atoms as special types, the “BX” atoms, where X was the 
elemental symbol of the ring atom to which the substituent was attached. This 
encoding is illustrated in Figure 3.3. 
 Splitting molecules in this way can already yield useful information, such as 
which ring systems occur, and which do not (like an N6-ring). But we could get even 
more information by also recording the frequencies of the substructures, as this would 
allow us to analyze frequency distributions and to explain why some fragments are 
more prevalent than others. 
 As a practical point, we had to find a method to encode the fragments uniquely, so 
that of each fragment mined we could determine whether it was already in the database 
or of a new fragment type. For this problem (the so-called “canonicalisation problem”) 
various algorithms and notations have been developed, such as Unique SMILES17. In 
this investigation, we implemented a canonical code of which the first part included the 
number of atoms, the number of rings (in the case of ring systems) and the number of 
attachment points (in the case of substituents and linkers). The second part contained 
the atoms, which were sorted first on their number of neighbors and the number of 
bonds of those neighbors, second on atom type and finally on hybridization (sp, sp2, 
sp3). Since the fragments were relatively small, this simple method worked well.  
 
Co-occurrence analysis 
After the entire molecule database was split into fragments we performed a co-
occurrence analysis: which fragments were unexpectedly often found together, and 
which seemed to “avoid” each other? 
 Of course, two fragments that are frequent would occur much more often together 
than two infrequent fragments; however, that would not necessarily mean that there is a 
relationship between the two. Therefore we decided to do a stochastic experiment. 
 First, we selected those fragments which occurred in more than 20 molecules (in 
order to obtain statistically significant and chemically useful results). Then we 
“simulated” an NCI database by randomly dividing the different fragments over as 
many “molecules” (bins) as they were part of in the real database. So if a certain 
fragment occurred in 500 molecules in the original database, it was divided over 500 
randomly chosen bins of the 250,251 available in the simulated database. We counted 
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how often each combination of fragments occurred, and repeated the simulation a 
thousand times. These results were compared with the co-occurrence counts of the NCI 
database. 
 For example, if we had taken a database of 1000 molecules, in which 500 phenyl 
rings occur and 100 methyl groups, there would be on the average 50 co-occurrences of  
these two groups. An experiment would find that they co-occurred together about 50 
times, with a standard deviation (SD) of about 4.7. However, if in the real database 
they occur 75 times together, which is 5.3 SD from the expected value, this indicates a 
correlation, which may have synthetic and/or biological reasons.  
 
Results of fragment finding 
The mined NCI database contained 250251 compounds. These molecules were split 
into ring systems, substituents, and several types of linkers, in total 13509 different 
ring systems and 52103 different non-ring fragments. Of these non-rings 19602 were 
unconnected fragments, mostly anions such as sulfate and molecules without rings. 
More interesting were the other non-ring fragments: 18015 were substituents, 9675 
linked two ring systems, 2531 linked three ring systems and 2280 linked four or more 
ring systems. The most highly connected linker was attached to eighteen ring systems. 
The number of different fragments in the largest categories, as well as the total 
occurrences in the molecules and some example fragments are shown in Table 3.1.  
 
Visual inspection of the fragments and their occurrences led to the following 
observations, some of which were already known qualitatively, but which could now 
be confirmed quantitatively through the data mining: 
1) Many of the ring systems and branches contain metal atoms or metallic atoms 
such as boron. In the case of rings, 2722 out of 13509 (20%) contained atoms 
other than C, N, O, and S, such as As, Fe, B and Si. Of the substituents, 1736 
out of 18015 contained atoms other than C, N, O, S, and the halogens, less 
than 10%. The two and three-connected branches had 11% and 24% 
respectively, while most linkers with six or more attachment points contained 
metals or less common heteroatoms (B, P, Si, and such). 
2) In general, the larger the ring or branch, the smaller its frequency seems to be.  
3) Metals and higher-weight non-metallic elements both occur relatively rarely in 
fragments and make a ring or branch occur less often. Carbon atoms dominate 
rings and other fragments, followed by nitrogen and oxygen, which are in turn 
more prevalent than sulfur, phosphorus, and finally the metals. 
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4) In branches, a higher number of attachment points seems to mean that it is less 
used. Bemis et al.11 did not find any frequent frameworks with 3-linkers or 
higher-order linkers in the Comprehensive Medicinal Chemistry (CMC) 
database18. Tables 3.1 and 3.2 confirm this observation.  
5) The only exception to the rule that the more attachment points a linker has, the 
less frequent it is, is going from 5-attached linkers to 6-attached linkers. 
Inspection of the structures of the 6-linkers shows that most of them are 
symmetrical and therefore possibly easier to synthesize. However, 6 and 
multiples of 6-linkers are uncommonly popular (Table 2; compare 12 to 11 
and 13, 18 to 17) – probably this is due to metal complexes and the high 
symmetry possible (both 2- and 3 fold symmetrical). Perhaps investigations of 
larger databases could confirm whether there really is a “rule of six”.  
6) The ratio of the occurrence of fragments to the number of unique fragments 
decreases as one goes from substituents to rings to linkers. The ring ratio 
(13509 unique rings, together occurring 416867 times in the database) is 31, 
for the 18374 substituents it is 33, for the 2-linkers 10, for the 3-linkers 3.2 
times and for the four-linkers 2.5. It may be that the more unique fragments 
there are in a category, the more lopsided the distribution will be.  
 
As illustration of our results, the top ten fragments of the most common fragment 
families are shown in Table 3.3. 
 
Results of the co-occurrence analysis  
Our investigations found 65612 fragment types in 250251 molecules. Correlating all 
these fragments to each other would have resulted in about 4 billion correlations, but 
most of these would be meaningless since about 70% of fragments occurs only once in 
the database. To reduce computational cost and find only the co-occurrences in a 
decently sized set of molecules (we set the threshold somewhat arbitrarily to at least 20 
molecules), we only calculated co-occurrences for fragments which occurred in 20 or 
more molecules – 1895 fragments, just 2.9% of the total. Among these fragments were 
also some metal-containing and therefore less interesting fragments, which we 
removed. The final set therefore contained 1730 different fragments, 2.6% of the total 
number. 
 We created one thousand simulated databases, as described in the methods section, 
and calculated the expected occurrence of each pair of fragments, as well as the 
standard deviation of these co-occurrences (for among different simulations, the  
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Table 3.1: Overview of some of the fragment databases we created by fragmenting the NCI 
database. For example, the database of substituents (groups attached to only one ring 
system) contains 18,374 different types of substituents, which together occur 617,722 times 
in the NCI database. Also given is an example of the particular type of fragment, for the 
substituents this is the methyl group attached to a carbon atom in a ring system. 
 








13509 416867  
 
 








































Table 3.2: Overview of the number of fragments linking seven or more ring 
systems. For example, there are 15 unique fragments which are attached to 
nine ring systems simultaneously. 
 
Number of attachment 
points 
7 8 9 10 11 12 13 14 15 16 17 18 
Number of fragment 
types  




Table 3.3: The most frequently occurring fragments in the NCI database. 
Listed are the top ten ring systems, substituents, 2-linkers and 3-linkers. 
The numbers in each cell represent the number of occurrences of the 
fragment in the database and how many percent this is of all occurrences of 
fragments of its type. For example, the keto substituent (C=O) occurs 
77,907 times in the database and thereby represents 13% of all substituent 
occurrences; if one would randomly pick a substituent from a molecule, the 
chance is 13% that it is a keto group. The numbers in the bottom row are 
the total percentage of the top ten fragments. 
 

































































































































































































Total 62% 66% 32% 21% 
 
number of co-occurrences of a pair of fragments can vary). Then we compared the 
expected co-occurrences and the deviation in SDs (the z-values) to the real co-
occurrences in the NCI database.  
 The distribution of z-values of a sample simulated database yielded a Gaussian 
like distribution, as expected (Figure 3.4). The distribution of fragment co-occurrences 
in the NCI database in the same figure is, however, remarkably different. 
 
         
 
Figure 3.4: Overview of the number of standard deviations that the real co-
occurrence of a fragment pair differs from how the co-occurrence would be 
if the distribution of fragments over the molecules in the database were 
random. The X axis displays the deviation range, the Y-axis the number of 
pairs in a certain range. Only pairs which occur over 20 times are counted 
here. The distribution of the simulated (random) database is Gaussian-like, 
but the real database has lots of fragments co-occurring much more or 






















Real database Simulated database
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The NCI database turns out to possess both a large number of fragment pairs which 
seem to avoid each other (1110 of z-value<-3), and an even larger number of fragment 
pairs which seem to group together (2897 of z-value>3). 
 
Table 3.4: Some fragment pairs which occur much less frequently together 
in one molecule than expected, and therefore seem to avoid each other. For 
example, the phenyl-group and the tetrahydrofuran group (row 3) are both 
very prevalent fragments, and would be expected to occur together in about 
2653 molecules of a 250,000 molecule database. However, in the NCI 
database they are combined in only 270 molecules, giving an “expectation 
fraction” of 270/2653 or 0.10. This relation is highly significant, being 67 
standard deviations under the expected value. 
 












































We first sorted our results on statistical significance, reaching z-values of up to 490 and 
down to -65. However, after viewing the results we realized that a significant effect 
does not have to be a very large effect. The most statistically significant negative 
correlation is that between the benzene and tetrahydrofuran rings, which occur about 
10 times less together than expected. The second most significant correlation is 
between benzene and pyridine, only a 2.4 fold difference. However, lower significance 
is given to higher co-occurrence factors, such as 6.5 for the benzene – tetrahydropyran 
pair. Therefore we sorted all pairs that had sufficient z-values on their ratio of expected 
occurrence to actual occurrence. To illustrate our results, we have listed six of the most 
“avoiding” combinations with z-values<-5 (Table 3.4). These combinations were 
expected to occur at least five hundred times in the database, but were found much less 
frequently. 
 Even more numerous than the avoiding pairs were fragments which seemed to 
group together. Many of them co-occur so often, that they could be termed “chemical 
clichés”. Often the z-values of the correlations were much bigger for these groups than 
for the avoiders. In Table 3.5 we show some of the fragment pairs with the strongest 
enrichment in occurrence for clichés which occur over a 1000 times, over 200 times, 





















Table 3.5: Some fragment pairs which co-occur much more often than 
expected; shown are four fragment pairs which occur in more than one 
thousand molecules, four pairs which occur in more than two hundred 
molecules, and four pairs which occur in more than fifty molecules. For 
example, the tetrahydrofuran group and the –CH2OH group would be 
expected to occur only 122 times together, but the pair appears in 2292 
molecules (the explanation is of course that these would be ribose-
containing molecules). The “gain factor” here is 2292 divided by 122 is 19, 
and the relation is highly significant, since the found occurrence is over 200 
standard deviations from the expected occurrence in a random database 
(making the chance that their occurrence is independent under 
0.0000001%). 
 

















































































0.39 68 173 
 
Discussion 
In this work we performed fragment mining and co-occurrence analysis on a diverse, 
medium-sized chemical database. In this section we discuss what we can learn from the 
results, compare our work with that of other investigators, consider uses of the 
fragment data acquired, and hypothesize about possibilities for extension and 
improvement of this work. 
 
First, we summarize our conclusions from the results obtained. 
 Our first observation confirms that of Bemis et al.11,12 and Xue et al.13, namely that 
chemical fragment distributions are extremely lopsided, with a few frequent fragments 
and many infrequent fragments. Our investigations of several different categories of 
fragments (rings, substituents, and linkers) however refine this rule; it seems that the 
classes of the most prevalent fragments, substituents and ring systems, have the most 
lopsided distribution. In the less used classes of fragments (such as 3- or 4-connecting 
linkers) the differences in occurrence between the “top-10” and the “bottom-10” 
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fragments are less pronounced (Table 3.3). It may be that in a category of fragments 
which has not yet been used often, strongly preferred substructures cannot arise or have 
not arisen yet. 
 One could speculate on what influences the occurrence of a certain fragment. 
Three factors come into mind. First, synthetic feasibility/availability; how easy is it to 
synthesize the fragment, or is the fragment already incorporated into commercially 
available starting materials? The phenyl group would be a good example of this. 
Second, versatility; how easy is it to attach other groups to it. Third, popularity: a 
popular fragment accumulates more and more knowledge which makes it more 
attractive for use by others, since there is more knowledge available for its 
manipulation. This could lead to a kind of “winner takes it all” effect, in which 
relatively small differences in fragment quality may lead to big differences in use. 
Distinguishing between these possibilities would require further study, for example to 
find out how many combinations with other groups a certain fragment has per 
occurrence. 
 The fragment co-occurrences give other insights into chemical space. From 
looking at the structures of the fragments that seemed to avoid each other we could 
think of different reasons why fragments co-occur less frequently than expected. The 
first reason may be that there are different classes of compounds, such as natural 
compounds and “synthetic” compounds. In natural compounds, sugar and nucleobase 
systems may be more prevalent, while in many industrial chemicals the phenyl group 
plays a dominant role. An example would be the third pair of Table 4, in which the 
tetrahydrofuran ring (as part of ribose) would occur in the natural compounds, while 
the phenyl is more likely to occur in “synthetic” compounds. A second reason may 
have to do with ease of combination: a keto group cannot be attached directly to a 
phenyl ring, and therefore tends to occur less often with it. It can of course be attached 
to another ring system in the same molecule, but since effectively one part of the 
molecule has no positions available for it, the overall chance of the keto group 
occurring in a phenyl-containing molecule will be lower than average. Finally, some 
combinations may be found by the statistics to be less frequent than expected since one 
group is used as a replacement for the other group. Thus, bromine and chlorine 
relatively rarely occur in the same molecule, possibly because they have similar 
electronic and chemical properties. Likewise, napthalene and benzene can take similar 





Let us now turn to the possible reasons for the clichés. Looking at the clichés we found, 
the first likely reason for their existence is that synthetically the clichés do not 
represent the smallest building block of a molecule. If moieties such as ribose (instead 
of unsubstituted tetrahydrofuran) are the real building blocks used to create larger 
molecules, the co-occurrence of the tetrahydrofuran ring (present in ribose) and -OH 
groups is certainly not surprising.  
 The explanation for a number of other clichés is that they represent specific 
classes of biologically active compounds. As examples, we found dihydrocholesterol 
analogs (Table 3.5, fifth pair), doxorubicin analogs (Table 3.5, sixth pair), mitomycins 
(Table 3.5, ninth pair) and folic acid derivatives (not shown) listed as clichés with 70- 
to 2700-fold occurrence relative to expectation. These clichés do not so much reflect 
the choice of building blocks, but rather show the active structures nature provided and 
chemists explored around. 
 Let us now compare our results with those of others. Fragment mining has been 
done by several researchers, both as main research subject11,12,13 and as a preparation 
for virtual synthesis14,15,16. In the methods section we already touched upon the 
different types of fragmentation, of which the retrosynthetic fragmentation, though not 
chemically perfect, has been applied and used by those researchers who want to 
perform virtual synthesis as a prelude to real synthesis. Studies with graph splitting 
have mainly focused on exploration of the (drug like) molecule space. 
 Co-occurrence analysis as reported here has to our knowledge not been done yet, 
and we therefore will focus our comparison on the diverse types of fragment finding as 
performed by other investigators and ourselves. The differences between our research 
in fragment frequency and that of others are caused by three factors: the database 
mined, the breaking points considered, and the ways in which the fragments are 
represented and distinguished. 
 Let us first compare the databases mined. Bemis et al.11,12 used a rather small 
database, the Comprehensive Medicinal Chemistry (CMC) database18, which was 
filtered to get an even smaller database containing only drugs and drug candidates 
(5120 compounds). On the other hand, Lewell et al.9 used a big database containing 
several millions of compounds, many more than we used. However, the relatively 
small size of the NCI is sufficient for an exploratory study such as ours, and our 
algorithm is fast enough to make mining of databases of 10 million compounds quite 
doable on a personal computer. Fragment mining, though not as “new” anymore as in 
199611, is something that has to be done periodically since the amount of data available 
is also growing and offering new opportunities. Another aspect is the quality of the 
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data; a drug-like database might give more valuable information for the pharmaceutical 
industry, but might give a skewed image of chemical synthesis. A more general 
database, such as the NCI that we mined, seems more appropriate for getting general 
information about chemistry, but will give fragments which would be unsuitable for 
drug development. 
 The investigations also differed in the breaking points considered. Most authors 
have divided drug molecules into substituents and a kind of framework that contains 
ring systems and linkers. Bemis et al.11,12 considered the substituents and the 
frameworks, which were the ring systems together with parts of the linkers. Lewell et 
al.9 concentrated on the rings, Xue et al.13 on a framework-like part of the molecule 
called the scaffold. To our knowledge, there has not been a separate investigation of 
linkers, especially not of the rarer linkers with more than two attachment points. 
However, linking ring systems together is important for drug development, and a 
catalogue of linkers of varying length could have similar usefulness as the ring system 
catalogue compiled by Lewell et al.9 So the use of the linker breaking points by our 
method yields additional useful information. 
 The last point is substructure representation. The aspects relevant here are the 
representations of the atoms and bonds in the substructure itself, and the encoding of 
the attachment points. The atoms and bonds can be given a general type (like a 
wildcard that can represent any atom, or any heteroatom), which results in more 
“general” fragments. These general fragments will necessarily be fewer in number than 
the original (normal) chemical fragments. A more important issue, from a chemist’s 
point of view, is that such a general fragment can encode many substructures of 
possibly vastly differing ease of synthesis. So before one chooses between using more 
general or more specific fragments, one should consider whether one just needs to 
know if frameworks with approximately the right size and shape are available, or 
whether one rather needs a specific substructure with a high chance to be synthesized 
easily. 
 Xue et al.13 treated the substituents as unattached R-groups and did not distinguish 
between a methyl attached to a carbon ring atom and a methyl attached to a nitrogen 
ring atom. We and Bemis et al.12 do distinguish between those options. For the ring 
systems, Lewell et al.9 also considered ring systems with different attachment points 
(for example ortho- and meta-substituted phenyl) as distinct ring systems. Chemically, 
some positions in rings are easier to modify than others, but it is unclear how important 
this difference in reactivity is. Would other substitution positions be impossible? It is 
difficult to estimate the advantage gained by using only known ring substitution 
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patterns against the loss of perfectly viable ring systems which accidentally have not 
been substituted in that particular pattern yet. For initial exploration of chemical space 
around a lead molecule, one would prefer substructures which are easy to incorporate 
in the molecule. For the fine-tuning of structures, however, it would be better to have 
more candidates available, even if not much is known yet on some of them. We could 
therefore say that the level of detail of substructure representation can be chosen 
relatively freely but different levels of details will be preferred for different phases of 
molecule design and by different chemists. Some chemists might choose a maximum 
amount of attachment information, while others might allow more “wildcards” in the 
structure. Ideally, one would therefore want to have a number of fragment databases, 
each with its own specificity, from which the most appropriate level of specificity can 
be chosen. 
 The next point is how we can make use of the fragment libraries and correlations. 
 The first use of the fragment libraries would be to give chemists more ideas for 
lead optimization. While investigators such as Lewell et al.9 mainly considered ring 
systems that are sterically and electronically similar to a lead ring system to be useful 
for chemists, we suggest that using the most common as well as the least common 
fragments could also be effective. The most common fragments could be used as a kind 
of checklist in the first and most exploratory phase of lead optimization; these 
fragments are apparently often easy to incorporate into molecules, and thus can lead to 
fairly diverse exploration at relatively low costs in time and effort.  
 For example, consider benzodiazepines, which are widely used as tranquilizers. A 
typical benzodiazepine is shown in Figure 5. 
 












Almost all benzodiazepines use the phenyl ring as group. However, is this biologically 
necessary or just usage of the well known phenyl cliché? Using the program 
SciFinder19 to search the CAS-database, we found over 14,000 phenyl-benzodiazepine 
compounds. Going down in our ring system list of Table 3.3, we found that the second 
and third most popular ring systems, pyridine and cyclohexane, have been tried a few 
hundred times as phenyl substitutes. The numbers four to ten of our list have in general 
only been used a few times up till a few dozen times, but numbers 6 (tetrahydrofuran), 
8 (tetrahydropyran) and 10 (purine) never. So while the compounds in Figures 6a and 
6b have been made, 6c and 6d are yet unexplored.  
 While it may be possible that these particular ring systems are difficult to 
incorporate, the search strongly suggests that by just going over the top positions of a 
list of ring systems or substituents one can easily generate a few dozen variations on a 
lead compound. Since all of these fragments are quite frequent, many of the 






























Figure 3.6: Non-phenyl benzodiazepines. Compounds with the first two 
types of attached ring systems (pyridine (a) and naphthalene (b)) are known. 
However, neither the tetrahydropyran (c) nor the purine ring (d) have so far 



























Figure 3.7: Finding cinchocaine derivatives: examples of local-anesthetic 
like tails which have been used (a, b) and which have not been used yet (c, 
d) with the quinoline group. 
 
Another example of clichés is the class of local anesthetics, many of which have a 
phenyl ring (procaine, benzocaine, prilocaine), with as one of the few exceptions 
cinchocaine, which has a quinoline ring instead of the phenyl. Searching at the typical 
local anesthetic tail-pattern of C(=O)OCxN in the substituent database yields many 
variants of the standard COOC2H4N(C2H5)2 pattern, all of which have been tried with 
phenyl (which is not surprising, since phenyl is the “golden standard” among rings), 
but some of the less frequent substituents have never been paired yet with the quinoline 
group (Figure 7). Some of these might also be worthy of further investigation. 
 Selecting fragments for rarity, conversely, can also pay off if the current scaffold 
is patent-protected; rare substructures can be especially helpful in this case as it is 
unlikely that many experiments have been done on them. Also, industries could 
deliberately add the more attractive of the rare fragments to their compound libraries 
and collections. In this way the libraries will become more diverse and thereby increase 





The fragment co-occurrence data can also have some applications. First, co-occurrence 
analysis can help database analysis by automatically finding clusters of biologically 
active or well-investigated structures. This can help “summarize” the database for a 
new user or alert an expert that a certain class of compounds is suddenly becoming 
popular. Secondly, co-occurrence analysis can add information to structure searching in 
databases. Often, when a substructure is entered, a long list of structures, each with its 
specific combination of R-groups, is returned. While currently there is only little 
attention paid to the number of times a certain R-group appears, a co-occurrence 
analysis could direct the chemist’s attention to the fact that a certain combination 
occurs quite often. So there would be something interesting with that combination.  
 A third application would be for chemists to find relatively unpopulated places in 
chemical space. For example, there would not be many good reasons why phenyl and 
tetrahydrofuran could not be combined into one molecule; the relative absence of the 
combination (Table 3.4, pair 3) suggests that a compound combining these groups 
might be worthwhile to synthesize.  
 In chapter 4 of this thesis we describe a procedure for generating new drug-like 
molecules. The molecules we discovered were small and relatively simple, but often 
not yet known in the literature as a compound or as a substructure of other compounds. 
The molecule we show in that article has a phenyl ring attached to a piperidine ring and 
a CH2OH group. While the phenyl ring itself is very much a chemical cliché, it usually 
avoids both the piperidine ring (avoiding pair rank number 75) and the CH2OH group 
(avoiding pair rank number 78) according to our data. This suggests that we might also 
be able to use this process the other way around: by combining fragments that are 
common but seem to avoid each other a person or computer program could find simple 
structures that have not been synthesized before. 
 Would we indeed be able to discover new compounds by considering the negative 
co-occurrences? To check that, we looked at three different pairs of rings, which were a 
strongly avoiding pair (phenyl and tetrahydrofuran, rank 7 of the list), the less strongly 
avoiding pair of phenyl and the somewhat less frequent piperazine ring (rank 75), and 
the cliché of the C4N2 ring depicted in the table together with the tetrahydrofuran 
(Table 3.6). The most strongly avoiding pair appears in about 10,000 molecules in the 
CAS database (so at a ratio of about one in 2,000 compounds in the database). 
Assuming independence, one would expect that the phenyl-piperazine pair occurs less 
often since the piperazine is (at least in the NCI database) rarer than tetrahydrofuran. 
However, since the groups avoid each other less, this combination occurs 
approximately 60,000 times, so six times as many. Finally, the C4N2-tetrahydrofuran 
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cliché, despite both rings being relatively rare on their own, occurs in over 111,000 
compounds, since this combination is the core of uracil and thymidine molecules. 
 
Table 3.6: The avoiding groups can indicate “holes” in chemical space, 
where relatively little research has been done. In the first column of this 
table pairs of fragments are shown. The second column contains the z-
value of correlation. Positive z-values mean that the fragments group 
together, negative z-values mean that they avoid each other. The third 
column contains a specific substructure which contains both fragments. We 
have always taken a substructure which contains the fragments directly 
connected to each other, and when there were multiple coupling 
possibilities, the substructure which was most frequently found by 
SciFinder19. In the final column the estimated number of known molecules 
containing the substructure is shown. So, the phenyl and tetrahydrofuran 
seem to avoid each other rather strongly (z=-57), and the substructure with 
the tetrahydrofuran attached at its 2-position to phenyl indeed occurs in only 
about 11,000 molecules.  
 

















It may also be possible to apply fragment analysis and fragment co-occurrence analysis 
to other problems such as measuring chemical diversity. While there are several 
different measures of chemical similarity, the methods most similar to ours are those 
which make fingerprints of molecules based on the presence and absence of fragments 










fingerprints usually work with only very small fragments, such as “an atom in a 
multiple, nonaromatic bond located two bonds away from an atom with at least two 
heteroatom neighbors”. In contrast, our method uses much larger and more specific 
fragments and generates only a few fragments per molecule, which will lead to a much 
larger emphasis on changes in framework (so naphthalene will be significantly 
different from benzene, though they both have aromatic carbon atoms). Diversity could 
be estimated by for example dividing the number of unique fragments by the size of the 
database. For the NCI this would be (not counting the unconnected fragments) 46010 / 
250251 = 0.18, or as Ertl’s research8 suggested, by dividing the log values, which 
would yield 0.91 in our case. Calculating the entropy of the distribution might also be 
worthwhile (a database with 999 times fragment 1 and 1 time fragment 2 could be 
considered less diverse than when the division is 500 – 500).  
 The result of using larger fragments instead of small fragments would be that 
chemical diversity is enhanced; a problem might be ease of synthesis or cost of 
acquiring such a library. But diversity does perhaps not have to be high, since the 
research of Bemis et al.11 has shown that half of all drug molecules have one out of 
only 32 different frameworks. One apparently does not need very high diversity to get 
active drugs on very different targets. On the other hand, if the NCI is representative of 
chemical space, most alternative frameworks have been rarely synthesized and 
screened, and would therefore have a much smaller chance of leading to a drug. Until it 
is shown that alternative frameworks are really much worse for drug design, the 
chemical diversity stimulated by our “big fragment” method could be a good start. 
 The final benefit of fragment mining and co-occurrence analysis might be 
psychological: thinking of substructures which have or have not been used together 
might make chemists more conscious of their choices, giving them more knowledge to 
decide whether to use clichés for use of synthesis, or avoid them to explore novel 
structural classes. 
 
As final part of this discussion we would like to reflect on what directions our fragment 
mining investigations could take. 
 
First of all, there are some possibilities for algorithm improvement. While doing a 
stochastic simulation of fragment pair expectance is relatively easy and 
computationally cheap (about 15 minutes on a 3 GHz PC), the averages and standard 
deviations can be calculated exactly with a so-called chi-squared distribution with one 
degree of freedom. This will be especially valuable for larger databases. Stochastics, 
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however, may continue to play a role since they make it easy to add certain restraints 
(such as a maximum number of fragments per molecule, or multiple identical 
fragments per molecule) that are more difficult to enforce by mathematics. It would 
also be interesting to mine larger databases, such as ZINC21 or PubChem22. In any case 
this is likely to add fragments to our databases, and perhaps discover new clichés or 
avoiding groups since more data can lead to more strongly pronounced z-values. 
 A second direction for further investigation would be to make the relationships of 
the co-occurrences more detailed. For example, currently we only detect whether two 
fragments are present in the same molecule. However, our method can be extended by 
taking into account whether the fragments are directly attached to each other, or 
whether the attachment point is consistent over many molecules. Additionally, 
detection of co-occurrences of three fragments or more could be a worthwhile 
extension. 
 A third development would be experimenting with different representations of the 
substructures; some chemists would not care whether a methyl group is attached to a 
ring-N or ring-C, others would like to be sure that a certain ring position is suitable for 
substitution. Atoms and bond types could be converted to wildcards to create a smaller 
library of general fragments, or conversely the connection points could be extended 
and classified for more certainty of ease of synthesis. In the end, we would like to have 
a system that provides the right kind of data for each application. 
 
Conclusions 
In this investigation, we mined the NCI database of 250,251 compounds. This resulted 
in over 60,000 fragments of different types: ring systems, substituents, and diverse 
kinds of linkers. Fragment occurrence is very skewed, with 70% of fragments 
occurring only once, and a few fragments (such as phenyl and methyl) being present in 
many molecules.  
 The fragment lists and co-occurrences can be used in different ways. In our 
examples we have shown how the fragment lists can be used to find new ring 
substituents for benzodiazepines and local anesthetics. Also, we found that co-
occurrence analysis can automatically detect groups of biologically active compounds, 
such as the doxirubicin and mitomycin analogs in the NCI. Finally, co-occurrence 
analysis of the avoiding fragments can show “holes” in chemical space where there is 
room for small, novel compounds which may be biologically active.  
 Future directions of this work could be investigating either larger or more focused 
databases, taking information of how fragments are attached to each other into account 
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and experimenting with different levels of substructural detail. Fragment analysis can 
show us many chemical patterns, but the conversion of pattern knowledge into 
chemical understanding has only just begun. 
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We developed a software tool to design drug-like molecules, the “Molecule Evoluator”, 
which we introduce and describe here. An atom-based evolutionary approach was used 
allowing both several types of mutation and crossover to occur. The novelty we claim 
is the unprecedented interactive evolution, in which the user acts as a fitness function. 
This brings a human being’s creativity, implicit knowledge and imagination into the 
design process, next to the more standard chemical rules. Proof-of-concept was 
demonstrated in a number of ways, both computational and in-the-lab. Thus, we 
synthesized a number of compounds designed with the aid of the Molecule Evoluator. 








It has been estimated that the combination of the four elements C, N, O and S only may 
lead to the design of 1060 molecules with maximally 30 non-hydrogen atoms1. 
Currently, only over 26 million (in between 107 and 108) organic and inorganic 
compounds have been synthesized since the foundation of organic chemistry in the 19th 
century2. Obviously, designing new molecules (de novo design) is crucial to cover 
more of the “chemical space”. Computational methods have been employed to this end, 
among which so-called evolutionary algorithms (reviewed in ref. 3). These algorithms 
are based on principles from biology, such as natural selection and Darwinian 
evolution through mutation and crossover.  
 There are at least two problems with the application of evolutionary algorithms in 
drug design. The first is that linear ‘genes’ as used in biological evolution are ill-suited 
to represent molecules. Molecules are graphs that have to obey certain chemical rules. 
Converting a molecule into a bit string or fixed-size vector of numbers as used in 
conventional evolutionary algorithms will therefore often result in mutation and 
crossover operations that produce invalid molecules.  
 The second problem relates to natural selection and a useful fitness function. 
While currently the most common methods use a similarity index to a reference 
compound4-7 or calculations of the binding strength to a target8,9, only a few examples 
have been published of successful applications of evolutionary algorithms to find new, 
biologically active structures. Only Schneider et al7 claimed success since their 
algorithm found a ligand with a similar kind of activity as the lead compound, be it 
approximately 1000 times less potent.  
 In this study we propose a new approach for the use of evolutionary algorithms in 
de novo drug design, called the “Molecule Evoluator”, to address these problems. We 
introduce an atom-based method with a set of mutation operators that contains all one-
atom and one-bond mutations. This will enable a fuller search of the chemical space 
and finer optimization of the molecular structure than is possible with most other 
published methods. Secondly, we use another approach to natural selection that is new 
in evolutionary algorithms in drug design: we make the medicinal chemist the “fitness 
function” of the proposed structures. This would largely eliminate structures that are 
difficult to make in the laboratory and enable the program to optimize the molecular 
structure by using the chemist’s knowledge about structure-activity relationships.  
 We will first introduce a new representation of molecules, the so-called 
TreeSMILES notation, and the evolutionary operators we used. Subsequently we will 
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discuss how the user’s choices affect the fitness of the molecules. We will then shortly 
describe the graphical user interface of the Molecule Evoluator, together with the 






A molecule can be considered to be a connected graph consisting of one or more atoms 
(nodes) connected by bonds (undirected edges). One of the main constraining rules of 
chemistry is the valence of each type of atom. Moreover, atoms such as sulfur can have 
several valence states, of which bivalent sulfur and hexavalent sulfur are the most 
common. In our genotype, the starting point in each evolutionary algorithm, we handle 
this by creating a separate symbol for each valence state, so that divalent sulfur atoms 
are encoded by “S” and hexavalent sulfur atoms by “Sh”. Thus, whether a graph 
represents a valid molecule does not merely depend on the structure of the graph, but 
also on the identity of each particular node. 
 Molecules are graphs that can be of different sizes; they may also contain branches 
and cycles. Since they too are subject to the laws of chemistry they additionally have to 
obey certain rules that usually prohibit changing one node/edge without changing its 
neighbors. To develop a computer representation of a molecule that can store these 
properties and that is convenient to mutate and cross over, we looked at some common 
molecular data formats.  
 There are various ways to represent molecules on the computer. Nowadays, the 
two most common representations are the MOL-file format10, which is a list of atoms 
and bonds in the molecule, and the SMILES-notation11, a line notation/string that is 
human-readable and that can easily be transformed into a 2D-structure. In the SMILES 
notation the nonlinear parts of a molecule are encoded with brackets to indicate 
branches and numbers to label rings, as is illustrated in Figure 4.1A. By default the 
hydrogen atoms are not incorporated into the SMILES notation, since their presence 
can be deduced from the rules of chemical valence. 
 Neither of these representations is ideal, however, when molecules are mutated 






















Figure 4.1:  
A) Example of a SMILES representation of a molecule. One bond of each 
ring is chosen at random (in this case, the bond from the top left to the 
bottom left atom) and is designated by a unique number. Both atoms 
participating in a ring bond get the bond number(s) immediately after them 
in the line notation. Branches are indicated by brackets. 
B) SMILES versus TreeSMILES. By making the hydrogen atoms explicit 
going from SMILES to TreeSMILES the notation becomes less compact and 
less human-readable. However, the positions available for substitution are 
now readily interpreted by the computer. 
 
 
atom has, both the most common 2D-MOL-file format and the SMILES notation take 
the hydrogen atoms and the bonds to which they are attached for granted. We should 
therefore calculate for each atom whether it has the right number of hydrogen atoms to 
be mutated in some way. To avoid these recalculations, we decided to explicitly add 
the hydrogen atoms to the representation. Also, we decided to use a SMILES-like 
structure as our main molecule representation, particularly for reasons of computational 
efficiency. Making the hydrogen atoms explicit we obtain a bracket-rich, expanded 
SMILES representation (Figure 1B) to which we can apply mutation by relatively 
simple algorithms. We coin this chemical notation “TreeSMILES”.  
 
Crossover and mutation 
Crossover is implemented like crossover in standard genetic programming12: subtrees 
of two different molecules are selected and swapped. The only complication in the 
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present study is that the trees represent graphs and can contain cycles, while subgraphs 
are not allowed to contain incomplete cycles. So when a subtree at a random “root” 
atom is selected, the subtree is first checked for unmatched ring bonds, and if these are 
present the current root is discarded and another subtree is selected for crossover. 
 Mutation, however, is the most important variance operator in the Molecule 
Evoluator. Theoretically, changing a graph into any other graph can be performed by a 
limited set of operations: adding nodes, adding edges, deleting nodes, deleting edges. 
While this would be sufficient from a graph-theoretical point of view, these operations 
are more complicated in a chemical system since the valence rules must be obeyed, and 
the graph must remain connected: deleting the indicated carbon atom in Figure 4.2 
would also require deleting its three attached hydrogen atoms and attachment of a 
hydrogen that replaces the carbon. In the Molecule Evoluator, deleting an atom 
involves removal of the hydrogen atoms attached to it and renaming the atom itself into 




Figure 4.2. Why simple mutations are often wrong mutations. When 
removing the rightmost carbon from the middle molecule, only removing the 
carbon (left picture) results in a wrong molecule: due to the loose hydrogen 
atoms the structure is unconnected (and therefore not a valid molecule), 
also the carbon atom to which it was connected has three bonds instead of 
four, violating chemical valence rules and also making the left molecule 
invalid. The molecule on the right shows the valid version of this mutation: 
the to-be-deleted atom is changed into a hydrogen and its own hydrogen 
atoms are removed. 
 
 






1) Add atom/group: this replaces a hydrogen atom in the molecule with a non-
hydrogen atom or a larger chemical group such as a phenyl group. In the case of 
atom addition, the remaining bonds of the added atom are filled with hydrogen 
atoms.  
2) Insert atom: also adds an atom, but does this by inserting the new atom (which 
should have a valence of two or higher) into a bond. The remaining bonds of the  
new atom are completed by adding hydrogen atoms to it. 
3) Delete atom: this removes an atom that is attached to only one non-hydrogen atom 
(with a single bond) by first deleting the hydrogen atoms attached to it, and 
renaming the atom to a hydrogen atom. 
4) Uninsert atom: This removes an atom that has exactly two non-hydrogen 
neighbors. It removes the atom and its hydrogen atoms and subsequently creates a 
bond between its two neighboring non-hydrogen atoms. 
5) Increase bond order: if two atoms that are bonded to each other both have at least 
one hydrogen atom, those hydrogen atoms are removed and an extra bond is 
created between the atoms (the bond order is increased from single to double or 
from double to triple). 
6) Create ring: similar to increase bond order, but works between two atoms that are 
not bonded to each other. These atoms are connected using a single bond (the two 
hydrogen atoms are changed into ring indices). 
7) Decrease bond order: if there is a double or triple bond between two atoms, its 
bond order is decreased by one and a hydrogen atom is attached to each of the two 
atoms. 
8) Break ring: this mutation chooses a single bond in a ring, breaks that bond and 
adds hydrogen atoms to correct the valences. The algorithm should be able to 
break any bond in the ring, which is not easy to do with a tree structure13. To solve 
this problem, we converted the TreeSMILES into an adjacency list. In the 
adjacency list, any ring bond can be broken easily and afterwards a new 
TreeSMILES representation is built. This is the only mutation where we found it 
necessary to temporarily convert the TreeSMILES representation of the molecule 
into an adjacency list format for easier modification. Since other operators such as 
crossover are more easily implemented for a TreeSMILES string, we decided not 
to use the adjacency list for the other mutations. Changing representations is 
probably a convenient way to accommodate different mutations. To our knowledge, 
this technique has not been used before in evolutionary algorithms in de novo 
design, and is probably also rare in evolutionary algorithms in general. However, 
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we think that it might also have applications outside the Molecule Evoluator. 
9) Mutate atom: a non-hydrogen atom is changed into another non-hydrogen atom 
which has a valence of at least the number of bonds of the original atom with other 
non-hydrogen atoms. 
 
Table 4.1: Schematic overview of the different mutations in the Molecule Evoluator. Most 
leave the TreeSMILES string fairly intact and can be performed by string editing. The only 































































































We also allow the user to select atoms and bonds that will remain unaltered by 
crossover and mutation (‘fix’ option). Therefore we have further modified the data 
structure of the TreeSMILES by using an array of character pairs instead of a normal 
string/array of characters, in which the first character of the pair is the normal 
TreeSMILES character and the second character is a flag, which indicates whether the 
atom or bond designated by the first character can be modified (Figure 4.3). 
 
 
Figure 4.3. The TreeSMILES notation of n-propane (C3H8) that incorporates 
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The final component of the evolutionary algorithm is the fitness function. So far, 
investigations on de novo design with evolutionary algorithms have used several types 
of a fitness function, including:  
• similarity to a target molecule4,5 
• QSAR-functions13 
• ligand-protein docking8,9 
• experiment14 
 
For drug design, each of these methods has its advantages and disadvantages. 
Similarity approaches often result in molecules very similar to the target molecule, in 
117 
 
many cases even the target molecule itself, which is not useful for designing truly 
novel molecules. QSAR functions should be able to optimize activity, yet have 
important disadvantages. First they require quite a lot of reprogramming for each new 
class of molecules that is investigated. Secondly, they are generally difficult to use for  
finding very active compounds since they grow less and less reliable as the molecular 
structures deviate more from the average structure (and thereby activity) of the training 
dataset15. Unfortunately, this is exactly what would happen during optimization. The 
last theoretical method (“docking”) is still too inaccurate for optimization, and may 
yield molecules with an activity that is orders of magnitude lower than the calculated 
value9. Experiments as fitness function, finally, are generally slow and expensive, and 
so far have only been performed for a class of molecules that was particularly easy to 
synthesize14. Thus experimental fitness has yet to prove to be practical in a more 
realistic drug design scenario. 
 As an entirely different approach, we decided to use the user as a fitness function. 
This concept has been recently employed in other application areas and is often called 
interactive evolutionary computing16-18. While a user cannot know the binding strength 
of a given molecule, this defect may not be much worse than the inaccuracy of scoring 
functions. A definite advantage in letting the user choose would be that intensive 
feedback from a medicinal chemist would make the compounds easier to synthesize, 
and steer the evolution away from areas which have already been explored. 
Furthermore, the algorithm could still be easily coupled to experimental results or 
advanced computed fitness functions if so desired. In Algorithm 4.1 the general 
workflow within the Molecule Evoluator is detailed, from the creation of the initial 
population to the interactive evolution of new molecules. 
 
 
Algorithm 4.1: General workflow of the Molecule Evoluator 
 
Create initial generation of 1..generation_size molecules  
// ( generation_size set by user, by default 12) 
For each molecule, get molecule structures from one of 
these sources: 
a. MOL or SD-files 
b. Sketches by user in editor of Molecule Evoluator 





Repeat while the user wants to continue: 
-The user may set or change ratios between 
modification, combination and de novo molecule 
generation. 
-The user selects m most interesting molecules of 
the current generation. 
Copy the m selected molecules to the next 
generation. 
-For each of the ( generation_size – m ) molecule 
slots left in the next generation, do the 
following: 
-generate a new molecule with one of the 
three methods in ratios set by the user: 
-modification: create a new molecule by 
mutating the old molecule  
-combination: create a new molecule by 
crossing over two selected molecules (can 
be the same molecule – this is allowed in 
tree-crossover)  
-de novo generation: create a new molecule 
by de novo generation, see algorithm 2. 
-add the new molecule to the next 
generation. 
-The user may change molecules by fixing (as 
explained in the text) or editing, or replace 
molecules by loading or drawing new molecules. 
-Make the next generation the current generation. 
 
 
As a further example, Algorithm 4.2 performs the random generation of molecules as 







Algorithm 4.2: Random generation of a molecule 
 
 set the current molecule to a methane molecule 
 
pick a random number x from 1 to MaxNumberOfAtoms 
repeat x times: 
replace a hydrogen atom of the current molecule 
by a random atom or fragment from the 
atom/fragment database 
 
pick a random number y from 0 to MaxNumberOfRings 
repeat y times or until no more rings can be made: 
  make a ring in the current molecule 
 
pick a random number z from 0 to 
MaxNumberOfDoubleBonds 
repeat z times or until no more bonds can be oxidized: 
oxidize a random bond in the current molecule, 
so increment the bond order 
 
 
Since a user cannot evaluate as many structures as a computer program and preliminary 
experiments have shown that users only want to see “good” structures, we added  
several descriptor calculations to the Molecule Evoluator. The selected descriptors are 
(physico-)chemical parameters of a compound, such as the number of hydrogen bond 
donors/acceptors, molecular weight, logP (lipophilicity), Polar Surface Area, the 
number of rotatable bonds, and the number of aromatic systems and substituents. 
Physico-chemical parameters of a compound, either calculated or experimentally 
determined, can also constitute a useful fitness function, for instance in a certain 
weighed combination. It is increasingly realized that they determine e.g., aspects of 
absorption and blood-brain barrier passage19, although they usually are of lesser 
importance for the interaction with the target protein. Upper and lower bounds for all 
these descriptors can be set by the user as a filter to create more ‘realistic’ molecules. 
Additionally, we implemented some ‘chemical’ filters. The aim was to eliminate 
molecules with undesirable (sub)structures such as strained paracyclophanes. Similarly, 
molecules not allowed because of Bredt’s rule20 are also automatically discarded. Both 
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The graphical user interface of the Molecule Evoluator 
When the program is started, a ‘seed’ molecule (indole in this case) can be either 
loaded or drawn and used for a first generation of derivatives (Figure 4.4). 
Alternatively, the Molecule Evoluator itself can initialize the population with random 
molecules. The latter is done by taking the computer’s clock time and using it as a seed 
in the rand function in the C programming language. 
 As an example one of the suggested molecules (3-methylindole) was selected for 
yet another round of evolution. Again by pressing the "Go" button a window appears 
that contains the selected molecule (this so-called elitism is on by default) together 
with the newly generated analogs (Figure 4.5). The user can again select the most 
attractive molecules, press “Go”, and this process is repeated until the user has 
gathered enough ideas. 
 Comments from medicinal chemists on previous test versions of the program have 
led us to include three extra features that allow the user more control over the evolution, 
i) editing the molecules directly, ii) fixing parts of the molecule, and iii) using filters to 
prevent that certain unrealistic molecules are shown to the user. We next discuss these 
features in more detail. 
  Editing molecules is useful when the user wants to start the evolution with a 
molecule that has not been stored yet in the computer and must be drawn. Additionally, 
if during the evolution a given molecule suggests a more interesting structure, editing 
the molecule into the desired structure can be done ‘on-the-fly’. This will allow the 
user to evolve molecules immediately from the desired structure, rather than wait until  
it will be generated by the program. Editing the molecules is performed in the 
"Molecule Edit" window (not shown), which pops up when the user clicks on a 
molecule in the main window. Editing is quite similar to that in normal chemical 
drawing programs. After the popup window has been closed, the drawn structure is 







Figure 4.4: A molecule, in this case indole (#1), is drawn or loaded as a 
‘seed’ for a population of 12 derivatives generated by pushing the “Go” 
button (green arrow in left-hand toolbar). In this simple example with atom 
additions only the methylated analog #6 was selected for further evolution 




Fixing part(s) of the molecule can be useful in cases where structure-activity 
relationships demand that a particular, necessary part of the molecule is present in all 
its descendants. The Molecule Evoluator allows this conservation with the “fix atoms 
or bonds” option in the “Molecule Edit” window, which enables the user to generate 







Figure 4.5: Pressing “Go” (green arrow in the left-hand toolbar) generates 
mutants of methylindole (see Figure 4) according to preset filters (PSA, logP 
and MW in right-hand panel). PSA and logP values are displayed in the 
individual boxes, according to buttons pushed in the upper toolbar.  
 
 
The filters are the third extra feature. In the “Physical Filters” panel (see also Figure 
4.5) the ranges are set within which the physicochemical properties of a molecule must 
lie for the molecule to be incorporated into the population (for example: molecular 
weight between 100 and 300). Molecules outside these boundaries imposed by the user 
will be automatically eliminated by the Molecule Evoluator and will therefore not be 
shown to the user. Additionally, some chemical structures which are usually 
undesirable, such as hemiketals, can be forbidden in the “Chemical Filters” panel. The 
Molecule Evoluator creates offspring molecules using mutation and crossover until 
feasible molecules – fulfilling all filter conditions – have been found. 
 
In addition to these three main control features, there is a “Parameters” panel (not 
shown), in which the user can influence the evolutionary process itself. The user is 
allowed to steer evolution by, amongst other things, enabling/disabling certain kinds of 
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mutations. For example, the “decrease bond order” mutation tends to partially reduce 
phenyl rings, which is chemically undesirable. As an alternative to fixing the phenyl 
bonds explicitly, disabling this mutation will protect the bonds from being reduced. 
This will however also prevent useful mutations, such as those which reduce a ketone 
(C=O) to an alcohol (CHOH). Another option would be a special version of the 
"decrease bond order" mutation that does not reduce aromatic rings; this is something 
we are currently considering. Other mutation types (eight in total) can also be toggled 
‘on’ or ‘off’. By default, each of these eight categories of mutations is applied with the 
same frequency (0.125). When mutation types are disabled, the remaining active 
mutation types are still applied with identical frequency, so if for example only three 
mutations are allowed, the probability of each of them is 0.33. Another option is to 
change the ratio of mutation/crossover. Since we learned that most medicinal chemists 
prefer mutation over crossover, the default settings are 90% mutation and 10% 
crossover (and so are applied with probabilities of 0.9 and 0.1, respectively). A third 
option is to allow the Molecule Evoluator to occasionally add random molecules to the 
population. The relative amount of random molecules is approximately 16% (so 1-2 
new random molecules in a new population). This option is off by default. Lastly, the 
user can toggle elitism on and off. Elitism conserves the selected molecules and makes 
them also the first molecules on the screen in the next generation. 
 
Experiments 
We conducted a computational experiment first for a simple proof-of-concept. For this 
we used a dataset of biological activities of neuramidase inhibitors21. Using the 
measured activities as input for the evolutionary algorithm we located the experimental 
minimum (IC50 = 1 nM, a 6300-fold improvement over the original structure) within 
four generations. 
 To test whether we could use the Molecule Evoluator to discover interesting new 
molecules with possible biological activity, we performed an experiment using its 
option for random molecule generation. 
 First we generated a library of 10,000 small molecules (150D < MW <250D) with  
drug-like features: either one or two aromatic rings, 5 or fewer rotatable bonds, 2 or 
fewer hydrogen donors, 4 or fewer hydrogen acceptors, and a polar surface area of at 
most 70Å2. Out of this library, three sublibraries of 100 compounds were chosen 
randomly. Each of these sublibraries was presented to a different chemist, who could 
choose and modify the molecules created by the program. Out of the 300 compounds, 
35 were chosen for further investigation. 
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Checking the latter molecules in the SciFinder2 and Beilstein databases22 (in April 
2003) we found that six structures represented chemical classes yet unknown in 
literature. Based on these six core structures ten molecules were designed, of which 
eight compounds were synthesized successfully. One typical compound with a 
calculated log P value of 1.65, a calculated polar surface area of 32 Å2 and a molecular 
weight of 191D, is shown in Figure 6. It proved active on both α1- and α2-adrenergic 
receptors, i.e. at 10 µM it displaced more than 50% of the radioligand used in binding 
assays on the two receptor subtypes. The full results of this experimental proof-of-
concept are described in chapter 7. 
 
 




Figure 6. One of the compounds synthesized on the basis of a random 






In this paper we have presented an evolutionary algorithm to help design new 
molecules. As reviewed very recently, evolutionary algorithms form one of the 
approaches to computer-based de novo design of drug-like molecules23. A large variety 
of methods is being used to this end, even when confined to evolutionary concepts only. 
The two most important components of all evolutionary algorithms used in 
chemistry/drug design are the molecule representation and the fitness function. 
 
The molecule representation 
One of the main choices when creating a de novo design algorithm is whether to make 
the algorithm atom- or fragment-based. Atom-based algorithms work by mutating 
atoms, and can therefore fine-tune each structure optimally4,5,13,24. On the other hand, 
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several investigators construct molecules using larger fragments7,9,24. This has the 
advantage that the representation can be simpler, since there is generally no need for 
the genome to contain cycles (for these are incorporated into the fragments). Also 
fragment-based methods have the potential benefit of easier synthesis. While the 
current version of the Molecule Evoluator uses both atoms and fragments to construct 
molecules, its mutations are atom-based. We believe that atom-based evolution is 
superior to fragment-based evolution for adapting the molecular structure. The main 
disadvantage of using fragments instead of atoms is that most mutations in fragment-
based evolution are “macromutations” that change the molecule into something 
completely different, with a vastly different fitness value. In most cases, it is not clear 
whether fragment-based evolution is an improvement over random search, unless the 
fitness function is fragment-based. However, this is certainly not the case in drug 
design where biological activity is subtly dependent on the molecular structure. We 
have observed that making an atom-based algorithm interactive, as in the Molecule 
Evoluator, partially compensates for the disadvantage that molecules generated on the 
basis of atoms are generally more difficult to synthesize. This is because the medicinal 
chemist has the option to immediately discard or modify structures at will. 
 
Using the user as a fitness function 
The most important problem of the de novo design programs which have been 
described in literature is the difficulty of creating a fitness function that is relevant to 
drug design. In this work, we propose to use an evolutionary algorithm not as a black 
box that will give the user the right answer when given the right question, but as a 
means of supporting the creativity and imagination of the user by interactive evolution, 
thereby automatically incorporating the user's explicit as well as implicit 
(subconscious) knowledge of the problem domain. 
 Using user feedback as fitness function has several advantages and disadvantages, 
and some consequences that require special adaptations and modifications of the 
software. 
 One disadvantage of user interaction is that the population must be small. It is 
unlikely that any chemist would want to see 50 to 100 molecules before pressing “Go” 
again. However, small population sizes (12 as a default in the current version of the 
program) may lead to premature convergence, i.e. tempt the user to stop (too) early. 
Another hurdle relates to programming the software: the more the user can interact 
with the program, the more is required from the user interface. In this project, more 
time was spent on constructing the user interface than on creating and fine-tuning the 
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evolutionary algorithm. Modifications of the evolutionary algorithm should in many 
cases be reflected by changes in the user interface, and this makes programming and 
testing new ideas more time-consuming than in a non-interactive system. Software 
validation is also more difficult – one cannot well run hundreds of tests automatically 
to objectively verify whether the algorithm outperforms other algorithms. A user is not 
an objective function that can be easily shared with others. Finally, the user may see 
the computer program as a competitor, not as a tool, and might not like to work with it 
since “someone else” has thought of the molecule. While the computer has so little 
knowledge that one should say that the user has invented the molecule (and recognized 
it as something interesting), the user may perceive his or her position differently. 
 There are however also many advantages to user interaction. One attractive 
advantage is that the feedback from the user can produce molecules which can be 
synthesized more easily in the laboratory than is possible with computer-generated, 
random molecules. The difficulty of synthesis would also be automatically adapted to 
the user’s level of knowledge and experience. 
 A second advantage is that the program can use all kinds of rules and problem 
domain knowledge that the user has. The alternatives, expert systems and flexible input, 
have distinct disadvantages in this case. Creating an expert-system is time-consuming 
and must be done anew for each optimization project. Flexible input would require the 
domain expert, namely the chemist, to learn a complicated language or user interface 
which would definitely diminish accessibility of the software and thereby its use 
greatly. The program can even benefit from the user’s subconscious rules, which 
cannot be programmed since they are unknown and may be very difficult to derive. 
Furthermore, as the user's problem knowledge grows, this knowledge is automatically 
updated and applied to the process without time-consuming intervention by 
programmers. In experimental sciences, seldom all required knowledge is known 
beforehand, and allowing experiments with the computer can also lead to finding new 
rules and discarding obsolete ones. 
 A third advantage is that the software can stimulate computer use by medicinal 
chemists. Far too often, compounds suggested by the "computational department" are  
rejected by medicinal chemists for reasons of synthesis, and collaboration between the 
departments is hampered by busy schedules and the necessity to have meetings for 
feedback. This makes collaboration slow and difficult, and probably results in chemists 
mainly designing their own compounds without the help the computer could give. We 
believe that creating a program for the problem domain experts instead of for computer 
experts can lead to better use of the help that the computer could give in the drug 
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design process, and perhaps even to increased understanding and a more fruitful 
collaboration between medicinal chemists and computer scientists. 
 Finally, a program such as the Molecule Evoluator may make a chemist more 
conscious of his/her own design process, i.e. which rules he or she follows. 
Consciousness of the rules and methods can lead people to experiment with them and 
occasionally break them for enhanced creativity. 
 
Adding extra user control to the evolution 
We found that when we added interactivity to the evolutionary algorithm, it was not 
enough to restrict the user’s influence to selection only. The users were generally quite 
"impatient" and wanted more control to accelerate or even directly manipulate the 
evolution, so we added features to enable this. First, we incorporated edit functions to 
directly modify the molecular structure. Second, we added an option for selecting a 
part of the molecule to remain constant. Third, we allowed the settings (which 
mutations are allowed, what range a property may have) to change interactively. We 
think that these options will make the Molecule Evoluator more attractive for drug 
design since they give the user more control over the evolution. We must however 
beware of the complication that having a feature is not enough if the user does not 
know that the feature is there or how to use it. Good user interface design is necessary 
for users to learn to use the multiple filters without having to read the manual. The 
second danger is perhaps more serious: by discarding “bad molecules” one may at the 
same time eliminate paths to escape from local optima. Secondly, if all molecules 
shown are good according to a specific user’s criteria, it may be exactly what the user 
had designed him/herself anyway, thus eliminating the added value of the program. 
However, lack of control may frustrate and bad structures may irritate the user, so we 
aimed for a middle road between control and creativity. 
 
 
Conclusions and future perspectives 
 
In this report we have described the “Molecule Evoluator”. It is a software program 
based on evolutionary algorithms and has been created to aid chemists in designing 
new drug-like molecules. With this program all relevant chemical mutations are 
possible. The most distinguishing feature of the Molecule Evoluator relative to other de 
novo design programs is that it has the user as fitness function. In this way it can 
combine the domain knowledge of the chemist with the memory and processing speed 
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of the computer. We therefore added a graphical user interface for the evolution and 
extended the program with options for directly editing the molecule, marking part of a 
molecule as conserved, and calculating relevant physicochemical parameters.  
 Considering the algorithms used and the feedback from users so far, there are 
several directions open for future investigation. First, many molecules generated by the 
program seem difficult to synthesize. Perhaps encoding explicit chemical knowledge in 
the program or using chemical databases could help improve this. A second direction 
would be to create a command-line version which links to other software such as 
docking programs, since the “high-resolution” optimization resulting from our atom-
based model might be very useful for optimizing lead compounds. Third, more 
selection criteria could be added such as additional physicochemical properties or an 
input method for QSAR-formulas. 
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We have developed an evolutionary algorithm-based program for drug design, the 
Molecule Evoluator. This program transforms known molecules into new molecules 
which may have improved properties relative to the parent molecule. Transforming the 
parent molecule into a derivative by mutation is necessary to find molecules with 
increased fitness. However, mutations that just randomly add and substitute atoms 
often result in molecules that contain undesirable chemical substructures, and can 
therefore not be used as drugs. We therefore want to add knowledge to the program 
about which mutations result in proper chemical structures and which ones do not. In 
this research we have mined a large chemical database, the World Drug Index, to 
obtain the frequencies of small substructures in drug-like molecules. Some of our 
mutation operators were subsequently modified to use these frequencies. Testing the 
new mutation frequencies on another large database of molecules, the NCI database, 
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we found that the knowledge-based mutations more often produced existing molecules 
than the original mutations. This suggests that the modified mutations produce 
molecules that are easier to synthesize and more drug-like compared to the molecules 





Pharmaceuticals have a major impact on both public health and the economy. The 
worldwide sales of pharmaceuticals were 491.8 billion dollars in 2003, and were 
expected to grow by several billion dollars in 2004 (Class 2004). Pharmaceuticals have 
also greatly improved human health. Many diseases that used to be dangerous or even 
deadly, such as pneumonia and tetanus, have become much less dangerous, and people 
with chronic ailments, such as diabetics and heart patients, live longer and healthier 
lives thanks to the currently available medication. 
 There are however still a number of diseases which are difficult to treat or where 
current therapy has severe side effects. Dementias such as Alzheimer’s disease are yet 
untreatable, advanced cancer can only be cured in rare cases, and viral diseases remain 
difficult to fight.  
 Given this demand for more and better treatments, pharmaceutical companies are 
continually working to expand their arsenal of drugs. This is however not easy. A 
medication such as a tablet works since it contains a specific chemical compound, the 
molecules of which bind to large biological molecules (such as proteins) that are 
involved in the disease. Drug molecules make these biomolecules more or less active 
by binding to them. A good drug molecule should influence the biological process of 
the disease in a beneficial way, but it should also be able to enter the part of the body 
that needs to be treated, and should not cause side effects which would make the 
treatment more damaging than the disease itself. It turns out to be very difficult to 
create such a compound; it is estimated that only one out of 5000 screened candidate 
compounds reaches the market as a drug (Rees 2003). 
 The difficulty of finding new drug molecules has pushed the pharmaceutical 
industry to try to improve its output using both experimental and computational 
methods. Of these computational methods, the Evolutionary Algorithms (EAs) are 
widely applied. Not only are they used to gain insight in the structures and functions of 
genes and proteins (Fogel 2004), which is important for discovering which proteins to 
target with a drug, they have also been applied to designing the drug molecules 
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themselves, such as designing compound libraries, docking small molecules into 
proteins, and finding structure-activity relationships. Good overviews are given in the 
book edited by Clark (Clark 2000) and in chapter 2 of this thesis. However, one of the 
most interesting applications is the design of new drug molecules themselves, the so-
called de novo design. 
 Several EAs for de novo design have been described in literature (Brown 2004, 
Douguet 2000, Glen 1995, Globus 1999, Kamphausen 2002, Nachbar 1998, Pegg 2001, 
Schneider 2000, Vinkers 2003, and others). The main differences between the various 
methods are the molecule representations and the fitness functions.  
 The molecule representation methods in EAs for de novo design can be divided 
into atom-based and fragment-based methods. Atom-based methods build and modify 
molecules by adding and modifying individual atoms. While atom-based methods can 
create many more molecules than fragment-based methods, they often create molecules 
which are difficult to synthesize (Douguet 2000). Fragment-based methods on the other 
hand create molecules by connecting existing substructures. Fragment-based methods 
therefore tend to create molecules that are easier to synthesize (though this is not 
guaranteed (Vinkers 2003)), yet these methods seem less suitable for optimizing 
molecular structures. Since the mutations replace/add or delete entire fragments (5-20 
atoms), each mutation is a macromutation which results in a very different molecule, 
the fitness of which may be very dissimilar to that of the parent. Also, since fragment-
based methods use bigger building blocks which cover only a small fraction of all 
building blocks theoretically possible, they cannot cover the search space of drug-like 
molecules as fully as atom-based methods. 
 In the EA-based program we are developing, the Molecule Evoluator (chapter 4 of 
this thesis), we want to be able to fine-tune molecular structures and to generate all 
possible drug-like molecules. Therefore we have chosen for the atom-based 
representation. 
 The second important aspect of the EAs for de novo design is the fitness function. 
The fitness functions that are most often used are “docking” (a procedure that fits the 
molecule into a three dimensional model of the target protein and returns the 
approximate binding energy), similarity to an existing drug molecule, and experiments. 
However, these have not yet proven to be very useful since they are either too slow and 
expensive to apply (experiments), or too inaccurate for optimization (docking, 
molecular similarity). The best result published so far seems to be a derivative evolved 




We therefore decided to try an alternative approach which could still use the 
optimization power of an EA but would tap a different source of knowledge, the 
medicinal chemist him/herself. Since the chemist performs the role of fitness function, 
the Molecule Evoluator can use the chemist’s knowledge about how the molecular 
structure influences the biological activity and how difficult the synthesis of the 
molecule would be. In a typical session, the user would take a known molecule to seed 
the population and let the program generate derivatives by applying various mutations, 
such as adding or deleting atoms, breaking or making rings, etc. The chemist will then, 
based on his/her estimates of structure-activity relationships and ease of synthesis, 
select the most interesting mutants, which will then be used by the program to generate 
a new population of derivatives. 
 The general mechanism of the Molecule Evoluator and a screenshot of the 
program in action are shown in figures 5.1 and 5.2, respectively. 
 
Now we arrive at the main topic of our paper: improved mutation. 
 One of the consequences of the atom-based mutations in the Molecule Evoluator 
is that changing an atom into another atom can result in a molecule that is unstable or 
difficult to synthesize, decomposing before it can exert any effect on the human body. 
For example, changing a hydrogen atom into a fluorine atom is fine when the hydrogen 
is attached to a carbon atom, but will result in a highly reactive and therefore un-drug-
like compound when the hydrogen is attached to an oxygen atom. Whether a mutation 
leads to a chemically acceptable molecule therefore depends for a large part on the 
atoms surrounding the mutation. We therefore want to modify the different mutation 
functions in such a way that they will result in more reasonable mutants. For this we 
however need knowledge about which mutations are reasonable.  
 Our plan is to derive this knowledge from large chemical databases and adapt our 
mutation operators accordingly.  
 The outline of the rest of the paper is as follows: first we discuss our data mining 
approach, then we introduce some of our mutation operators and discuss how we 
adapted them using the data mining results. Subsequently we will present the results of 
our experiments with the adapted mutation operators, comparing them with the original 
operators and finally we will give our conclusions and indicate some of the remaining 










            
 
Figure 5.2: The Molecule Evoluator generating variants of acetylsalicylic acid 
(AspirinTM), the top left molecule. 
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Data Mining Approach 
 
The process of discovering knowledge in databases is often called data mining. There 
are many data mining methods (Witten 2000), able to handle widely different kinds of 
data. However, the chemical applications of data mining are currently still quite limited. 
This is probably because the most important data mining one can do in this field is 
finding the relation between molecular structure and particular properties. This is 
however very difficult. One of the reasons for this is that many of the existing data sets 
are relatively small (dozens to hundreds of items). Also, the question remains how to 
represent a chemical structure (a graph) so that it can be related to its properties. This is 
still an open question and may depend on the specific application. 
 One of the problems of the Molecule Evoluator was that many of the molecules 
created by it were estimated by medicinal chemists to be difficult to synthesize. While 
of course the chemist can filter out these molecules manually, in general there were so 
many “bad” molecules per generation that evolution slowed down (many mutants were 
not attractive, had very low fitness), even to the point that the user, who provides the 
necessary fitness function, got annoyed. 
 The most obvious fix, as proposed by the chemists, would be a library of 
“forbidden substructures”. However, this fix has some disadvantages. First, chemical 
rules are seldom absolute. Many substructures which are not particularly stable can and 
do occur in drug molecules, only relatively rarely. Eliminating them entirely would 
make the Molecule Evoluator incapable of finding some real drugs, which would 
strongly limit its usefulness. Second, forbidding substructures does not solve the 
problem of frequent versus infrequent substructures. While C-N-C is a perfectly 
reasonable substructure, it is much rarer than C-C-C, and a program creating equal 
amounts of both would produce molecules which look rather unusual and still may be 
difficult to synthesize. Third, all chemists are necessarily subjective and may have 
studied only about a few thousand structures in their lives, a small fraction of all 
molecules ever made. A computer can easily search the millions of molecules which 
have been created so far and can update its knowledge much more quickly.  
 This gave us the idea to use a large database of drug molecules (the World Drug 
Index) to find the frequencies of all occurring substructures and adapt the mutation 
operators so that the mutants will be more drug-like and easier to synthesize than when 
using “uninformed” mutations. 
 We used the 2002 edition of the World Drug Index (Daylight 2005), containing 
approximately 32000 drugs and other pharmacologically active compounds. An in-
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house program counted the frequencies of all atoms (X), atom pairs (X-Y), atom 
triplets (X-Y-Z) and sets of four atoms (both the linear X-Y-Z-A and the T-shaped X-
Y(-Z)-A). The types of substructures mined are shown in table 5.1. The substructures 
and their occurrences were collected in a file. The counting algorithm counted all 
groups starting at each atom in the molecule. So an N-C substructure yields 1 N-C and 
1 C-N count, while a C-C substructure yields 2 C-C counts. For our mutations we have 
corrected for this factor by dividing the counts of symmetric pairs and triplets of atoms 
by 2, the T-structure-occurrences were divided by 6 if the three atoms surrounding the 
core atom were identical, and divided by 2 if only two of them were the same. 
 For computational efficiency, the frequencies of the substructures are read into 
memory at the start of the program, so for each mutation there are typically only about 
10 numbers which have to be fetched and scaled to determine the type of mutation, 
which is a negligible amount (<0.1%) of the total runtime of the Evoluator. 
 
 
Table 5.1: The substructure patterns mined from the World Drug Index. The 
letters denote any possible atom type, the ‘-‘ characters all possible bond 






























Adaptation of the Mutation Operators  
 
To investigate the effects of adding knowledge to the mutation operators, we chose to 
modify three mutations that the Molecule Evoluator uses to create new molecules. 
These are the “add atom”, “insert atom” and “change atom” mutations, shown in table 
5.2. 
 
Table 5.2: The effects of the three mutation operators in this study. 
 
Mutation name Initial structure  Final structure 
Add atom  
  







• The “add atom” mutation adds a non-hydrogen atom to the structure by replacing a 
hydrogen atom by another atom, and adding hydrogens as necessary to fill the 
remaining bonds of the new atom. 
• The “insert atom” mutation takes a single bond between two non-hydrogen atoms 
and inserts an atom between them.  
• The “change atom" mutation changes a non-hydrogen atom into another non-




























The three mutations originally used estimated frequencies of the diverse atom types, 
chosen such that the resulting molecules seemed drug-like. These estimates are shown 
in table 5.3. 
 
Table 5.3: The initial probabilities to add a certain type of atom to a 














However, since the mutations were still context-independent, rare and reactive 
subgroups such as O-O and N-F did occur much more frequently than would be 
expected from looking at the World Drug Index. For example, the reactive O-O bond 
occurs only 1.5 times per 10000 C-C bonds in the World Drug Index, but in the 
original Evoluator it was generated 62 times per 10000 C-C bonds, 40 times more 
frequently. 
 We therefore decided to try and improve the mutations by making them context-
dependent. We introduce new versions of three of our mutation operators, the add atom 
mutation, the insert atom mutation and the change atom mutation. 
 
Add atom mutation: The add atom mutation works by picking a hydrogen from the 
molecule and replacing it by a non-hydrogen atom. This non-hydrogen atom was 
originally picked from the standard frequency table (table 5.3). We however modified 
the algorithm to first look at the atom to which the hydrogen was attached (a hydrogen 
atom has only one bond and is therefore attached to only one atom). 
 If the hydrogen was attached to an atom of type X, the program looked up the 
counts of the various X-Y substructures and converted these into a probability table. 
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This table indicated the probability that the hydrogen atom would be replaced by an 
atom of type Y. So since there were 8246 C-Cl bonds, 2.5·10-3 part of the total number 
of C-X bonds, and 12 O-Cl bonds, 3.5·10-5 of the total of O-X bonds, the probability of 
substituting the hydrogen by Cl would be 2.5·10-3 in the case of a C-H group, and 
3.5·10-5 in the case of an O-H group. 
 Based on these frequencies, the Y-type was selected using a random-number 
generator. 
 In our experiments we found that using the raw WDI data improved upon our 
original frequencies. To our initial surprise, however, the substructure frequencies of 
the resulting molecules were significantly different from the WDI-frequencies. One of 
the causes seemed to be that carbon atoms, having four bonds, have on average 2-3 
hydrogens attached, other atoms less. This skewed the distribution markedly, resulting 
for example in 60% more nitrogen atoms per carbon than expected. We have improved 
on this situation by changing the input frequencies by an adaptive procedure until the 
output frequencies resembled those of the WDI fairly well. This algorithm is depicted 
as algorithm 5.1. Its results are illustrated in figure 5.3. 
 
Insert atom mutation: When the Molecule Evoluator must choose an atom type to 
insert between two atoms of type X and Y, the program searches for all X-A-Y-
patterns in the substructure database and makes a probability table of how likely it is to 
find an atom of type A bonded to type X and Y. For example, if the bond is between C 
and O, the probability of finding a carbon-in-between pattern (CCO) is 0.97, and 
nitrogen in between 0.012, in contrast to the “raw” probabilities of C versus N of 0.37 
versus 0.04 in the entire World Drug Index. 
 
Change atom mutation: The change atom mutation was the most complicated 
mutation to modify as the atom to be changed can have one, two or three non-hydrogen 
atoms surrounding it. Depending on the number of surrounding non-hydrogen atoms, 
the X-A, X-A-Y or X-A-(Z)-Y patterns are looked up and the frequency table is 










Algorithm 5.1: Algorithm for iterative refinement of the input two-atom 
frequencies to produce molecules with similar two-atom substructure 
frequencies as the World Drug Index. 
 
 inputFrequencies = WDIfrequencies; 
 do 
   generate database of molecules using  
    inputFrequencies; 
   newFrequencies = count two-atom frequencies 
    in new database; 
   frequencyCorrectionFactors= 
    newFrequencies/WDIFrequencies 
 mediumCorrectionFactors  
  =(frequencyCorrectionFactors + 1 ) / 2 
   inputFrequencies = inputFrequencies *  
    mediumCorrectionFactors 





             
 
Figure 5.3: Iterative refinement results in the substructure counts getting 
closer and closer to those of the World Drug Index (all counts are scaled to 
make the count of CC-bonds 10000). Since the y-scale is logarithmic, some 
of the gains in accuracy seem smaller than they are: the number of C-N 
bonds went from 66% too much to 8% too much, and C-Cl from 23% too 










































Table 5.4: Using substructure counts to calculate the probability that an 
atom flanked by a C and a N atom is changed into a specific other atom 
type. Substructures which are chemically impossible, such as “C-H-N” in 
which the hydrogen has two bonds instead of the allowed maximum of one, 
are indeed not found in the database (count is 0). 
 
Substructure Count Probability 
C-C-N 323618 0.964 
C-H-N 0 0.000 
C-O-N 1179 0.004 
C-N-N 9060 0.027 
C-S-N 1693 0.005 
C-P-N 11 0.000 
C-F-N 0 0.000 
C-Cl-N 0 0.000 
C-Br-N 0 0.000 





After we had modified the three mutation operators to use the data of the World Drug 
Index, we wanted to find out whether making the mutation operators context-sensitive 
increased their likeliness to generate “normal” molecules. As a test, we took the 
database of the National Cancer Institute (National Cancer Institute 2005), 250251 
compounds. The NCI database contains molecules which were tested for biological 
activity, i.e. anti-tumor activity. It has only about 3% overlap with the World Drug 
Index (Voigt 2001), making it suitable for validation in this study. 
The question then remaining is how to validate whether modifying the mutation 
operators improves the drug-likeness and ease of synthesis of the mutants. 
The best proof of this would take an existing compound, apply a mutation to it, and 
find that the derived compound also exists in the database.  
However, as it has been estimated that there are over 1060 molecules possible 
(Bohacek 1996), it seemed unreasonable to demand that our new algorithm would 
transform all existing NCI molecules into other existing NCI molecules. However, we 
can reduce the search space by splitting the molecules into fragments (figure 5.4). The 
143 
 
chance that a certain fragment is mutated into another known fragment is likely to be 
much larger than the theoretical molecule to molecule “mutation success ratio” of 
2,5·105/1060, since the smaller size of the fragments will greatly reduce the search 
space. 






Figure 5.4: Splitting an example molecule, folic acid, into fragments. 
 
 
The set of fragments we took from the NCI database was the 6765-item ‘one-connected 
branches’ set, that is, all non-ring parts of the molecules that were attached to only one 
ring, such as the =O, -NH2 and –C(=O)NHC(COOH)CCCOOH groups in figure 4. 
First we removed the branches with atom types that the Molecule Evoluator does not 
recognize, such as metal atoms (which are extremely rare in drugs) to get a data set of 
6564 branches. We then performed atom mutations on the 1000 most frequent branches 
of the set and recorded how many were mutated into other existing branches. This 
experiment was repeated 20 times for both the old and new versions of the three 
mutations. Student’s t-test indicated that all three mutations were improved 
significantly (values ranging from 0.01 to 7·10-14). The details of the runs are shown in 
the appendix at page 152. 





Table 5.5: Average probability that a specific mutation of a NCI branch will 
produce another NCI-branch for the informed and uninformed mutations. 
The t-test column contains the probability that the observed differences in 
performance are due to chance. 
 
 Old average New average t-test 
Add atom 0.3107 0.3205 0.0108 
Insert atom 0.3626 0.4134 6.73E-14 





Using knowledge to guide mutation seems to improve upon the old, uninformed 
methods. Could we improve the Evoluator further by using even bigger substructures 
to guide the mutations? To some extent, this may be desirable. For example, a 
C(=O)OC is an ester group, and the second O can be easily exchanged for N, probably 
more easily than when the (=O) is lacking. However, one should be cautious when 
interpreting the extra data gained from using larger groups since: 
 
1) Larger groups have lower frequencies, conclusions drawn from them will be 
statistically less reliable. 
2) High occurrence of very large substructures may just reflect existing chemicals, 
chemical “prejudice” and biological coincidence rather than fundamental rules of 
chemistry. For example, in the NCI database are many sugar groups attached to 
purine rings. This however does not reflect any chemical rule that this is especially 
easy to synthesize but merely the biological coincidence that some nucleosides 
contain a purine attached to a sugar group, and since many nucleoside-like 
compounds are active against cancer or HIV, many researchers have made variants 
of sugar-purine compounds.  
3) The further atoms are removed from the atom that is to be mutated, the smaller is 
their influence; there will be diminishing returns in taking larger and larger 






So while we could enlarge the substructures used by the mutation operators, the value 
of such an extension should be critically investigated. 
 Another extension would be to modify the other mutation operators so that they 
use the knowledge in the database. This might not be very straightforward for some 
operators: the “delete atom” would have to go over each 3-atom set in the molecule, 
and delete atoms with a probability inversely proportional to the occurrence of the 3-
atom set relative to the two-atom set. On the other hand, to perfect the “make ring” and 
“break ring” mutations we would have to mine the distribution of ring sizes and ring 
frequencies instead of the substructure frequencies. Mining and implementing the 
acquired data would probably be quite straightforward in that case. 
 Data mining to modify the mutation operators seems useful in this investigation. 
While we do not know the extent in which data mining to make mutations context-
dependent is applied in the EA community, it may be quite useful when there are large 
databases available of reasonably fit individuals. However, the question remains 
whether an individual does not exist in the database because it is not fit or just because 
it has not been thought of yet. A “negative” database of very unfit individuals could 
help resolve such cases, though these unfortunately do not seem to be very prevalent, at 
least not in the drug development community. 
 In any case, it seems useful to add data to our EA. Of course, we should apply the 
mining with care, and not impose so many rules on newly generated compounds that 
they cannot have novel or interesting structures anymore. Using our non-informed 
mutations, the Molecule Evoluator was probably a bit too much “original”, making 
large parts of the offspring molecules unsuitable for further evolution. Data mining will 
help to diminish this percentage of molecules and thereby speed up evolution. However, 
the logical limit would be requiring absolute certainty that a compound can be made. 
And that can currently only be reached by knowing that the molecule already exists in 
a molecular database. This would unfortunately preclude finding any novel molecules 
and greatly limit the optimization. We should therefore find a way between unpractical 
novelty and conservative clichés. But such a discussion will only be about how 











In this research, we have improved the mutations of the molecule design program “The 
Molecule Evoluator” by using data mined from a drug database. Using the counts of 
various small substructures in the database, we found that the amount of unusual 
substructures decreased, and that mutations had a larger chance to transform existing 
molecular fragments into other existing molecular fragments. We think that the 
enhanced generation of existing structures additionally suggests that also the non-
existing mutants generated by our “informed” mutation operators may be closer to 
molecules that are drug-like and can be synthesized than the mutants generated by the 
uninformed mutations are. Mining databases may be a good method to making the de 
novo generated molecules easier to synthesize while keeping the advantages of 
covering the full space of drug-like molecules and the likely faster and more robust 
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Appendix: Comparing the old with the new mutation operators 
 
To assess whether incorporating mined data into the mutation operators of the 
Molecule Evoluator resulted in producing more realistic molecules, the 1000 most 
frequently occurring one-connected branches of the NCI database were mutated using 
both the knowledge-less and the knowledge-including versions of three mutation 
operators. The old versions did not use any substructure frequency data, the new 
versions used this data to calculate the relative frequencies of each substitution. The 
number of branches in each run that was mutated into one of the other 6564 branches 
was counted for 20 runs (maximum score of each run is 1000). In the table the results 
of the individual runs are shown, as well as the averages over the runs and the t-test 
probabilities that the new mutation versions differ from the old mutations. 
 
 












1 299 305  373 416  68 75 
2 309 355  344 406  77 77 
3 317 326  356 418  75 78 
4 303 315  374 401  69 77 
5 316 317  350 423  74 78 
6 305 320  354 413  72 78 
7 320 297  355 408  74 76 
8 317 350  387 410  78 77 
9 302 309  376 419  71 79 
10 313 317  349 421  72 75 
11 300 324  349 400  69 75 
12 311 318  361 419  74 77 
13 312 323  365 415  69 77 
14 325 318  356 412  72 78 
15 314 328  352 429  72 77 
16 300 321  389 419  71 76 
17 316 302  365 404  71 76 
18 305 331  371 409  73 76 
19 324 321  388 404  70 75 
20 306 312  337 422  72 78 
AVERAGE 310.7 320.45  362.55 413.4  72.15 76.75 
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Traditionally, drugs have been discovered by scanning libraries of natural and synthetic 
compounds. Compounds that were identified as having a desirable biological activity 
were subsequently optimized for use as drugs, a process being performed by medicinal 
chemists suggesting and trying out structural modifications. Nowadays, however, there 
are also investigations to whether the design process can be sped up by letting 
computers do part of the molecule design. In theory, computers could generate and 
(virtually) test many more structures than a medicinal chemist could design in a similar 
amount of time, possibly yielding better compounds at a smaller cost. Of these 
computational methods for drug design, a prominent category is that of evolutionary 
algorithms, which attempt to optimize drug molecules similar to how nature optimizes 
animals and plants: by mutation, cross-over and selection. While the general approach 
of using evolutionary algorithms seems promising, current literature lacks comparisons 
on which approaches and parameter settings work better or worse for drug design. 
Since evaluation of new compounds is expensive, whether it is done computationally 
or experimentally, it is important to develop efficient evolutionary algorithms that 
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require as few evaluations as possible to find molecules with higher drug-likeness or 
enhanced affinity to the target protein. In this study, we investigate the effect of one of 
the major choices in evolutionary algorithms for drug design: what difference it makes 






It is hard to develop a molecule that can activate or inhibit a particular disease-related 
enzyme or receptor, since there is usually barely any information on what kind of 
structure would be needed, nor on how to adapt a lead molecule to improve affinity or 
selectivity. Therefore, much effort goes into synthesizing and screening large numbers 
of compounds, in the hope that a large amount of trial and error will discover 
compounds with the desired properties (Rees, 2003). 
 However, investigators hope to be able to replace at least part of the expensive 
“wet” trial and error with “virtual” trial and error, on the computer. Nowadays, many 
computer programs exist that can aid in the design of new molecules and molecule 
libraries. Such approaches and programs have been summarized in a number of 
reviews (Westhead, 1996; Gillet, 2000; Hann, 2000), as well as in chapter 2 of this 
thesis. A major class of these computational methods applied in de novo drug design is 
that of the evolutionary algorithms (EAs). EAs are promising for drug design, since 
they mimic the powerful optimization process of natural evolution. Biological 
evolution can be considered to be an adaptation of designs (organisms) to optimally 
solve a specific problem (fill a biological niche). Evolutionary algorithms, following 
that example, also mutate and combine designs, and preferentially procreate designs 
with the highest quality (‘fitness’). EAs have been applied to fields as diverse as stock 
market prediction, optical systems, and car safety (Carter, 2005; Koza, 2005; Tan 
2005). Not surprisingly, there have been quite a few applications in drug design too, 
varying from docking to library design to QSAR (Hopfinger 1996; Jones, 1997; Morris, 
1998; Kimura, 1998; Gillet, 1999; Sheridan, 2000). In this investigation, however, we 
focus on their application in de novo molecule design. 
 Evolutionary algorithms have been applied quite often to de novo molecule design 
(Payne, 1995; Nachbar, 1998; Globus, 1999; Douguet, 2000; Schneider, 2000; Pegg, 
2001; Vinkers, 2003; Brown, 2004; Dey, 2008; Nicolaou, 2009), and most authors 
have claimed some success in optimizing molecular structures. However, the 
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abundance of methods hides the fact that we actually know very little about what 
kind(s) of evolutionary algorithm should be used for drug design.  
 While each published method has been claimed to have some success in designing 
new lead compounds, that unfortunately is not a good guide: all optimization methods, 
even random search, will eventually produce results that improve upon a given starting 
situation. If we assume that all optimization methods can theoretically produce all 
possible drug-like molecules, the main question is not so much whether a particular 
method can optimize molecules, but how efficiently it does so. If a search method is 
more efficient, it is superior. And efficiency in this field is not just a theoretical 
concern. When designing compounds for real world applications, it will always be 
necessary to synthesize and test a number of compounds, with all associated costs. 
Therefore, it matters a great deal whether an optimization process needs one hundred or 
one hundred thousand molecules to improve the activity of a lead compound to a 
certain extent. In this respect, it is unfortunate that the investigations described so far 
use different evolutionary approaches and different test systems, since this makes it 
difficult to compare evolutionary methods and settings, and find out which work best. 
 In our opinion, a good start of the investigation of how to design an evolutionary 
algorithm for drug design is by investigating the impact of which is perhaps the main 
decision for every EA designer in this field: the choice of molecular building blocks. 
From which “units” molecules are constructed determines in which ways a molecule 
can be changed and optimized, and which molecules can and cannot be created by the 
EA. For example, if the basic building set does not include halogen atoms, a large part 
of chemical space, including drugs such as fluoxetine and haloperidol, cannot be found. 
And if the building blocks are large, over 10 atoms, the evolutionary algorithm will not 
produce many small molecules. 
 In general, EA designers choose one of two main options. The first option is to 
consider atoms and bonds as the basic building blocks of molecule construction. This is 
called “atom-based” evolution. Alternatively, a molecule can be considered to be built 
out of several multi-atom fragments, considered to be unchangeable semi-independent 
units, like a carboxylic acid group, a phenyl ring, etc. This is called “fragment-based” 
evolution. The choice between atom-based evolution and fragment-based evolution 
influences which molecules can be designed by the evolutionary algorithm, in which 
ways molecules can be mutated and combined, and how much difference there is 
between a molecule and its offspring. The choice between atom- and fragment-based 
evolution could therefore have a great influence on the molecule optimization process, 
yet we could not find any previous investigations into the effect of building block 
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choice. We therefore chose to investigate this factor. 
 Literature shows that many if not most investigations (Payne, 1995; Nachbar, 
1998; Globus, 1999; Douguet, 2000; Brown, 2004) use the atom-based approach. 
Typical mutations are removing an atom, adding an atom, breaking a bond, or making 
a bond, for example in ring formation. Sometimes a method uses both atoms and 
fragments, such as the investigation by Nicolaou et al. (Nicolaou, 2009), but even then 
the method retains the basic benefits and drawbacks of atom-based approaches: since 
every individual atom can be changed, the entire chemical space can be covered, but 
some of the molecules suggested may be difficult to synthesize or chemically unstable. 
 Fragment-based evolution has also been applied by researchers (Schneider, 2000; 
Pegg, 2001; Vinkers, 2003; Dey, 2008), be it perhaps less frequently than the atom-
based approach. The main difference with the atom-based approach is that molecules 
are considered to consist of several independent multi-atom units, which are 
unchangeable. This means that an isopropyl-fragment could never be mutated into a t-
butyl fragment, though it could be replaced by one. Fragment-based mutations 
commonly add fragments to a molecule, remove them, or combine the fragments of 
two molecules. Fragment-based evolution also requires the designers to make some 
additional choices: what kind of fragments should be used, which and how many 
fragments should be used, in which ways are the fragments allowed to be attached to 
one another, and should one take the similarity of fragments into account when 
mutating a molecule (and if so: how?).  
 It is not clear from existing literature whether atom-based or fragment-based 
evolution should be preferred, as no study has compared them yet on the same problem. 
The main advantage of fragment-based evolution over atom-based evolution is that the 
produced structures seem easier to synthesize. While this apparent ease of synthesis 
can be quite deceptive in practice (Vinkers, 2003), it is certainly preferable over the 
much larger chance that a molecule created by atom-based algorithms needs major 
modifications before synthesis can take place (see for example the work of Douguet 
(Douguet, 2000)). On the other hand, atom-based evolution has advantages too. First of 
all, atom-based evolution does not require one to make the–always somewhat 
haphazard–choice of building blocks and attachment rules. Secondly, atom-based 
evolution can in theory construct all possible molecules, in contrast to the fragment-
based approach which can typically “only” create 1010 to 1020 (Pegg et al. estimate a 
lower bound of 1012 for their HIV-RT library (Pegg, 2001)). Being able to create 1012 
molecules may look impressive, however it represents only a tiny fraction of the total 
number of possible drug-like molecules, estimated to be 1060 or higher (Bohacek, 
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1996). This implies that fragment-based evolution can only construct about 1 of every 
1040 possible molecules, which is far less than one molecule in a database containing 
all compounds currently known to man (which would have about 107-108 entries, as the 
largest compound databases such as CAS (CAS, 2009), Beilstein (Beilstein, 2009) and 
PubChem (Pubchem, 2009) contain about 48 million, 10 million and 19 million entries 
respectively as around June 2009. Thirdly, the big jumps taken by fragment-based 
evolution through changing 5-10 atoms simultaneously may make optimization much 
more difficult than when only one or two atoms are changed at a time. This could be 
compared to carving a statue with a pickaxe instead of with a chisel: it is almost 
impossible to exert the precise and subtle control needed for creating the exact result 
one wants. Also, having fewer choices may result in fewer pathways to get to one's 
destination, and more dead ends.  
 Arguments such as the above can theoretically justify preferring either atom- or 
fragment-based evolution. However, the real relative efficiencies of the approaches are 
yet unknown since investigators have used one method or the other, and a comparison 
of atom-based evolution versus fragment-based evolution has not been reported. We 
therefore decided to undertake a study to find out what the differences in performance 
are, if any, between atom-based and fragment-based evolution. 
 We compared atom-based with fragment-based evolution by creating a population 
of 50 molecules, and evolving it for 10 generations with either method. To simulate the 
drug optimization process (at least the optimization of affinity), we decided to optimize 
molecule binding to HIV-reverse transcriptase (HIV-RT), one of the major targets for 
AIDS therapy. HIV-RT was used in earlier fragment-based evolution studies (Vinkers 
2004, Pegg 2001), and continues to be of interest to drug designers and a test for de 
novo design methodologies (for example Jorgensen, 2006; Barreiro, 2007). Therefore, 
HIV-RT seems more or less a benchmark drug target that can make comparisons 
between different de novo design algorithms easier. 
 The fitness of the molecules during the evolution was defined as their docking 
score in HIV-RT. While docking scores are not very accurate for predicting binding 
affinity of a potential drug to a protein, of all evaluation methods it seems best suited to 
base our investigations on. The highly complex interactions between a flexible ligand 
and a heterogeneous, irregularly shaped cavity, as modeled by docking, resemble the 
biological binding process more than for example 2D similarity to known ligands does. 
We do not expect docking in combination with the evolutionary algorithms described 
in this paper to result in 'true leads' for RT-inhibitors, as docking algorithms are not yet 
accurate enough for that purpose. However, for an investigation into making 
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evolutionary algorithms as efficient as possible in designing drug-like molecules, 
docking is probably a good approximative method to weed out inefficient evolutionary 
algorithms, before performing the final fine-tuning with the more realistic but also 
much more expensive and time-consuming synthesis and biological testing of 
compounds. One could compare this to first testing a probe for exploring the planet 
Mars in a cold desert on earth: while the circumstances of the test are not totally 
accurate, it is a much easier, faster and cheaper method to detect flaws than simply 
sending the design to Mars for the real test.  
 Specifically, the fitness of each molecule was defined as its docking score into the 
crystal structure model of HIV-RT using the docking program GOLD (Jones, 1997). 
The GoldScore is a unitless quantity which should be increased to obtain more 
favorable affinities. We use the same crystal structure as Vinkers (Vinkers, 2003) and 
Pegg (Pegg, 2001), pdb-code 1RTI (Ren, 1995). However, since the scoring functions 
in this investigation differs from that of, for example, Vinkers, we cannot easily 
compare our optimized molecules with those of others. Different scoring functions 
mean that molecules optimized for our scoring function may not do so well in Vinkers’ 
fitness measure, and vice versa. However, if ever more comparative studies such as this 
one are undertaken, 1RTI seems a good place to start. 
 
In this paper we will first discuss the evolution settings, the mutations we used, and the 
docking approach taken. After that we will focus on the structures of the compounds 
and on the improvements in docking scores over the course of the atom- and the 
fragment-based evolution. Finally, we will compare our methods and results with those 





Description of the algorithm 
The evolution experiments required several steps: generating the initial population of 
molecules, selecting and modifying the molecules, and evaluating their fitness by 
docking and scoring them. The general algorithm of the evolution is given in 
Algorithm 6.1. The following paragraphs will discuss the various steps in more detail. 





Algorithm 6.1: The basic algorithm used for evolving molecules with a high 
fitness (in our case, a high docking score). 
 
A) Create initial population 
-while the initial population contains fewer than 50 
    molecules: 
  -generate a molecule out of NCI fragments 
  -add this molecule to the population if it satisfies 
    the physicochemical restraints. 
B) Perform evolution 
 -while there are fewer than 10 generations 
  -calculate the fitness of each molecule in the current  
   generation by docking it into HIV-RT  
  -if the current generation is not the initial  
   generation: 
   -select 10 molecules by tournament selection 
    from the previous generation 
   -add these molecules and their fitnesses to the  
    current generation 
-make a new generation next to the current generation. 
-while there are fewer than 45 molecules in the new 
generation 
   1] choose one molecule from the current generation  
      by tournament selection. 
 
 
   2] choose crossover or mutation 
    -if crossover:  
     -select a second molecule from the current  
      generation by tournament selection 
     -cross the two molecules, and pick one of  
      the products at random 
     -if crossover cannot be performed since  
      there are no suitable breaking points, go  
      back to step 1. 
    -if mutation: 
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     -pick a mutation type at random 
     -perform the mutation on the selected  
      molecule 
     -if the mutation cannot be performed due to 
      lack of suitable atoms or bonds, go back  
      to step 1. 
   -if the resulting molecule obeys the 
    physicochemical constraints and was not part of a  
    previous generation: 
    -add the new molecule to the new generation 
  -endwhile 
  -for j=1 to 5 
   -generate a molecule at random 
 -if the molecule obeys the physicochemical 
    constraints: 
    -add the molecule to the new generation 
  -rename the current generation to “previous  
   generation”, and the new generation to “current  
   generation” 
 -endwhile 
 
The molecules of the initial population were built out of fragments from the NCI 
database (NCI, 2000). To obtain these fragments, the molecules in this database were 
divided into parts by an algorithm we described in chapter 3, which splits molecules 
into fragments by breaking the bonds which connect the ring systems with the rest of 
the molecule. This splitting results in ring systems, branches and linkers, as illustrated 
in Figure 6.1. The branches and linkers also store information about the atom type of 
the ring atom(s) they were attached to, to help virtual “reverse synthesis”.  
 Splitting the molecules of the NCI database across ring attachment bonds also 
resulted in data about their fragment composition. For example, 7.5% of all molecules  
consisted of exactly two ring systems, two branches, and one linker connecting two 
fragments, like the acetophenazine molecule in Figure 6.1. This information was also 
used in constructing the random molecules of the initial population. Each molecule was 
created by first picking a fragment composition (for example, a 7.5% chance to have 
the “2-2-1” composition), and then picking the fragments themselves out of the 300 
most occurring ring systems and the 300 most occurring non-ring systems (branches 
157 
 
and linkers). The probability of a particular fragment being selected was proportional 
to its occurrence in the NCI. Since our database however also incorporated data to 
which atom type each non-ring fragment was attached, initially selected fragments for 
which there was no suitable atom type in the rings to connect to were replaced by other 
fragments. For example, the keto group created by dissecting the molecule in Figure 1 























Figure 6.1. The fragments used in molecule construction and fragment-
based evolution were obtained by splitting the molecules in the NCI 
database into ring systems, linkers and branches. This example shows 
which fragments would be obtained from an acetophenazine molecule. 
 
atom, and not to for example a nitrogen atom in piperidine. In some cases, the atom 
type demanded by a particular fragment was not available in the fragments that should 
be linked to it: for example, a methyl fragment that in the NCI was attached to a 
nitrogen atom ( (bn)-CH3 ) could not be attached to a phenyl ring (other fragments, like 
(bc)-CH3, however, could). 
 Molecules were generated until there was a population of 50 molecules that 
satisfied the following demands that we considered suitable for lead-like molecules: 1) 
polar surface area (calculated according to (Ertl, 2000) smaller than 120 Å2, 2) 
molecular weight between 150 and 300, 3) at most 5 hydrogen bond donors, 4) at most 
10 hydrogen bond acceptors and 5) at least one hydrogen bond acceptor. In addition, a 




After the initial population was generated, it was evolved (via atom- and fragment-
based evolution) as follows. First the fitness scores of all molecules were calculated by 
docking them with GOLD in the HIV-RT crystal structure and selecting the best 
ranked pose for every molecule (the preparation of the molecules for docking in GOLD, 
and the settings used in GOLD, are described in more detail on page 167). Then the 
next population was made by first creating 45 molecules through mutating and crossing 
over parent molecules, selected by 4-sized tournament selection, which means that out 
of four random molecules in the parent population the molecule with the highest 
docking score was chosen. The 45 new molecules also had to obey the constraints 
listed in the previous paragraph, be it that after the first population up to 10 rotatable 
bonds were allowed, and the maximum molecular weight was increased to 500. In the 
last step, 5 molecules were added from the 200-molecule database containing random 
molecules similar to those of the initial population (the initial population actually 
consisted of molecules 1-50 of this database, the five molecules added to the first 
generation of the atom-based evolution were molecules 51-55, the five molecules 
added in the second generation of the atom-based evolution were molecules 56-60, etc. 
The fragment-based evolution added other series of five molecules from this same 
database, so a random molecule would never appear more than once in either the atom-
based evolution or fragment-based evolution). The new population therefore also 
consisted of 50 molecules in total. 
 Since we did not want to evaluate molecules more than once, we introduced the 
restraint that molecules created by mutation and crossover would only be added to the 
new population if they had not occurred yet in previous generations. This could, 
however, hamper optimization, since the best molecules would be forgotten after one 
generation. In contrast, most evolutionary algorithms allow a good individual to 
survive indefinitely and to even clone itself, so it can eventually fill the entire 
population. We tried to avoid such loss of diversity yet conserve the memory of the 
best molecules by adding some old molecules to each generation. After the 50 
molecules of a population were generated in the normal way, we added 10 of the best 
molecules of the previous generation (selected by tournament selection), making the 
effective population size 60. The next generation was created by mutating and crossing 
those 60 molecules. So, in principle, a superior molecule from generation 1 could 
contribute its genetic information directly to several generations by first being a parent 
for the molecules in the next generation (generation 2), and subsequently be added to 
the generation of its children by being chosen as one of the ten grandparents (so 
forming the extended generation 2 together with its direct offspring). In this way, it can 
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produce offspring into the generation of its grandchildren (generation 3). As a member 
of the extended generation 2 it could be also added to the generation 3 as one of the 
best of the generation 2, into the extended generation 3, becoming one of the sixty 
parents for the molecules in generation 4. While the randomness of tournament 
selection makes it unlikely that any molecule, no matter how good, will remain 
producing offspring for more than three generations, it will buy the best molecules two 
or three generations extra time to produce high quality offspring.  
 
Manual filtering of molecules 
Occasionally, a molecule generated by atom-based evolution seemed extremely 
difficult to synthesize. This was often the result of the evolutionary algorithm creating 
an extra bond within a benzene ring or another small ring. Examples are given in 
Figure 6.2. To prevent evaluation, evolution and accumulation of these ‘useless’ 
structures, we visually inspected all molecules created and removed the structures 
deemed unsynthesizable (to not fall below our target of 45 structures, we actually 
created initial populations of 50 molecules, of which the last five molecules were 
spares which could be used to replace molecules among the official 45 if any were 
flawed). Filtering did not take much time for these small-scale experiments, and 
molecules were only rarely rejected (typically two or three molecules out of 50). We 
have recently added a ring structure filter (based on existing NCI rings and NCI ring 
templates), which will probably make such manual filtering unnecessary in future 
experiments. 








Figure 6.2: Atom-based evolution occasionally produced structures which 
contained ring systems that seemed far too strained to allow for a feasible 
synthesis. Such structures (a few examples are shown here) were manually 




All evolution experiments were performed with the Molecule Evoluator (chapter 4), 
which was adapted to include fragment-based mutations and crossover. Both the atom-
based mutations (which were already present in the Molecule Evoluator) and the 
fragment-based mutations (which were added during this investigation) will be 
described in the next paragraphs. 
 The atom-based mutations either manipulate atoms (adding atoms, inserting atoms 
in a bond, removing atoms, ‘uninserting’ atoms, changing atom type) or bonds 
(increasing bond order, reducing bond order, making or breaking rings). These nine 
operators were also described in chapter 4. 
 While the mutations create a derivative from one parent molecule, the atom-based 
crossover operator combines two input molecules. The crossover first chooses a 
random non-ring single bond in each molecule, and, by breaking these bonds, splits the 
molecules into two parts. Subsequently, one part of the first molecule is recombined 
with one part of the second molecule, and the other part of the first molecule is 
recombined with the other part of the second molecule. This results in two offspring 
molecules, of which one is chosen randomly as the crossover product. The crossover is 
shown in Figure 6.3. 
 The second approach, fragment-based evolution, considers a molecule to consist 
of a small number of fragments, and its mutations therefore replace and move bigger  
parts of the molecules than the atom-based approach does. The mutations and 
crossover move the fragments which have been defined in the previous paragraphs: 
ring systems, linkers, and branches. In our implementation the fragment-based 
evolution uses two types of mutations: “rotation”, in which a ring substituent is moved 
to another position of the same ring, and “exchange”, in which two fragments that are 
connected to the same ring or linker swap positions. Examples of these mutations are 
given in Table 6.1. It should be noted that branches should always be attached to the 
same atom type to which they were originally attached, since this attachment 
information is part of our branch data (as explained above). 
 The fragment-based crossover, like its atom-based counterpart, takes two 
molecules, but instead of breaking a random bond, only breaks the bonds that connect  
fragments. Therefore, only intact fragments are moved around and recombined with 
each other. The requirements of the fragment-based crossover are that the fragments to 
be exchanged are of the same type (ring or non-ring) and that, if the fragments are 
rings, they are attached to the same number of non-ring fragments. For example, a 
phenyl ring with three substituents and a cyclobutadiene ring with two substituents 
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Figure 6.3: The molecule crossover used in atom-based evolution. a) Two 
parent molecules are selected, b) the molecules are split in two by breaking 
random non-ring bonds, c) the molecule parts are recombined, d) one 
molecule is selected at random as the crossover product.  
 
cannot be interchanged, while a phenyl ring with two substituents could be 
interchanged with the cyclobutadiene. This second requirement was introduced to 
improve ease of synthesis, since it could prevent too big steps in chemical space, like 
for example replacing a phenyl ring with three substituents by a cyclopropane ring 
which usually has only one or two. Lastly, the branches and linkers should be 
reattached to their correct atom types; the crossover will not link a cyclohexane ring to 
a (bn)-isopropyl fragment. The fragment-based crossover is illustrated in Figure 6.4. 
 In both atom-based and fragment-based evolution, the mutation:crossover ratio 
was set to 85:15, based on experience with the interactive version of the Molecule 
Evoluator. All mutation subtypes were applied with equal probability; so the 
probability of applying one of the nine atom-based mutations, such as “insert atom”, 
was 11%, and the fragment mutations ‘exchange’ and ‘rotate’ both had a 50% chance 
of being chosen. While these ratios are almost certainly not optimal, we chose them as 
the starting point for this study, to be adjusted for future investigations depending on 






Table 6.1: The mutations used in fragment-based evolution. Rotation 
moves branches (non-ring structures) around rings, 'exchange' exchanges 
the positions of either two rings or two branches. 
 



















Protein preparation and automated docking simulations 
The crystal structure we used, (pdb-code 1RTI (Ren, 1995)) is a co-crystal of the HIV-
RT with a small-molecule inhibitor, HEPT (1-(2-hydroxymethyloxymethyl)-6-phenyl 
thiothymine). Despite the similarity of this ligand to a nucleoside, HEPT does not bind 
to the site where the new DNA is synthesized. Instead, like nevirapine, it binds at some 
distance from it, at the so-called non-nucleoside binding site (Ren, 1995). Compounds 
binding at the non-nucleoside site force HIV-RT in a non-active conformation. Figure 
6.5 shows the binding mode of HEPT in the 1RTI crystal structure. In some HIV-RT-
ligand crystal structure complexes, H-bond interactions between the ligand and a water 
molecule located in the solvent channel are observed (Esnouf, 1997; Shen, 2003). 
While in many cases it is advisable to keep the water molecules in or near the binding 
site when docking (Klebe, 2006), this water molecule is not observed in the 1RTI 
crystal structure and is not conserved amongst all HIV-RT-ligand crystal structure 
complexes. Furthermore, it was not found to significantly influence automated docking 
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a. b. c. d.  
Figure 6.4: Fragment-based molecule crossover, which can both be 
performed on ring systems (top) and on branches (bottom). a) Two parent 
molecules are selected, b) the molecules are split: in both molecules a 
random fragment of the same type (branch or ring) is selected and the 
bonds between the chosen fragment and the rest of the molecule are 
broken c) the molecule parts are recombined, d) one molecule is selected at 
random as the crossover product. Note that the CH2NH2 group could also 
have been exchanged with the methyl or chlorine, the pyridine-
cyclopropane interchange is however not possible since the ring systems 





simulations of HIV-RT-ligands (Titmuss, 1999). Therefore, protein mol2 files for 
GOLD docking were generated using the Biopolymer module in Sybyl (TRIPOS) by 
removing the ligand and crystallographic water molecules from the pdb-file, and 
adding all hydrogen atoms. Molecules were generated as 2D structures in MDL MOL-
file format (Dalby, 1992) by the Molecule Evoluator and converted to 3D structures in 
mol2 format by the program MOE (Chemcomp. Corp.) GOLD docking was performed 
using “7-8 times speed up” settings (Jones, 1997). The active site centre as determined 
by the PASS program (Brady, 2000) was taken as the starting position of the GOLD 
flood fill algorithm. To meet aspects of calculation time and data size on one hand, and 
convergence criteria and statistical relevance on the other hand, 15 independent 
docking runs were performed for each docking case. 
 
Estimating ease of synthesis 
As last part of the experiment, we checked ease of synthesis. We asked an experienced 
medicinal chemist, J.B., to check of each structure whether it could be synthesized 
reasonably easily. If not, we asked him to suggest a suitable derivative. All suggested 
replacement structures were docked using the normal docking procedure, and their 
fitness values gathered and compared to the fitness scores of the original compounds. 
 
 
Results and discussion 
 
Docking the molecules into HIV-RT 
Docking the EA-generated compounds in the HIV-RT crystal structure resulted in the 
dockings shown in Figure 5. The binding pocket can be divided into a large 
hydrophobic subpocket 1 (enclosed at the top by residues Y188, W229, F227), and two 
small subpockets 2 (formed by L234, P236, and Y318) and 3 (formed by V178 and 
Y181) (Hopkins, 2004), which is located close to a hydrophilic solvent channel, 
proposed to be the ligand access channel (Shen, 2003). Typical NNRTIs like HEPT 
form H-bonds with the backbone of K101 and/or K103, and in some cases also with a 
water molecule located in the solvent channel (Ren, 1995; Esnouf, 1997). Furthermore 
typical NNRTIs bind to subpocket 1 via hydrophobic and aromatic interactions 
(Titmuss, 1999) and can form additional hydrophobic and aromatic interactions with 
subpockets 2 (e.g., HEPT and efavirenz) and 3. The compound with the highest fitness 
in the first generation only occupied subpocket 1, while the best compounds found by 








Figure 6.5. The dockings of the compounds generated by the evolutionary 
algorithm into the original crystal structure of HEPT bound to HIV-reverse 
transcriptase. HEPT is shown as a transparent brown structure. In addition, 
(a) contains the compound with the highest fitness in the first generation 
(yellow) docked into the crystal structure, (b) the docking pose of the best 
compound found by atom-based evolution (green), and (c) the docking pose 
of the best compound found by fragment-based evolution (cyan). 
 
respectively, in addition to subpocket 1. None of the compounds formed H-bonds with 
the backbone of K101 and/or K103. However, hydrophobicity is another key feature 
driving the potency of inhibitor binding to the NNRTI site (while GoldScore does not 

















interactions and therefore assigns a higher score to a ligand that better fits the three-
dimensional structure of the binding pocket). Optimization of hydrophobic interactions 
in pocket 1 is already observed in the first generation cycle (see the left panel of Figure 
6.5), in which an S-phenyl group attached to a two-ring ring system dips into the 
aromatic cluster of Y188, W229, F227. A two-ring core, consisting of two fused 6-
rings, is maintained throughout both atom-based and fragment-based evolution (see 
Figures 6.6 and 6.7), even though the original 1,2,3,4-tetrahydroisoquinoline ring 
system is changed during atom-based and fragment-based evolution into a 1,2-
dihydronaphthalene ring system and a naphthalene ring system, respectively. 
Furthermore, the initial aromatic ring dipping into pocket 1 is only slightly changed 
into other functional groups of the same hydrophobic character along the different 
evolution pathways. The evolution has led to probing and optimization of hydrophobic 
interactions with different smaller subpockets of the HIV-RT binding site. Re-
positioning of the pocket 1-occupying subsituent from the 5’ to the 6’ position 
accommodates interactions of hydrophobic substituents on other positions at the two-
ring core with subpockets 2 and 3. In the atom-based evolution, the initial hydroxyl 
group sticking out in the direction of subpocket 2 (Figure 6.5a) is replaced by an S-
phenyl group which can interact with subpocket 2 formed by L234, P236, and Y318 
(Figure 6.5b). During fragment-based evolution, an ethenesulfinate group was attached 
meta to the hydrophobic group interacting with subpocket 1. This ethylenesulfinate 






















Figure 6.6. The optimization trajectory leading to the best molecule of the atom-
























Figure 6.7: The optimization trajectory leading to the best molecule 
produced by the fragment-based evolution. The numbers under the 
structures indicate their fitness score. Note that the SO3C2H3-group of the 
second parent molecule was modified to a SO2C2H3-group by an error in 
our program. This bug was later fixed. In later fitness comparisons, not 
much influence on fitness was found by the presence or absence of the 




The change in fitness over the generations 
To study the differences between the atom-based and fragment-based evolution, we 
first gathered of each generation the maximum fitness value (the fitness of the “best” 
molecule) and the average fitness value. These values are plotted in Figure 6.8.  
 

























Figure 6.8: The average and the best fitness of molecules in each 
generation for the atom-based and fragment-based evolution. 
 
Figure 6.8 shows that both the average fitness and the maximum fitness of the 
molecules in the population grow as the evolution proceeds. This means that new and 
better molecules are found, which implies that evolution improves upon pure selection 
(since pure selection would cause the average and maximum fitnesses of the later 
generations to approach the maximum of the first generation). However, virtual 
screening of a large library will also increase maximum fitness, as there is always a 
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probability that a new molecule will improve upon the known compounds. We should 
therefore analyze our data further to be able to say whether evolution is truly more 
effective or efficient than random search. 
 Fitting the fitnesses of the randomly generated first generation to a Gaussian 
(Figure 6.9) results in a best fit with mean value 36.7 and a standard deviation of 4.3.  
 












Figure 6.9: The distribution of fitness scores of the molecules of three 
populations fitted to Gaussians. The populations are the initial population, 
the atom-based population containing the highest-scoring atom-based 
molecule (8th atom-based generation), and the fragment-based population 




The best overall result of evolution (score=76) lies about 9 standard deviations from 
this average. Therefore the probability that a random search would produce a molecule 
with this or a higher fitness would be smaller than 10-9%. Scanning 500 molecules and 
getting the improvement shown in Figure 6.9 suggests that this improvement cannot be 
the result of a random search only. Therefore evolution seems truly more efficient than 
random search. We should note hereby that the distribution of the initial population, as 
shown in Figure 9, is Gaussian-like, but not exactly Gaussian. For example, there are 
about 5 molecules with a fitness score of about 50, which is more than would be 
expected from a true Gaussian distribution. Therefore, putting the odds that random 
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search produces a similar improvement as the evolutionary algorithm at 1:1011 may be 
mathematically questionable. However, the distance between the best fitness found by 
the EAs and the average and best fitnesses of randomly produced molecules seems 
large enough to indicate that both of our evolutionary algorithms noticeably improve 
on random search.  
 
Fitness peaks/plateaus 
While evolution improves molecular structures significantly, the improvement (at least 
in atom-based evolution) stops quite quickly, around the 8th generation. It is very 
unlikely that by then the ‘best possible’ molecule has already been found. What then 
causes this stagnation? And how could it be prevented in future experiments? 
 The first explanation is that we simply have evaluated too few generations for full 
optimization. EAs are known to have periods of stasis, and are usually run over many 
more generations than 10: in other applications of evolutionary algorithms to de novo 
design molecules are evolved over 50 to 20,000 generations (Nachbar, 1998; Vinkers, 
2003; Brown, 2004). Often, lack of improvement in fitness only means that the 
population is at some local optimum, and needs to be evolved for a few more 
generations before better molecules are found. Running the EA for more generations 
(something we did not do due to limitations on computational time and our own time – 
a number of steps such as screening for unusual structures had not yet been automated 
and required manual intervention) may result in renewed improvement with better 
molecules found. 
 Our second hypothesis is that the stagnation and deterioration of scores has 
uncovered an inefficiency in the EA that should be addressed instead of compensated 
through evaluating more generations. The most likely explanation of the decrease is 
that our rule that each molecule generated must be “new” forces the evolution away too 
quickly from a local optimum; better variants of the best molecule cannot be built 
anymore since the best molecule has already been “forgotten”. The result is a downhill 
trend in the fitness scores, the molecular structures going away from the last found 
optimum, until a novel structure is found which can be optimized again. In our case, it 
may be that the requirement that each molecule must be new may prevent a true local 
optimum to be reached since eight generations is too short for full optimization; of any 
compound, including the best compound, several hundreds of derivatives can be made 
through atom-based mutation. Therefore, the one or two generations the best molecule 
had to procreate are not enough for a good “full” local optimization. Therefore, it 
would be best to drop the “only new molecules” requirement. Interestingly, the 
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fragment-based evolution does not show a similar deterioration. It is possible that the 
fragment-evolution has not reached a similar plateau yet, since it reached its peak later 
than the atom-based evolution. 
 
Comparing the molecules created by atom-based and fragment-based 
evolution 
Next to the fitness scores, we compared the molecules resulting from atom-based and 
fragment-based evolution. The top 5 molecules found by both approaches are shown in 
Figure 6.10, together with their fitness scores. 
 The most interesting observation to us was that fragment-based evolution seems 
approximately as good as atom-based evolution. This seems to refute our hypothesis 
that atom-based evolution should go more smoothly and therefore be better than 
fragment-based evolution. Why were we wrong? To find an explanation, we studied 
the different optimization trajectories and the molecules produced in more detail. The 
evolution trajectories leading to the best molecules found by the atom-based and the 
fragment-based evolution, respectively, are shown in Figures 6.6 and 6.7. 
 Though there are obviously differences between the optimization trajectories, the 
atom-based evolution and the fragment-based evolution are quite similar in terms of 1) 
the part of the initial population that is used, 2) the presence of local optima, and 3) the 
high occurrence of crossover. Each of these similarities will be discussed shortly below. 
 To produce their best molecules, both atom-based and fragment-based evolution 
apparently use only a small part of the initial population (3 to 5 molecules), and no de 
novo molecules which have been later added appear in the trajectories of Figures 6.6 
and 6.7. This suggests that the 4-size tournament selection is quite strict, and quickly 
fills the population with high-scoring mutants of the best molecules, giving 
“newcomers” little chance to contribute to the gene pool. It may be worthwhile to 
experiment with less strict selection (such as 3-sized tournaments or 2-sized 
tournaments) to see if this allows more of the information in the population to be used 
in developing more diverse and eventually even better molecules.  
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Figure 6.10: The most highly scoring five molecules found by atom-based 
evolution (left) and fragment-based evolution (right). The numbers in the 
brackets indicate the docking score. 
 
 
Another reason for not making the selection pressure too high is the presence of local 
optima. It is quite common for a high-scoring molecule (like the bottom-left molecule 
in the atom-based evolution, score 53) to produce a lower-scoring molecule (score 46 
in this case) which however gives birth to new molecules that have a fitness 
comparable to or even higher than that of its (great)grandparent (52 and 57, 
respectively). One may argue that this could be caused by imprecision in the docking 
procedure, which may assign somewhat different scores to one molecule if the docking 
experiment were to be repeated. In such a case the intermediate molecule may indeed 
have an intermediate score if more calculations would be performed. Alternatively, 
there could really be local maxima in an optimization trajectory, which would trap a 
greedy (“only better offspring”) algorithm too easily. Methods like evolutionary 
algorithms (used here) or simulated annealing, which generally explore around local 
optima, may therefore be inherently more suitable for molecular space than a greedy 
search which discards all variants with a lower score than the highest scorer. Another 
reason not to select too greedily is that both computational fitness functions and 
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experimental affinity measures are bound to have some noise, with some superior 
molecules perhaps scoring slightly worse than their competition due to the random 
nature of the docking process and the random variations in experimental measurements. 
An evolutionary algorithm, to be effective, should therefore tolerate this noise and not 
select too strictly and too greedily. We also stress that the accuracy of the docking 
score is not too relevant for the comparisons made here. Our aim was not to find novel 
HIV-RT inhibitors, but to evaluate the two EAs in a realistic setting. Docking 
procedures possibly assigning different scores over different runs to the same molecule 
can even be considered to incorporate an extra element of realism since biological 
experiments also tend to yield ranges of values, and a good optimization algorithm 
should work despite these irregularities.  
 The third similarity between the different evolution methods is the relatively high 
occurrence of crossover. While our settings should have led to about 15% crossover 
versus 85% mutation for modifying molecules, the optimization tree of highest scoring 
compound in the atom-based evolution had 4 crossovers versus 9 mutations, 31%, 
while that of the highest-scoring compound in fragment-based evolution had 7 
crossovers versus 10 mutations, 41%. The reason the crossover was set at 15% in the 
first place was because medicinal chemists evaluating the Molecule Evoluator did not 
like the large changes in molecules introduced by crossover; the structure of crossover 
products was often so different from that of its parents that the compounds created by 
crossover seemed unlikely to have any related biological activity. Apparently, however, 
crossover does not always make such activity-destroying changes, and is a useful 
operator for finding good molecules. Therefore, we should consider setting its 
prevalence higher in follow-up experiments. Interestingly, molecule crossover has also 
been found useful to create drug molecules in practice (Lazar, 2004).  
 
Surveying our results, we learned that atom-based and fragment-based evolution have 
lots in common and that both seem approximately equally efficient in this experiment. 
However, there are also differences. First of all, the evolution trees show more clearly 
than the fitness plot that atom-based evolution does run more smoothly. It reaches a 
better molecule than the fragment-based evolution, and it does so in fewer generations. 
It truly seems to be more efficient, though not by a large amount. In the fragment-based 
evolution shown in Figure 6.7, big substituents make large jumps around the molecular 
core. An example would be the SO2C2H3 group in the middle column of Figure 6.7, 
which moves to very different positions of the ring system. If a large substituent is 
attached at very different positions in parent and offspring molecules, this would imply 
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that either the substituent of the offspring molecule is docked in another part of the 
binding pocket than it was in the parent molecule or that the offspring’s core is docked 
in another place. Since the dockings of parents and offspring in fragment-based 
evolution are therefore more likely to be dissimilar, the evolution is probably less 
efficient. If, for example, in fragment-based evolution only half of the offspring of a 
good molecule is docked in the way of their parent, it is likely that only this half will 
have a good or even better score than the parent molecule, and the time spent to 
evaluate the other half of the offspring is wasted. The smaller changes in atom-based 
evolution should result in offspring of which a large part will be docked similarly to the 
parent, say 90%, leading to fewer offspring with low fitness scores due to radically 
different docking. Quantitatively, one would have to analyze the correlation between 
the fitness scores of parent and offspring. It would definitely be interesting in future 
investigations to automate such a “docking comparison” process and get the actual 
numbers. 
 The second difference between the atom-based and fragment-based approaches is 
the result of the optimization. While the molecules found by the atom- and the 
fragment-based evolution have similar fitnesses, their structures are definitely 
dissimilar (Figure 6.10). The most striking difference between the best molecules 
found by the atom-based evolution and those found by the fragment-based evolution is 
the lack of diversity in the top-5 fragment-based molecules. These molecules all have a 
sulfur-bound cyclohexadiene group and a ethylenesulfinate group attached to 
naphthalene or a naphthalene-like ring system. In contrast, the top-5 of atom-based 
molecules contains four different structural classes. This diversity is beneficial, since it 
improves the chance that at least one class of molecules is found with suitable 
biological and physicochemical properties. 
 The difference in diversity between the molecules optimized by atom- and 
fragment-based evolution led us to investigate the cause of the similarity of the top-5 
molecules created by fragment-based evolution. Was the fragment-based population 
highly diverse and did it contain several different structural groups, of which one was 
superior, or were all molecules in generation 10 similar, and hence the best molecules 
too? We measured population diversity by counting the number of different ring 
systems in each generation of the atom- and the fragment-based evolution. Figure 6.11 




















Figure 6.11. The number of different ring systems in the population during 
the atom-based and the fragment-based evolution. In the last generations, 
the fragment-based population only contains cyclohexadiene, naphtalene 
and the 1,2,3,4-tetrahydroisoquinoline system from the best compound n 
the first generation, while the atom-based population has 3-, 4-, 5-, 6- and 
7-rings with a variable number of double bonds, and a number of two-ring 
systems (5:6, 6:6) and three-ring systems. 
 
 
The diversity plot shows that while the diversity of the population undergoing atom-
based evolution fluctuates, the diversity of the population undergoing fragment-based 
evolution dwindles fast. This difference probably arises because the atom-based 
evolution has several options to generate new ring systems: oxidizing/reducing bonds, 
breaking rings and making rings, as well as mutating, inserting and uninserting atoms. 
In contrast, the fragment-based evolution currently implemented in the Molecule 
Evoluator cannot introduce new fragments, only recombine and copy existing 
fragments. Therefore, it entirely depends for its new ring systems on the 5 de novo 
molecules that are inserted at every generation, and we have seen that these molecules 
rarely survive in a population of already optimized molecules due to the high selection 
pressure. Fragments which are less competitive in the current generation can thus go 
quickly extinct, with no chance of reappearing. The resulting lack in diversity bodes ill 
for further optimization. While the atom-based evolution may crawl out of its crisis 




It is interesting to compare the change in fitness over the generations to the change in 
diversity over the generations. It turns out that the minimum of the atom-based 
diversity (generation 8) coincides with the occurrence of the best compound found in 
the run. Apparently, before generation 8, the evolution is on the trail of a good 
compound and concentrates the search in that direction, diminishing structural diversity 
to focus on a few good groups. Afterwards, the obligatory removal of the best 
molecules pushes the evolution away from the local optimum, and thus back into the 
high diversity that is necessary for efficient exploration. 
 
Synthetic feasibility 
So far we have seen that atom-based evolution seems slightly better than fragment-
based evolution regarding the speed of evolution and the fitness of the molecules 
obtained. However, this does not address the argument of some investigators that 
fragment-based evolution should be used because the molecules created by it are easier 
to synthesize. In reality, the difference in ease of synthesis may be not as important as 
it seems, since both atom- and fragment-based molecules often need to be adapted by 
experienced medicinal chemists to create molecules which can be synthesized within 
reasonable time (Douguet, 2000; Vinkers, 2003). Fragment-based molecules might 
need fewer adaptations than atom-based molecules, but the importance of this 
difference in ease of synthesis has, to our knowledge, not been investigated yet. 
 To assess the effects of ease-of-synthesis requirements on the molecules reached 
by atom-based and fragment-based evolution, we submitted a selection of the top-10 
atom-based molecules and top-10 fragment-based molecules to a chemist, who 
suggested improvements to enhance ease of synthesis. The resulting modified 
molecules were docked in HIV-transcriptase to determine their fitness values. The 
results of six of the compounds, selected for diversity in structure, are shown in Table 
6.2. 
 From comparing the structures and scores of the molecules in Table 6.2 we 
conclude that fragment-based evolution indeed produces superior results respecting 
ease of synthesis. This is mainly because fragment-based molecules need fewer 
modifications, which leads to a smaller change in structure, which leads to a smaller 
change in activity, and since changing an optimized structure is likely to decrease 
activity, the smaller adaptation needed for the fragment-based molecules is beneficial. 
From our results, it seems that the position of the modifications also plays a role; if 
modifications are in or near the core of the molecule, the change in activity is much 
more dramatic than when a substituent at the “edge” is changed. For example, only 
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modifying the central ring of the 4th best atom-based compound (Figure 6.10) from 
cyclobutadiene to phenyl made the docking score fall from 66 to 9. In contrast, the 
decrease in fitness in the fragment-based molecules is generally much smaller, about 
10 units, probably because only the substituents are changed. 
 
 
Table 6.2: Some of the molecules designed by the evolutionary algorithm, 
their derivatives with improved ease of synthesis suggested by our chemist, 
and the docking scores of the original and derived molecules. 
 































































































Comparison with literature 
As last part of this discussion, we compare our work with literature and investigate 
whether our results are consistent with the findings of others, and whether literature 
together with our own results can suggest directions for further investigations. 
 
Atom-based evolution. To our knowledge, the earliest publication that described 
computational evolution of molecules was by Glen and Payne (Payne, 1995). Their 
mutations and crossover were more or less the same as our atom-based operators, 
though they included a 2-point crossover (which exchanged the central parts of two 
molecules) and limited insertions to methylene (only carbon-atoms could be inserted). 
Douguet et al. (Douguet, 2000) also included the 2-point crossover, but did not use a 
ring breaking operator, and seemed to focus much on changing larger parts of the 
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molecule at once, which resulted in a hybrid fragment-atom evolution. Globus et al. 
(Globus, 1999) used only one-point crossover, and no mutations. According to the 
authors, their algorithm worked quite well, even though it was sometimes impossible to 
reach a certain target structure because the starting population or an intermediate 
population did not contain all necessary structural elements (the same can be said of 
our current fragment-based evolution). The crossover of Nachbar (Nachbar, 1998) also 
was one-point, and his mutations were similar to our own atom-based mutations 
(insertion, deletion, atom type mutation, oxydation and reduction of bonds, etc.) 
However, there were more restrictions on atom change mutations, as insertion and 
uninsertion were apparently only allowed in rings, and rings could only be broken at 
one predefined ring bond (though this latter shortcoming was corrected in his later 
work (Nachbar, 2000)). Brown et al. (Brown, 2004) used mutations similar to ours, 
though the two crossover operators were quite elaborate and differed considerably from 
our simple one-point crossover. Finally, the atom-based mutations of Nicolaou et al. 
(Nicolaou, 2009) also involved modifying atom and bond types and insertion and 
removal of atoms. However, it seems that cycles were neither formed nor broken in 
this investigation, possibly because the atom-based mutations were supplemented with 
fragment-based mutations which could simply insert entire ring systems. Nicolaou's 
atom-based crossover is similar to that of Globus (and ours), picking one bond to break 
in two molecules and pasting one of the parts of the first molecule to one of the 
fragments of the second molecule. The general impression left by comparing the work 
of others to our atom-based mutation and crossover operators seems to be that our set 
of atom-based mutations is essentially complete, and at least as versatile as in other 
work. However, of crossover many variants seem possible, and it should be 
investigated which types of crossover are most beneficial for de novo design, especially 
considering the large contribution crossover made in our investigation. 
 
Fragment-based evolution. The fragment-based evolutionary approaches we found in 
literature are those of Schneider et al. (Schneider, 2000), Pegg et al. (Pegg, 2001), 
Vinkers et al. (Vinkers, 2003) and Dey et al. (Dey, 2008). The evolutionary algorithm 
of Nicolaou et al. (Nicolaou, 2009) used both atom-based and fragment-based 
evolution, their atom-based operators were discussed in the preceding paragraph, while 
their fragment-based operators will be discussed here. Schneider obtained his 
fragments by using retrosynthetic rules on the WDI database (Daylight, 2005), 
resulting in over 24,000 fragments. From these fragments, molecules were constructed 
by applying the same retrosynthetic rules in the reverse direction. The algorithm did 
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not contain crossover, just mutation which replaced a fragment by another fragment of 
the same type. Dey et al. (Dey, 2008) used a commercially available database of 20,000 
pre-selected fragments. Interestingly, the genotypes in their algorithm did not encode 
for a complete molecule, each gene encoded a docked pose of an unattached fragment; 
every member of their population was therefore not a molecule, but a collection of 
unconnected fragments, which were connected later by another optimization algorithm. 
Mutation and crossover involved changing the value of a gene (making it represent 
another docked fragment) or exchanging the values of the genes at a certain position 
between two members of the population. Nicolaou et al. used a smaller database, 
consisting of 2363 fragments of tested ligands (so somewhat focused on the problem at 
hand, not a truly general search through molecular space). Fragments could be inserted, 
removed or exchanged, according to the retrosynthetic rules as defined by RECAP 
(Lewell, 1998). In stark contrast to Schneider and Dey, Pegg et al. used only a handful 
of fragments (about 15 in one experiment), which could be attached randomly to each 
other. The mutations here were replacing fragments and connecting fragments to other 
points, which is similar to our “rotation”. Finally, Vinkers et al. used 32,000 molecules 
and a collection of 70 reactions which could extend and combine molecules. In the first 
iterations, molecules could only “grow” by reacting with other compounds, in the later 
phase of evolution, reactants in any position of the chain could be replaced by other 
ones from the database.  
 From the diversity in the fragment-based studies one can conclude that many 
different approaches to fragment-based evolution are possible, with a varying role of 
synthesis rules in molecule construction, and fragment databases that vary from under 
20 fragments to over 30,000 fragments. One of the few similarities between the 
fragment-based methods is that they can replace fragments in a molecule with 
fragments from the database, something our fragment-based evolution cannot do yet, 
but may be good to implement. Our fragment-based evolution does have an extra 
feature, however, as it considers each ring atom a potential attachment point; therefore 
exchange and rotation can create many more combinations from the same fragments 
than the more synthetically strict methods can. Not being able to get new fragments 
into the population is a disadvantage for optimization, but is partially compensated in 
our algorithm by this ability to create more combinations out of a fixed number of 
fragments. The flexibility in attachment points might reduce the synthetic feasibility of 
the designs, but could increase the speed and efficiency of the optimization, since the 




Next to comparing the mutation and crossover operators, it may be useful to compare 
the parameters of evolution of our investigation with those in literature. In the above-
mentioned investigations, population sizes ranged from 30 to 1000, and the number of 
generations allowed ranged from 50 to 1000. Settings were varied to some extent; 
Douguet et al. tested population sizes from 10 to 80, and found 20 to 40 to be an 
optimal size. Glen and Payne investigated sizes from 10 to 100, and considered 50 to 
100 to be the best size. In general, too small sizes are thought to result in premature 
convergence, too large sizes produce slower running optimizations, and may “drown” 
the best compounds by making the probability that they are selected for procreation too 
small. However, premature convergence can also be caused by high selection pressure, 
and this is likely to be the case with our atom-based evolution.  
 Another issue is whether we should or should not use elitism to conserve our best 
molecules. Both approaches are present in literature: occasionally (Pegg, Vinkers, Dey) 
elitism has been used, but in other cases (Glen, Nachbar) not. Douguet tested whether 
elitism was advantageous, and found that it is. Douguet’s findings on elitism support 
our impression that it would be good to allow molecules be copied unmodified into the 
next generation, in a more reliable way and perhaps a larger scale than is used now.  
 A final point is that we have used far fewer generations than the other researchers. 
This was mostly because we wanted to optimize the efficiency of the evolution itself, 
and expose poor methodology which would have been masked by throwing in huge 
computational resources. We can only guess what would have happened if evolution 
had been allowed to go on for more generations. In the current setup, the fragment-
based evolution would have converged in a few more generations, the atom-based 
evolution would have intermittently found new structures with activities comparable to 
or even better than our current maximum. However, in drug discovery it would have 
probably been more efficient to use 50 independent populations of 20 runs than it 
would have been to evaluate one population during 1000 runs. Having many diverse 
ideas is likely to be better than spending many generations refining a local maximum, 
which, despite advanced docking scores, would only have a small chance of being a 
suitable and active lead (Vinkers, 2003). Another argument for having many short runs 
instead of a few long ones is that using atom-based mutations on the fragment-based 
initial population tends to guide the evolution into generating increasingly uncommon 
groups, so ease of synthesis will probably decrease as molecules are “optimized” by 
the evolutionary algorithm. 
 One important point to consider is whether our test system, docking and its score, 
are suitable as fitness function. For example, Verdonk et al. (Verdonk, 2004) have 
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shown that docking scores tend to increase approximately linearly with the number of 
heavy atoms in a compound. Chemically, it is reasonable that the average compound 
with 20 heavy atoms should bind more tightly than the average compound with 10 
heavy atoms for the simple reason that having more atoms allows a compound to have 
more interactions with the target. However, we should be wary if the fitness scores of 
individual compounds correlate linearly with the number of heavy atoms. After all, this 
would mean that the fitness score is biologically unrealistic, since the specific types of 
atoms and the three-dimensional shape of the molecule should influence ligand binding 
much more than the atom count. We therefore took all of the compounds generated by 
the evolution and plotted fitness against heavy atom count. For the atom-based 
evolution, the plot is shown in Figure 6.12. For both atom and fragment-based 
evolution, the r2 values of the correlation were less than 0.35, implying that most of the 
docking score could not be explained by heavy atom count. Our findings imply that the 
GOLD scoring function is in line with biochemical expectations: bigger molecules in 
general bind better, but atom count is not the only contribution to binding. 
 




























Figure 6.12: The relationship between heavy atom count and docking score 
for the molecules produced by the atom-based evolution; while a higher 








One of the main practical obstacles during this investigation was that it required quite 
some manual intervention to convert the 2D structures generated by the Molecule 
Evoluator to 3D structures, dock them, and feed the results back into the evolutionary 
algorithm. While the small scale (about 1000 molecules in total) allowed us to 
thoroughly analyse the strengths and weaknesses of the competing algorithms and give 
us some ideas of what we should or could change and improve, it would be impractical 
to scale our current method up for proper statistical analysis on dozens of runs. For 
future investigations, it would be certainly worth the time and effort to either create 
intermediate software or batch-files to automate as many of the intermediate steps as 
possible. 
 Next to automating the evolution-docking cycle, it would also be beneficial to 
'trace' the evolution of compounds automatically, for example creating a sort of 
extended file format identifying the parent(s) of each compound and which mutation 
gave rise to it. This would be similar to the approach Nicolaou et al. (Nicolaou, 2009) 
use for their graph-based chromosomes, even though it is unclear from their paper 
whether they indeed used that data to optimize their evolutionary algorithm. In this 
way, we could automatically collect data detailing the average change in fitness after 
specific mutations, and let the computer quickly create all evolutionary trees, which 
could be helpful in analyzing exactly when and why a particular run stagnates or 
improves. 
 In addition, there are some factors which may hamper the optimization. One of 
those is the conversion of the molecules from 2D to 3D. The encoding of molecules in 
the current version of the Molecule Evoluator does not specify stereochemistry. This 
means that the conversion of the molecule “genome” to 2D will give rather randomly a 
cis or trans stereoisomer for each double bond outside rings, and the subsequent 2D to 
3D conversion with MOE will add undefined R/S stereocenters. The Molecule 
Evoluator and (as far as we could observe) MOE are deterministic in their conversion 
procedures, which would ensure that a molecule genome would always be converted 
into one specific stereoisomer, so this will not affect reproducibility. However, 
offspring, even if modified outside the stereocenters, might have different 
stereochemistry assigned to them. Such “non-genetic” jumps in fitness would add noise 
and hamper the optimization. It would therefore be useful to encode stereochemistry in 
future versions of the Molecule Evoluator. Another concern is that some structures 
might be in a different tautomeric state in a biological environment (an enol might be a 
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keto group in solution). Since bonds are coded into the genes, the tautomer remains 
fixed over generations and does not give rise to offspring in a different configuration, 
in contrast to enantiomerism. Therefore tautomerism will disturb evolution less than 
enantiomerism. However, a chemist should inspect the molecules with the highest 
scores for possible tautomerism, and dock the tautomers to explore the effects of the 
equilibria on the fitness score. 
 
 
Summary and conclusion 
 
In this investigation we compared the relative usefulness of atom based (small step) 
evolution and fragment based (large step) evolution for optimizing potential drug 
molecules. As was expected, atom-based evolution found a better molecule after fewer 
steps (although the difference was not large), while the fragment-based evolution 
produced molecules that seemed easier to synthesize. By comparing the two 
approaches, also a number of other lessons were learned concerning molecule 
evolution and how to improve the Molecule Evoluator. 
 Firstly, there is no need to add entirely novel molecules after the first generation. 
The fitness of the population increases so steeply, that the new molecules do not 
contribute any useful “genes”.  
 Secondly, and somewhat surprisingly, crossover can be a valuable operator in 
molecule optimization; in contrast to “normal” optimization strategies in 
pharmaceutical research, in which variations are made on one molecule, it may be 
worthwhile to combine one molecular core and some of the side groups of other high-
scoring molecules.  
 Future modifications to improve the Molecule Evoluator would be to stop adding 
de novo molecules each generation, experiment whether allowing a molecule to appear 
more than once in a generation would find an even better optimum, and implement 
automatic gathering of statistical data of all evolved molecules to analyze the 
contributions of the various possible mutations or crossovers to molecule fitness. 
Finally, new mutation operators such as “add/delete fragment” will have to be added to 
the fragment-based evolution to prevent excessive loss of diversity and premature 
convergence. 
 Optimizing molecule optimization techniques is still complicated and requires lots 
of experiments and sufficiently sophisticated fitness functions. However, if drug 
designers want to explore a greater part of the huge number of potential drug-like 
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molecules (over 1060) or want to use accurate and therefore slow fitness functions for a 
more reliable in silico screening, efficiency in optimization is needed. We hope that 
studies like this one will not only lead to faster optimization methods, but will also give 
insight into the general craft of molecule optimization. 
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We used a new software tool for de novo design, the “Molecule Evoluator”, to generate 
a number of small molecules. Explicit constraints were a relatively low molecular 
weight and otherwise limited functionality, for example low numbers of hydrogen 
bond donors and acceptors, 1 or 2 aromatic rings, and a small number of rotatable 
bonds. In this way we obtained a collection of scaffold- or template-like molecules 
rather than fully “decorated” ones. We asked medicinal chemists to evaluate the 
suggested molecules for ease of synthesis and overall appeal, allowing them to make 
structural changes to the molecules for these reasons. On the basis of their 
recommendations we synthesized 8 molecules with an unprecedented (not patented) yet 
simple structure, which were subsequently tested in a screen of 83 drug targets, mostly 
G protein-coupled receptors. Four compounds showed affinity for biogenic amine 
targets (receptor, ion channel and transport protein), reflecting the training of the 
medicinal chemists involved. Apparently the generation of lead-like solutions helped 
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the medicinal chemists to select good starting points for future lead optimization, away 





Chemical space is vast – the number of potential drug-like molecules has been 
estimated to be beyond the number of atoms in the universe.1,2 This is in sharp contrast 
with the total count of molecules in large compound databases such as CAS, with 
approximately 25 million references to chemical compounds.3 Hence, de novo design is 
crucial to cover more of the chemical universe. Computational methods are particularly 
suitable for this goal, as they can quickly generate and store thousands of putative 
structures. Currently, there are dozens of de novo design programs, many of which 
have been covered in a recent review.4 For example, the program CoG (Compound 
Generator) of Brown et al.5 constructs molecules based on atoms and fragments that 
have been given as input to the program, eventually yielding molecules that resemble a 
number of selected ligands. Other programs construct new molecules based on the 
structure of the target protein. For example, DycoBlock6 takes a list of fragments and 
searches for their optimal position in the active site of the protein. Then it searches for 
combinations of building blocks that could be linked together to form a new molecule.  
 We have recently developed a software tool to help medicinal chemists in 
designing new active structures; we called it “The Molecule Evoluator” (see also 
chapter 3 of this thesis). The Molecule Evoluator constructs molecules from atoms and 
a limited number of predefined larger fragments (such as phenyl and carboxylic acid 
groups). The use of atoms and the ability to attach atoms to any other atom and make 
rings at all chemically valid positions of a molecule allows an exhaustive search of 
chemical space and fine–tuning of the molecular structure.  
 An important difference between the Molecule Evoluator and most other de novo 
design programs is the focus on interaction with the user to produce lead compounds. 
Instead of generating a large database which is then screened virtually by docking or 
molecule similarity calculations, it presents a number of molecules to the user, who 
selects and edits the molecules to make them more lead-like. This cycle of computer 
generation and user modification can go on for several rounds, hence the name 
“Molecule Evoluator”. This user involvement was inspired by new approaches in 
computer science that stress the collaboration between computer and user, such as 
interactive evolutionary computing.7 The user is able to use his implicit knowledge, e.g. 
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of synthetic feasibility, to eliminate structures suggested by the program that are 
difficult to make in the laboratory. The user may also bring in other areas of expertise, 
such as domain knowledge for a certain drug target, for example in the form of 
structure-activity relationships. 
 The aim of the present study was to determine whether combining computational 
inspiration with the domain knowledge of a number of medicinal chemists could 
produce novel, biologically active, lead-like structures. We used the Molecule 
Evoluator in a more constrained way than the usual cycle, in which the molecules 
modified by the user are fed back to the computer program to “breed” new molecules. 
Instead, we just created one database of molecules, the structures of which were refined 
by the medicinal chemists alone. For that we asked a panel of medicinal chemists to 
select, comment on and amend a limited number of compounds out of the library, 
which were subsequently checked for novelty. On the basis of their recommendations a 
limited number of the chosen and amended compounds, further simplified for reasons 
of chemical feasibility, was synthesized and tested on an array of drug targets. Half of 
the compounds synthesized possessed significant activity for biological targets, 
indicating that our combination of computer-based generation of molecules and 






De novo design of template molecules 
We used the Molecule Evoluator to generate a virtual library of 300 compounds 
according to a number of restrictions meant to produce template-like rather than drug-
like molecules. These limitations, extended on but stricter than Lipinski’s “rule of 
five”,8 were as follows: 
1) At least one and at most two aromatic systems 
2) Polar surface area equal to or below 70 Å2 
3) A maximum number of two hydrogen bond donors and four hydrogen bond 
acceptors 
4) Not more than five rotatable bonds 
Although we also experimented with molecular weight restrictions we learned that the 
above four criteria invariably resulted in compounds with molecular weights lower 
than 400 D, hence lower than “Lipinski’s” cut-off of 500 D. 
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The 300 compounds were presented to a panel of five medicinal chemists with 
different backgrounds (chemistry of peptides, biogenic amines (2x), nucleosides/ 
nucleotides, and chiral synthesis). They were asked to select at least 10 compounds to 
their liking. Specifically, the selected compounds had to look drug-like and 
synthetically feasible, or at least be amenable to be changed into such compounds by 
minor modifications. This led to a total of 34 compounds (Table 7.1).  
 
 
Table 7.1: The 34 compounds selected from the 300-member library 
generated by the Molecule Evoluator. The left-hand column shows the 
structures as generated, while the right-hand column lists the structures 
after initial amendment by the medicinal chemists. Those molecules marked 
with a star were selected for further amendment and synthesis.  
 
























































































































































































































































































Our next step was to inspect the 34 molecules for novelty, ease of synthesis and drug-
likeness. Novelty in this case was defined as absence from both the Beilstein and 
SciFinder databases either as a structure or substructure.3,9 This process took place in 
March 2003; we did not check for later occurrence. For ease-of-synthesis we allowed 
the chemists to modify the suggested structures to reduce the anticipated number of 
synthetic steps (maximally 3 from a commercially available starting material). Drug-
likeness was not only based on the filters that we already applied when the virtual 
library was generated, but also on the intuition of the individual medicinal chemist. All 
in all this led to a top-nine of compounds that formed the start for our synthetic 
program (see Figure 7.1). Two chemists (R.T. and R.S.) were allotted a restricted 
period of time to try and synthesize these compounds. It was decided to rapidly 
terminate a project whenever synthetic feasibility in practice was less than anticipated 
‘on paper’. This was particularly true for compounds 1f and 1g. It was also decided to 
allow further variations on the nine molecules presented in Figure 7.1 on the basis of 
experimental findings in the synthetic program. As a consequence the final series of 
compounds, although much inspired by the very first suggestions, deviated from the 
original structures. In general, the computer-generated molecules were simplified by 
eliminating most substituents, while the core structure was retained together with one 
or two of the most important or interesting substituents. Further variation was produced 
by making derivatives of the remaining substituents (such as oxidizing a CH2OH group 
to COOH). Eventually we prepared and characterized eight compounds as represented 
in Figure 7.2. Their synthesis is outlined in the chemistry paragraph below and 







































Figure 7.1: The final selection of nine compounds (1a-1i), amended by the 























Compound 3 was prepared by substitution of 3-(bromomethyl)benzonitrile with 2-
piperidinone which was deprotonated with one equivalent of butyllithium.10 Synthesis 
of compound 4 was performed by alkylation at the 3-position of 2-piperidinone via the 
enolate anion in which the nitrogen atom was temporarily protected with TMS.11 
Hydrogenation of compound 4 with Pd/C as catalyst afforded the benzylamino 


















Scheme 7.1: a: 1 eq. n-BuLi, 3-(bromomethyl)benzonitrile. b: TMSCl, n-
BuLi, 3-(bromomethyl)benzonitrile. c: Pd/C 10%, H2. 
 
Synthesis of 2-(3-piperidyl)-benzyl alcohol (6) was done by a two step reaction. First 
2-(3-pyridyl)-benzyl alcohol was prepared by a Suzuki reaction of diethyl(3-
pyridyl)borane and 2-bromobenzyl alcohol under microwave conditions.12 The product 
of this reaction was hydrogenated under acid conditions with PtO2 as catalyst and 
provided compound 6. Benzyl alcohol 6 was oxidized with chromic acid and isolated 
as zwitterion. Purification was problematic, however preparative HPLC provided pure 
product 7 (Scheme 7.2).  
 
b ca











Scheme 7.2: a: Na2CO3, TBAB, (Ph3P)4Pd, H2O, MW. b: HCl, PtO2/H2. c: 
Jones' reagent. 
 
The most straightforward way to prepare compounds 8 and 9 was the Suzuki coupling 
reaction of 3-bromofuran with boron derivatives of 3- and 4-aniline respectively, under 
microwave conditions. Compound 10 was prepared from 9 by reaction with succinic 




















Scheme 7.3: a: 3-aminophenyl-boranic acid, Na2CO3, TBAB, (Ph3P)4Pd, 
MW. b: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, Na2CO3, 




We tested the 8 compounds in a commercially available screening program. 
Radioligand binding and enzyme assays, 68 and 15, respectively, were the read-outs to 
probe the interaction of the individual compounds with this large collection (83) of 
drug targets. These included G protein-coupled receptors (rhodopsin-like, class A; 
metabotropic glutamate-like, class C), ion channels (for Na+, K+, Ca2+), nuclear 
hormone receptors (e.g., estrogen, progesterone), transport proteins (e.g. for dopamine, 
norepinephrine, GABA), and enzymes (several phosphodiesterases, Na+/K+-ATPase, 
etc). All compounds were tested in duplicate at a single concentration of 10 µM. In 
Table 7.2 the percentage inhibition of specific radioligand binding to the indicated 
target (with a minimum of 30%) is shown. Negative values indicate an increase in 
specific binding. This might indicate an allosteric mechanism of enhancement,13 but 
this was not investigated further. Four out of eight compounds displayed activity in a 
number of radioligand binding assays, while none of the compounds appeared active in 
the enzyme assays. Compounds 5 (imidazoline and muscarinic receptors), 6 (α-
adrenergic receptors), and 8 and 9 (norepinephrine transport protein) caused 
approximately 50% radioligand displacement or more. It should be mentioned here that 
compound 7, being inactive at all tested targets, appealed to one of the chemists for a 
different reason, i.e. it being an unnatural and new amino acid, which will be used for 




Table 7.2: Percentage inhibition of specific radioligand binding (min. 30%) 
to the indicated target by 10 µM of test compounds 3-10. Negative values 
indicate an increase in specific binding. 
 
 
Target   3 4 5 6 7 8 9 10 
          
CB1    -33      
I2    49 36  41 32  
M1-5    50      
NAch     45  42   
NE transp.       80 77  
DA transp.       -62   
5-HT transp.       -31   
kainate        -37  
α1-adrenerg.     47     
α2-adrenerg.     62     
NK1     -32     
opiate     35     
5-HT     39     
 
CB1: cannibinoid receptor 1; I2: imidazoline receptor 2; M1-5: muscarinic 
receptors 1-5 in rat brain; NAch: nicotinic acetylcholine ion channel; NE 
transp: norepinephrine transport protein; DA transp: dopamine transport 
protein; 5-HT transp: serotonin transport protein; kainate: glutamate/kainate 
receptor; NK1: neurokinin receptor 1; opiate: all opioid receptors in rat brain; 





For a medicinal chemist, drug-likeness, synthetic feasibility and overall ‘molecule 
appeal’ are very important criteria in drug design. However, these features are very 
difficult to quantify, such that good ‘scoring functions’ are often lacking. For instance, 
computer-assisted organic synthesis was recently reviewed by Todd,14 who concluded 
that available software invariably required human intervention to be useful. Similarly, 
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computational approaches to predict ligand binding affinity for a given target protein 
(“docking”) are notoriously inaccurate. Aware of such considerations we decided to 
rely on the user as evaluator. A user cannot know the binding strength of a given 
molecule a priori, but we reasoned this defect may not be much worse than the 
inaccuracy of scoring functions. A definite advantage in letting the user choose would 
be that intensive feedback from a medicinal chemist would make the compounds easier 
to synthesize, and steer the idea generation away from areas which have already been 
explored. Furthermore, user feedback could still be combined with experimental results 
or advanced computed fitness functions if so desired. Considering these advantages we 
developed a software tool for de novo molecule design, called the Molecule Evoluator, 
which we recently described. It contains a graphical user interface and has options for 
directly editing the molecule, marking part of a molecule as conserved, and calculating 
relevant physicochemical parameters.7  
 It should be noted that the Molecule Evoluator mainly uses the atom-based 
approach to construct molecules, that is, a molecule is built from individual atoms and 
bonds, though some predefined fragments can be added. A number of other researchers 
have also constructed molecules in an atom-based way, for example Nachbar15, 
Douguet et al.16 and Brown et al.5 Others construct molecules from a number of multi-
atom fragments, such as Pegg et al.17, Vinkers et al.18, and Schneider et al.19 The main 
difference between atom-based and fragment-based methods is not so much the size of 
the fragments used (atom-based methods often also use fragments, and vice versa) but 
the emphasis placed on synthetic feasibility. Atom-based methods such as ours sample 
the entire chemical space but also produce molecules of doubtful synthetic feasibility, 
and fragment-based methods like the one of Vinkers et al.18 stress synthetic 
accessibility and therefore sample a much smaller part of chemical space, excluding 
hard-to-synthesize molecules but also many potential drugs. In the Molecule Evoluator, 
we have chosen for the flexibility of the atom-based approach, although we are aware 
of the sensitive issue of synthetic ease and have developed a number of features which 
allow the user to restrict the variety of molecules produced.7 
 In the present study we generated 300 molecules according to the criteria specified 
in the Results section. These criteria are well below the classic ‘rule-of-five’9 to largely 
yield template or scaffold-like molecules only. For example, the number of hydrogen 
bond donors was confined to a value of two, rather than five. Repeating the experiment 
would yield a largely different library of molecules due to the random-number 
generator in our algorithm. While by setting the criteria identical to our original 
experiment the average physicochemical properties of such molecules would be similar 
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to those in the original library, the enormous number of molecules possible with a 
molecular weight between, say, 150 and 300, would ensure that there would be barely 
any molecules in common between the two libraries. Changing the parameters would 
force the algorithm to sample another part of chemical space, however the 
physicochemical properties of the lead structures might not change as greatly as the 
parameters since the chemists generally adapt the molecules to the complexity of their 
taste. 
 The 300 molecules were shown to a panel of medicinal chemists. They examined 
them for drug-likeness, synthetic feasibility, and overall appeal as mentioned above, 
and identified their preferences. It should be noted that human judgment is not 
unequivocal. In a study by Takaoka and coworkers, five chemists judged a collection 
of almost 4000 molecules in a Japanese corporate database for their drug-likeness and 
ease of synthesis. Their scores showed considerable variation.20 A similar 
inconsistency was noted among 13 medicinal chemists at a US-based company when 
asked to reject compounds with undesirable properties from one or more lists of 2000 
compounds each.21 Apparently unanimity among medicinal chemists is not self-evident. 
On a more positive note, their diversity in opinion may in fact constitute an important 
and discriminative asset for a research group. While our computational generation of 
the library benefited from human intervention, the chemists themselves also found that 
the computational generation of molecules added value. They appreciated the many 
choices possible, which emphasizes that it is easier to recognize a “good” structure 
than to invent one.  
 We did not give the chemists explicit instructions on which molecules should be 
chosen or rejected, other than that the molecules should seem lead-like and not too 
difficult to synthesize. Analyzing their choices in retrospect, it became clear that the 
chemists did use some general “implicit” rules for molecule choice. Molecules without 
heteroatoms (or with only one heteroatom if that was a nitrogen) were almost always 
rejected, as were molecules with more than two ring systems, cyclophanes (having a 
bridged benzene ring), molecules with odd or unwanted groups like halogen atoms or 
nitro groups, and molecules with many alkyl substituents. However, if anything, these 
rules seemed more like a weighing of attractive and inattractive features than a black-
or-white approval or elimination. For example, one molecule with only one heteroatom, 
a nitrogen, was nevertheless selected, probably because the nitrogen was in a two-ring 
system instead of somewhere in a substituent. Occasionally the chemists disagreed 
about the appropriateness of a certain selection. So instead of general rules one could 
say that the chemists used general guidelines, which were weighed according to 
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individual experience and taste. 
 The compounds that were suggested (Figure 7.1) and eventually synthesized 
(Figure 7.2) all had a relatively small number of hydrogen bond donors and/or 
acceptors, next to their low molecular weight, as a logical consequence of the strict 
criteria imposed. They largely adhere to a recently proposed “rule-of-three” for 
fragment-based lead discovery, in which molecular weight is <300, the number of 
hydrogen bond donors is ≤3, the number of hydrogen bond acceptors is ≤3 and the 
calculated logP value is ≤322, and can be considered leads23 or fragments rather than 
potential drugs. In this view fragments should have features that, when combined, still 
adhere to Lipinski’s “rule-of-five”. The differences between “rule-of-three” and “rule-
of-five” allow a further “decoration” of our compounds. At the same time, fragments 
tend to have very low affinity for a given target, in view of the limited options for 
interaction.22 Surprisingly, quite a few of our compounds displayed affinities that 
allowed them to be recognized in conventional radioligand binding assays, as opposed 
to more sophisticated and demanding NMR- or X-ray-based screening that is generally 
applied in fragment-based approaches.  
 It appeared that most of our ligands intervened with targets for biogenic amines 
(e.g., adrenergic, muscarinic and serotonin receptors, norepinephrine transport protein, 
nicotinic acetylcholine ion channel). Interestingly, the background, education and 
training of some of our medicinal chemists involved in the selection of the compounds 
had been focused on this important ligand class, suggesting that medicinal chemists can 
indeed develop a “feel” for a certain target or family of targets. 
 The chemical structures of the suggested molecules as well as those synthesized 
are simple, or, as some medicinal chemists put it, “quite boring”. Apparently, chemical 
space is vast, but also nearby, i.e. entirely novel structures can be far from exotic. It 
suggests that medicinal chemists when asked tend to prefer more uncommon structures. 
Interestingly, it has been shown on a number of occasions that currently available 
drugs in fact have low diversity.24,25 In a recent analysis of the NCI database harboring 
over 250,000 molecules tested for biological activity we learned that in it 80% of all 
ring systems found in molecules belonged to one out of the 66 “top” ring systems – 
which was only 0.5% of the total variety in ring systems in the database. The same 
analysis taught us that a phenyl ring was present in almost half of the compounds, 
whereas the next most prevalent (pyridine) ring occurred in less than 3% of the 
molecules,27 “quite boring” indeed. The reason may be that exotic ring systems and 
substituents have undesirable synthetic or biological properties. It emphasizes that our 
method of template development, which puts “ordinary” parts in novel combinations, 
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Computational generation of novel molecules, as implemented in the Molecule 
Evoluator, appeared useful in de novo template and scaffold design. It helped a panel of 
medicinal chemists in generating, amending and selecting a number of ‘simple’ yet 
novel chemical entities. A number of low-molecular weight compounds was eventually 
synthesized and tested on a diverse panel of drug targets. Some of the compounds 
proved to be active, mainly on targets for biogenic amines, in line with the background 
and expertise of some of the medicinal chemists. It seems that nearby chemical space 






De novo design algorithm 
The 300 molecules were generated by taking a methane molecule, and growing the 
molecule for a number of iterations by attaching atoms to it at random positions, and 
adding double bonds and rings. The algorithm is shown in Figure 7.3. 
 If a molecule did not obey pre-set criteria (at least one and at most two aromatic 
systems, polar surface area (calculated according to Ertl et al.26) equal to or below 70 
Å2, a maximum number of two hydrogen bond donors and four hydrogen bond 
acceptors, not more than five rotatable bonds) it was discarded and a new molecule was 




Figure 7.3: Flowchart of the de novo design algorithm. A molecule is 
generated by adding a random number of fragments (varying from 1 to 16) 
to a methane molecule, and subsequently adding bonds, thereby creating 
double bonds and rings. The exact number of rings and double bonds is 
determined by a weighted probability table, as is the ring size (so a 5-
membered ring is more frequent than an 8-membered ring, like in normal 
chemical databases).  
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Microwave reactions were performed in an EmrysTM Optimizer (Biotage AB). Wattage 
was automatically adjusted so as to maintain the desired temperature. Column 
chromatography was performed on Baker Silica Gel (0.063-0.200 mm). For TLC 
analysis, Schleicher and Schuell F1500/LS 254 silica plates were used. Spots were 
visualised with ultraviolet light. 1H NMR and 13C NMR were recorded with a Bruker 
AC 200 spectrometer at room temperature. Tetramethylsilane was used as internal 
standard; δ in ppm, J in Hz. Melting points were determined with a Büchi melting 
point apparatus and are uncorrected. High Resolution Mass spectroscopy was 
performed on a PE-Sciex API Qstar instrument. Elemental analyses were within 0.4% 
of the theoretical values. 
 
1-(3-Cyanobenzyl)-piperidin-2-one (3) 
A solution of 2-piperidinone (5 mmol) in THF (25 mL) was stirred for 1 h at 0 °C 
before 1 eq. of n-BuLi (5 mmol, 3.2 mL of a 1.6 M solution in hexane) were added 
dropwise. After stirring for another hour at 0 °C 1 eq. of 3-(bromomethyl)benzonitrile 
(5 mmol) was added rapidly. The mixture was allowed to warm slowly to room 
temperature and stirred overnight. After quenching by adding 15 mL of brine, the 
solvent layers were separated. To the aqueous layer was added 20 mL of water. After 
extraction of the water layer with CH2Cl2 the combined organic layers were dried 
(Na2SO4), filtered and the solvents evaporated. The product was purified by column 
chromatography (eluent: CH2Cl2/MeOH, 99/1→97.5/2.5 v/v). Yield: 24%. White solid. 
M.p.: 53-55 °C. Anal. (C13H14N2O) C, H, N. 
 
3-(3-Cyanobenzyl)-piperidin-2-one (4) 
To a solution of 2-piperidinone (10 mmol) in THF (15 mL) was added at -78 °C 1 eq. 
of n-BuLi (10 mmol; 6.3 mL of a 1.6 M solution in hexane). After stirring for 15 
minutes at -78 °C 1.1 eq. of TMSCl was added and the solution was allowed to warm 
to room temperature and left to stir for 45 min. The resulting solution was added 
at -78 °C to a solution of 11 mmol of 1,1,1,3,3,3-hexamethyldisilazane and 11 mmol of 
n-BuLi (6.9 mL of a 1.6 M solution in hexane) in 20 mL of THF. After stirring for 15 
min 3-(bromomethyl)benzonitrile (11 mmol) was added and the mixture was allowed 
to warm slowly to -25°C, before the reaction was quenched by adding an aqueous 
NH4Cl (sat.) solution. After extraction with diethyl ether the combined organic layers 
were washed with a saturated NH4Cl (aq.) solution, a saturated NaHCO3 (aq.) solution, 
dried (MgSO4) and the solvents removed by evaporation. The product was purified by 
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column chromatography (eluent: CH2Cl2/MeOH, 99/1→98/2 v/v). Yield: 47%. White 
crystals. M.p.: 95-96 °C. Anal. (C13H14N2O) C, H, N. 
 
3-(3-Benzylamino)-piperidin-2-one (5) 
Compound 4 (2 mmol) was dissolved in methanol, and 2 mmol of concentrated HCl 
and 100 mg of Pd/C 10% were added. The mixture was hydrogenated at 3 atm for 3 h. 
After the catalyst was filtered off and the methanol was evaporated the residue was 
dissolved in water and the pH was adjusted to 4. This solution was washed with ether 
and the water layer was adjusted with 0.1 M NaOH to pH 12. The free amine was 
extracted with CH2Cl2, dried (Na2SO4) and the solvent evaporated. White powder. 
Yield: 31%. M.p.: 114-116 °C. Anal. (C13H18N2O) C, H, N. 
 
2-(3-Pyridyl)-benzyl alcohol 
A suspension of 2-bromobenzyl alcohol (1 mmol), and diethyl(3-pyridyl)borane (1 
mmol), Na2CO3 (3.8 mmol), TBAB (1 mmol), and (Ph3P)4Pd (3%) in 2.5 mL of water 
was heated in a microwave for 12 min at 150 °C. The product was extracted with ethyl 
acetate. The combined organic layers were dried (MgSO4), filtered and the solvent was 
evaporated. The product was purified by flash column chromatography. Eluent 
column: CH2Cl2/MeOH, 99/1→96/4 v/v. Yield: 79%. Oil.  
 
2-(3-Piperidyl)-benzyl alcohol (6) 
A mixture of 5.77 mmol of 2-(3-pyridyl)-benzyl alcohol, HCl (5.77 mmol) and PtO2 
(0.38 mmol) in 46 mL of absolute ethanol was placed in a Parr apparatus under H2 (3 
atm) for 3 days. The catalyst was filtered off and the solvent evaporated. After addition 
of water to the residue the pH was adjusted to 12 and the product was extracted with 
ethyl acetate. The combined organic layers were dried (MgSO4) and the solvent was 
evaporated. Recrystallisation from ethyl acetate provided the pure product. Yield: 27%. 
White needles. M.p.: 135 °C. Anal. (C12H17NO) C, H, N. 
 
2-(3-Piperidyl)-benzylic acid (7) 
Compound 6 (2 mmol) was dissolved in 50 mL of acetone. Jones' reagent (chromic 
acid) was added slowly until the orange colour persisted. The pH of the mixture was 
adjusted to 7 with 1 M NaOH and the product was extracted with ethyl acetate. The 
combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. 




3-(3'-Furyl)-aniline (8)  
A suspension of 3-bromofuran (1 mmol), 3-aminophenyl-boranic acid (1 mmol), 
Na2CO3 (3.8 mmol), tetrabutylammonium bromide (1 mmol), and (Ph3P)4Pd in 2.5 mL 
of water was heated in a microwave for 12 min at 150 °C. The product was extracted 
with ethyl acetate. The combined organic layers were dried (MgSO4), filtered and the 
solvent was evaporated. The product was purified by flash column chromatography. 




A suspension of 3-bromofuran (1 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline (1 mmol), Na2CO3 (3.8 mmol), tetrabutylammonium bromide (1 mmol), and 
(Ph3P)4Pd in 2.5 mL of water was heated in a microwave for 12 min at 150 °C. The 
product was extracted with ethyl acetate. The combined organic layers were dried 
(MgSO4), filtered and the solvent was evaporated. The product was purified by flash 
column chromatography. Eluent: CH2Cl2. Yield: 78%. Yellow solid. M.p.: 92-93 °C. 
Anal. (C10H9NO) C, H, N. 
 
4-Oxo-4-[4-(3'-furyl)-phenylamino]-butanoic acid (10) 
To a solution of 0.63 mmol 4-(3'-furyl)-aniline (8) in 10.5 mL of CH2Cl2 were added 
succinic anhydride (0.63 mmol) and 4-methylmorpholine (0.63 mmol). After stirring 
for 4.5 h the mixture was filtered, the residue washed with CH2Cl2 and the filtrate 
evaporated to dryness. The product was purified by chromatography (eluent: 
CH2Cl2/MeOH, 9/1 v/v). Yield: 27%. Yellow solid. M.p.: 198 °C (dec.). Anal. 




The final compounds (Figure 7.2) were tested at one concentration (10 µM) in 
duplicate in the Diversity Profile program, including 68 receptors and 15 enzymes, at 




For the template design we used the Molecule Evoluator software package (Cidrux 
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In this project, we have developed a computer program for de novo molecule design, 
the Molecule Evoluator. It is unique among programs for de novo molecule design 
since it combines three features: an atom-based approach, an evolutionary algorithm 
that can optimize structures, and its interactivity which allows it to profit from the 
knowledge, intuition and creativity of its user. 
 The first feature, the atom-based approach, helps the Molecule Evoluator to search 
all of chemical space, and fine-tune the structures. When using the much more 
common fragment-based approach, one first faces the problem of whether all 
synthetically possible and drug-like fragments have been included, and second there is 
the question whether the reconnection algorithm uses all realistic possibilities of 
synthesis. Covering chemical space with the atom-based approach is much easier and 
more natural. Secondly, our exhaustive repertoire of atom-based mutations (several of 
which lack in other work) allows the molecules to change gradually and adapt 
themselves to their target, instead of making big jumps in structure which usually result 
in large loss of fitness and may tend to force the population into premature 
convergence. 
 The second defining feature of the Molecule Evoluator is the evolutionary 
algorithm on which it is based. While several optimization methods exist (like random 
search, simulated annealing, or just molecular growth), evolutionary algorithms make 
good use of two features of molecular space. First, that molecules close in structure 
generally have related biological activity; evolution’s concept of heredity, of inheriting 
good genes from the parents, makes methods which base the new molecules on the 
previous ones (instead of searching randomly) a good choice. Secondly, both in 
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literature and in our own experiments we found that perhaps the most defining feature 
of evolutionary algorithms, namely crossing different solutions, is also advantageous 
and viable in drug design. Evolutionary algorithms not only use heredity, but also 
crossover, and therefore automatically use the structure of biological activity space to 
their advantage. 
 The third, and perhaps most distinguishing feature of the Molecule Evoluator is its 
interactiveness. While interactive evolutionary computing (IEC) has been used for 
quite some time in diverse applications, it had not yet been used for molecule evolution. 
However, there are good reasons to use interactive evolution in this field. First, there is 
a lack of good “fitness functions” – methods to calculate “how good” a molecule really 
is. Programs to estimate ligand binding energy and ease of synthesis are still very 
unreliable, so evolution without any human intervention will rarely yield good 
structures. However, human domain knowledge on ease-of-synthesis and pattern-
recognition may help. Second, it can be difficult for people to accept the computer 
“prescribing” molecules out of the blue: most chemists would either like a good reason 
or some input of their own. The limitations of current automatic structure evaluation 
would lead to rejection of flawed structures, instead of correction. Third, evolutionary 
algorithms do not only “exploit” existing knowledge, they also explore new 
possibilities. Since a computer can quickly generate many possibilities and has other 
prejudices than a human chemist, interactive evolution can be a valuable idea-
generating machine to complement human creativity. 
 During the development of the Molecule Evoluator, we discovered that the first 
versions needed to be refined to be acceptable to the chemists using them. In the 
following paragraphs we describe some of the problems encountered and the 
modifications implemented in response. 
 The main problem of the first version of the Molecule Evoluator was that many 
structures just did not seem possible to synthesize at all. In particular, common 
substructures like phenyl were almost completely absent, weird substructures like 
peroxide were common, and many structures had overly complicated rings or 
disobeyed chemical rules of thumb, like Bredt’s law which states that a bridgehead 
carbon atom cannot have a double bond (unless the rings have a certain minimum size). 
 To make the molecules more “appealing” and easier to synthesize, we first 
allowed the ME to not only add atoms to a growing molecule, but also a number of 
predefined fragments (carboxy, phenyl, cyanide, etc.). Secondly, we mined the NCI 
database to find the frequencies of the different atom types and 2/3/4-atom 
substructures. Based on the frequency of, for example, O-O in the NCI database we 
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modified the chance that an oxygen atom would be connected to another oxygen atom. 
This automatically enforced chemical rules that state that peroxides are rare, using 
statistics instead of qualitative human intervention. Third, we implemented a couple of 
rules, such as Bredt’s rule and a prohibition of CH2-imines. These rules act like filters 
that prevent molecules that do not obey the given chemical constraints from being 
shown to the user. Mining the NCI also gave us a catalog of ring structures (see the 
“Chemical Clichés” chapter) which were also implemented to filter unknown and 
probably strained rings out. Note that the filters can be activated and deactivated by the 
user, and that the full idea generation potential remains available if desired. 
 The second main point for improvement was user control. For example, chemists 
often had certain ideas about which part of a molecule was important, and should be 
conserved. Also they preferred that the best molecule from the previous generation was 
to be saved always (which is not guaranteed in a normal evolutionary algorithm). 
Thirdly, occasionally a chemist could see an obvious modification of an existing 
molecule, and wanted to put the adapted molecule in the Molecule Evoluator. And 
finally, the molecules produced should preferably be drug-like and obey a number of 
physicochemical restraints. 
 We made various adaptations to address these points. We added atom and bond 
fixation, which can conserve any atom (even hydrogen atoms) and can therefore focus 
evolution on the variable part of the molecule. Secondly, we added elitism, so the 
chosen molecules of the previous generation appear as the first molecules of the current 
generation, allowing a chemist to easily see if their offspring improves over them. 
Thirdly, we added a molecule editing window, which allows the user to adapt ME-
generated molecules and feed them back into the evolution, or even to sketch new 
molecules as input of the evolution. Lastly, we added physicochemical filters to allow 
the user to determine the allowable physicochemical properties of a molecule, such as 
the range in which the molecular weight should fall, and the maximum permissible 
number of hydrogen bond donors. 
 Finally, we tested the Molecule Evoluator to examine whether the concept was 
sound and useful. 
 First we ran a number of small experiments, in which we evolved certain drug 
molecules from scratch (that is, without editing the molecules, though we fixed certain 
atoms/bonds to accelerate optimization in a certain direction) to show that we can 
indeed convert simple substances into drugs. We also were able to reproduce, using 
experimental fitnesses, an optimization pathway of neuramidase inhibitors, which 




 The value of the idea-generating function was tested by creating 300 random 
molecules that obeyed certain physicochemical restraints. A panel of chemists chose 
the most “drug-like” 34 structures, of which a number did not appear as structure or 
substructure in existing databases, and therefore could be considered potential new 
molecule templates. Synthesis of eight of the compounds yielded four compounds 
which showed biological activity in the used essays. It seems that chemists indeed have 
a valuable intuition, and that the ME can inspire the synthesis of truly new classes of 
molecules, unknown before yet possible to synthesize. 
 The Molecule Evoluator has become more advanced over the years, and is at the 
time of writing (May 2008) commercially available. In the Leiden group of Medicinal 
Chemistry, where it has been developed, it is now used in each synthesis project as an 
interactive, idea-generating but responsive aid to get new ideas for structure 
modifications. Several companies have bought versions, and some are quite happy with 
it, as is evident from the following quote:  
 
"Both computational chemists and medicinal chemists have explored the Molecule 
Evoluator and have been excited about the output in terms [of] novel ideas being 
generated and the potential for further enhancements in the future. The real 
advantage of the current programme is that it can be iteratively influenced by trained 
chemists to propose new structures, some of which may look immediately obvious but 
yet had not been previously suggested. Three of our current GPCR-based projects 
have benefited in this way." 
 
Software that allows humans and computers to combine their particular strengths is 
still rare, for drug design the Molecule Evoluator is the only one to our knowledge 
which is currently commercial. This has two likely causes. First of all, interactive 
evolution is itself a young field, most programs for designers (of molecules or 
buildings) are drawing programs which do not give any creative input of their own, as 
they were designed to be computerized replacements for real drawing boards. Second, 
most complex software for molecule design has been created for computational 
chemists and therefore only runs under Unix/Linux workstations and has powerful but 
complex interfaces. The medicinal chemists, the people who design and modify most 
of the molecules and are experts on molecules rather than computers, have been left out. 
Only in the last two or three years software companies are also starting to develop 
versions for Windows and thus for the “normal” chemists. (See for example the 
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Software section in the biweekly ‘Chemical and Engineering News’ of the American 
Chemical Society). But even when a Windows version is available, it will be a long 
road for most programs to also become user-friendly for people who are not experts in 
computational chemistry. As of yet, the Molecule Evoluator is quite lonely in the 
software landscape, but we hope that in the coming years it will be joined by followers 
and colleagues which bring both the computational and creative potential of computers 
to the medicinal chemists directly. Software has a vast potential for changing drug 







 Prediction is very difficult, especially about the future. 
 Niels Bohr (1885 – 1962) 
 
Science is never finished. The research described in this thesis may have produced a 
useful computational tool for the medicinal chemist, and it may have given more 
insight into chemical databases. However, we nor others have as of yet produced the 
perfect medicinal chemistry tool, and many problems in drug design remain. The 
previous chapters of this thesis have covered what we have done in our research. This 
last part will contain reflections on where to go from here. I hope this chapter will 
provide ideas and inspiration to researchers and non-researchers alike on what subjects 
in computational drug design would be worthwhile to investigate, and in which 
directions we could go. 
 I will begin with some thoughts on future directions for the Molecule Evoluator, 
then discuss the possible evolution of evolutionary algorithms in drug design, and will 
end by zooming out to look at the general role of software in drug development, and 
talk about some of the ways in which we can increase the ability of software to help us 
design new drugs. 
 
 
The future of the Molecule Evoluator 
 
At the time of this writing, we have performed experiments which have shown that the 
Molecule Evoluator can at the very least help find novel biologically active molecules. 
We may never know if chemists without the Molecule Evoluator would have been as 
creative as chemists using the Molecule Evoluator, but it is very likely that computer-
generated structures can complement the brainstorming by chemists, which may 
mainly design variations on the molecules they already know. For that reason, the 
Molecule Evoluator as it is now may remain useful for a long time to come. 
 To enhance the usefulness of the Molecule Evoluator further, there are numerous 
possibilities: improving the speed at which molecules are generated, comparing the 
effects of different crossover functions, making the user interface even more intuitive, 
improving the display so that the user can see very quickly which mutations have been 
generated, offering calculations of more physicochemical properties (for example pKa) 
or linking the Molecule Evoluator to third-party software that can calculate those 
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properties, and numerous other tweaks and enhancements. At the moment there are 
however three points which I think most promising for future updates: changing the 
structure generation to yield even better structures, linking the Molecule Evoluator to 
other software and databases, and experimenting with computational fitness 
evaluations. 
  
Ease of synthesis: less boring, less impossible, more novel? 
From conversations with users, we found that the main factor determining how much 
they liked the Molecule Evoluator was the ratio of “good” molecules to “bad” 
molecules. Good molecules are those molecules that are novel and seem relevant or at 
least can be easily changed into a molecule with a good structure. “Bad” molecules are 
those molecules which are boring (not very novel), irrelevant, or plainly impossible to 
synthesize. 
 The most significant way to enhance the use that chemists get out of the Molecule 
Evoluator would therefore be increasing the number of good molecules while 
preferably decreasing the number of bad molecules. With previous adaptations we have 
already succeeded partially in this, and it is certainly possible to further improve our 
results with some additional adaptations of the code. 
 At the moment the best method to improve the ratio of good to bad molecules 
seems to be to diminish the occurrence of the main types of bad molecules: the 
'impossible' molecules, the 'irrelevant' molecules, and the 'boring' molecules. 
 The 'impossible' molecules are those molecules which cannot be synthesized. We 
have already reduced their number with chemical filters and giving the user the option 
to only allow known ring structures; further feedback will undoubtedly allow us to 
increase the number of filters that can be applied to a molecule. The 'irrelevant' 
molecules are only created when the Molecule Evoluator cannot find a mutation that 
works, which mostly occurs in molecules where many atoms or bonds have been 'fixed' 
by the user. The solution to this is to rewrite the mutation algorithm: at the moment it 
picks a random atom from the molecule to mutate, which fails if that atom has been 
fixed by the user – forcing the Evoluator to create a random/irrelevant molecule instead. 
Rewriting the mutation algorithm so it picks only from the atoms which are not fixed 
will give a much greater mutation success rate and therefore a much lower production 
of irrelevant molecules. 
 The final way to decrease the amount of “bad” molecules is to tackle the boring 
molecules (this is for interactive evolution. An automatic fitness function cannot be 
bored). A chemist may find certain mutations boring or “not novel”. The aim therefore 
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is to find out which mutations are generally found interesting, and which are not. 
Finding out these preferred or unpopular mutations can be done by either directly 
observing a user or by creating special statistical subroutines to observe which 
mutations (atom addition, deletion, insertion) produce molecules that are most often 
selected or not selected, and what kind of additions/deletions/insertions are most 
interesting. Such an investigation might for example find that adding a methyl group to 
a benzene ring is “boring”, while adding a hydroxy group to the same ring is 
“interesting”. The probabilities of those specific mutations can then be adjusted 
appropriately. 
 In conclusion, adapting the Molecule Evoluator to change the ratio of good to bad 
molecules in a beneficial way is certainly possible with user observation and feedback 
and some reprogramming. Of all the possible options to improve the Evoluator, this 
optimization may have the strongest impact on user-friendliness and frequency of use, 
and would therefore be a prime target for implementation. 
 
Linking the Molecule Evoluator to databases 
A second area for improving the Molecule Evoluator turned up during our own tests. 
While trying to find novel biologically active molecules, every compound the chemists 
found interesting had to be manually looked up in the CAS database. While this 
database search was by far not as much work as eventually went into synthesizing the 
truly novel compounds, it taught us that it would be incredibly handy if one could look 
up the Molecule Evoluator-generated structure or similar structures in the user's 
favourite chemical databases by just pressing a button. A useful improvement would 
therefore be a link to databases that would allow chemists to find whether the molecule 
suggested by the Molecule Evoluator exists in its entirety or as a substructure, and if it 
exists, how it can be synthesized (or ordered). For large and wealthy institutions, links 
to commercial databases like Beilstein and CAS may be possible, but more exciting is 
the opportunity brought by the advent of large public databases like PubMed, 
PubChem, eMolecules and ChemSpider to give all users of the Molecule Evoluator the 
chance to have structures automatically checked with literature.  
 Databases could not only be used for checking structures, but can also help to 
create structures. If, for example, a chemist is looking for alternatives for a certain ring 
in a molecule, it would be very useful if he could view a list of the most common ring 
systems from our 'chemical cliché' database next to the molecule editing window, as 
that could give many ideas for changes. A similar approach could be taken for 
substituents, where the chemical clichés fragment database or a specialized database 
227 
 
like a bioisosters database could be used to find replacements that the chemist might 
not have thought of yet. 
 
The Molecule Evoluator and automated evolution 
Interactive evolution has some major advantages over automated evolution, mainly that 
it can use expert knowledge much more easily than any fitness function designed by 
computer programmers. However, this requirement for expensive expert time is also a 
disadvantage, and given the successes of the interactive mode of the Molecule 
Evoluator, one could consider adding options for computational chemists who want to 
use automated evolution. 
 While adding a feature for automated evolution is possible (in fact, it has already 
been done in one or two individual cases), to make the automated evolution perform 
optimally one needs to change more than the code for the fitness function. Automatic 
evolution and interactive evolution, despite their apparent similarity in approach, are as 
dissimilar (if not more dissimilar) as tennis and table tennis.  
 The first dissimilarity of automated versus interactive evolution is the absence of 
user fatigue. This opens up the desirable possibility to create larger generations than 
the 12-20 which are practicable for user feedback (50-100 molecules seems to be about 
the optimum size if we consider investigations such as that of Douguet et al.1, since it 
may avoid the premature dead ends which endanger small populations and the 
'drowning out' of the good genes in very large populations. Larger populations seem to 
work better when split into 'islands'). Also, automated evolution doesn't need settings 
that prevent molecules that differ only slighly from their ancestor being created, as a 
small increase in fitness is useful, whereas such a molecule would strike a human as 
uncreative and increase user fatigue.  
 The absence of user selection, however, also has some disadvantages. First of all, 
automatic evolution makes it necessary to implement a selection function: for if the 
user isn't selecting the “good” molecules, the programmer has to decide how to select 
the best molecules for further evolution. Take the best five molecules? Or ten 
molecules? Use tournament selection? Roulette wheel selection? A second 
disadvantage, which we discovered during the docking experiment (Chapter 6), is that 
atom-based evolution when not supervised by humans tends to produce molecules 
which over time become more and more difficult to synthesize. Therefore, automated 
evolution needs stricter filters to sufficiently dispose of unwanted structures. 
 In summary, unlocking the full potential of automated evolution requires changing 
more parts of the Evoluator than the fitness function – the automatic evolution would 
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need to be at least partially split from the code for interactive evolution. On the positive 
side, automated evolution also offers opportunities. Performing automated evolution 
with a good fitness function may give us a better idea what parameter settings and what 
mutations or crossover operations are optimal for drug design, and allow us to adjust 
the Molecule Evoluator accordingly. If we keep studying drug design and evolutionary 
strategies for drug design, the Molecule Evoluator may one day not only be the best 
interactive evolutionary algorithm for drug design, but also the best evolution-based 
program for automatic drug design available. 
 
 
General perspectives on evolutionary algorithms in drug design 
 
Useful as they are, evolutionary algorithms aren't the “cute new kid” in computational 
drug design anymore. They were immensely popular in the late 1990's, but interest 
waned as it grew more and more difficult to think of yet-unpublished applications and 
it turned out that evolutionary algorithms, like all methods before them, were not the 
“cure-all, one-size-fits-all”-solution that drug designers have been seeking for so long. 
I have discussed my view of the future of Evolutionary algorithms in 2005 in my 
review on evolutionary algorithms in drug design (Chapter 2), in which I discussed 
various possible developments such as creating standardized test databases for 
chemical problems and evaluating newer types of evolutionary algorithms. Currently, 
evolutionary algorithms are already unobtrusively integrated as standard tools for 
experiments, for example for descriptor selection in a virtual screening experiment2. 
For new problems too, evolutionary algorithms are becoming easier to try out as 
flexible optimization methods, due to the development of EA toolkits such as the GA 
Playground, OAT, Lil-gp, and ECJ3. However, in my mind two ideas seem most 
important: adding further domain knowledge to evolutionary algorithms, and the use of 
evolutionary algorithms in novel or at least uncommon ways in drug design, such as 
modelling and data mining. 
 
Adding knowledge to evolutionary algorithms 
The main bottleneck in successful application of evolutionary algorithms in drug 
design is that finding the best solution (or even a very good solution) often takes more 
computer time than is available. This is both because of the “high dimensionality” of 
many drug design problems (many parameters need be optimized simultaneously) and 
because fitness functions often take much time to be calculated. While the increasing 
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computer speeds may help here, it may even be more important to perform the 
optimization itself in more intelligent ways. 
 Evolutionary algorithms can be improved by testing and comparing different 
models (differing in population size, selection pressure, etcetera), but more important 
will be the collaboration between computer scientists and experts in the problem 
domain, such as drug design. Currently, relatively simple evolutionary algorithms are 
often used since they shorten programming time – unfortunately, these same 
algorithms are afterwards too easily carried over into the commercial version where the 
'saving' of programming time is paid back with interest as the inefficient algorithm is 
run thousands of times. Only with knowledge of the problem itself can one develop 
rough fitness functions which can eliminate patently bad candidates before they are 
subjected to a more accurate fitness calculation, create meaningful mutations that turn 
good solutions into other good solutions instead of impossible ones (for example, 
producing a carbon atom with five bonds), split the solutions as much as possible in 
semi-independent sub-systems for faster optimization, and make optimal use of the 
knowledge obtained by the evolution so far (for example, learning that a certain type of 
atom at a particular position produces very good scores). It may be difficult for 
computer scientists and drug designers to understand each other and communicate 
one's knowledge and aims clearly to the other party, but in the end the algorithms that 
will survive and turn out to be most useful in a given problem domain will not be the 
newest generic computer science methods, but well-chosen basic methods, carefully 
optimized to suit the problem at hand. 
 
Future applications of evolutionary algorithms  
Evolutionary algorithms are currently experimentally or routinely used in most phases 
of drug discovery. The most important of their current applications are their 
contributions to the “core” business of finding new leads by computer, namely by 
library design, de novo design, and virtual screening. Of these, “virtual screening” 
(evaluation by computer) of a potential lead is hardest by far, since proper 
computational evaluation needs to answer six questions: 1) is the target important in 
the disease, 2) does the candidate molecule interact strongly enough with the target, 3) 
can the molecule get to the place of action, 4) how and how fast is the molecule 
metabolized, 5) are the molecule and/or its metabolites toxic, and if so, how much, and 
6) is the molecule excreted slowly enough.  
 While docking tries to answer question 2, and Lipinski's rules and calculating the 
polar surface area of the molecule help us somewhat with 3 (barring active transport), 
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reliably predicting any of these relevant properties requires good-enough predictive 
models, and even a much-researched subject such as docking can definitely be 
improved greatly yet. The main challenge of computational drug design is therefore to 
develop better models for the interaction of a molecule with the human body.  
 Creating models generally starts with collecting large amounts of raw data (for 
example, molecules and their intestinal absorption), calculating descriptors (properties 
of the input molecules, such as the weight or the polar surface area of each molecule) 
and picking a computational model (linear regression, neural network, support vector 
machine) that links those descriptors to the measured property. With the unavoidable 
measurement errors in experimental data, perfect mathemathical relationships are 
generally not possible, but evolutionary algorithms could help in parameter selection 
(as they have done for QSAR), and even with computational model selection. In some 
relatively simple cases this is already possible, such as evolutionary algorithms 
producing mathematical equations out of pictures of moving systems4. In the end, 
evolutionary algorithms could become more independent and work on more complex 
problems, becoming untiring generators and testers of hypotheses. Even more than 
today, future evolutionary algorithms may supplement human brain power in making 
better models to predict how a particular molecule will fare as a drug. 
 
 
The future of computational medicinal chemistry 
 
While medicinal chemistry changes, its basic challenges stay the same. People will 
continue to have diseases and want to get rid of them, and unless genetic modification 
of living humans becomes easy, reliable and safe (which seems very unlikely to happen 
this century) we will in most cases need to fight the diseases with drug molecules. 
These will remain difficult to find since we do not always know the mechanism of the 
disease or the best protein to target, and even if we know those we may struggle to find 
the molecule that interacts effectively with that target, can get to the place of action, 
and does not have unacceptable side effects or toxicity. 
 
Most current sub-fields of computational medicinal chemistry, such as docking and 
prediction of ease of synthesis will probably grow and improve over time, though that 
is likely to be a slow and laborious process. The algorithms may never be perfect, but 
they may become so good as to be too useful to ignore. The three areas which interest 
me most, however, are still much earlier in their development: automated data analysis, 
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simulations and interactive software. 
 
Automated data analysis 
In theory, knowing the DNA encoding for a protein should be enough to calculate the 
three-dimensional structure of the protein and find molecules which bind to it, by 
applying quantum mechanics and molecular dynamics. Similarly, an optimum-yield 
synthetic route for a new molecule could be found by using retrosynthesis and quantum 
mechanical calculations on a library of available reagents. In practice, however, we 
need lots of data both as primary input (you can't understand an organism without 
knowing at least its entire DNA), and as a substitute for calculations which would be 
theoretically possible but far too computationally intensive to be practical. If you 
would need either 50 years of computer time to correctly calculate the affinity of a lead 
compound to a protein using quantum mechanics and thermodynamics, or one hour of 
biochemical testing, the latter is far preferable. Therefore drug design still needs lots of 
experimental data to be efficient. 
 These experimental data are increasingly becoming available through scientific 
journals creating online versions, electronic lab journals collecting the primary data 
generated by researchers, and the growth of public databases such as PubChem and 
Wikipedia. This increase of data is promising, but current search methods have 
difficulties exploiting it: it can be incredibly hard to find the particular piece of data 
one is looking for. For example, in my stints as a science journalist I have spent much 
time being frustrated and giving up searches when Google couldn't locate a proper 
answer to even elementary scientific questions such as which hormones affect the 
release of GnRH from the hypothalamus. This information undoubtedly exists in 
reviews and/or books, and a more elaborate searching through reviews could probably 
uncover it, but still the (time) cost of finding particular information is much higher than 
would be technologically necessary. Making information easier to find can reduce both 
the time and the cost of any research project. 
 A large part of making better use of existing data will be economical and 
organizational: somebody has to pay for the servers to house the data and the 
transformation of (scientific) texts and tables into a computer-readable format; in many 
cases the 'owner' of the data (such as a scientific journal) will also want financial 
compensation. But what are the technological aspects? 
 The first part of technology will be disambiguation and transforming text into 
something the computer can more easily relate to search queries; for example a text 
like “the melting point of benzene is +5.5 oC” would fit better in a computer database 
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as “object=”benzene”::==reference=”www.merckindex.com/benzene”=>property =  
“melting point”=>value=”278.5”=>unit=”K”. Ontologies/synonym lists and lists of 
standard terminology will remain necessary to transform raw data into something that 
is as standardized and unambiguous as programming language statements (for example, 
instead of “melting point” my version of the Merck index occasionally uses the less 
standard “solidif”). 
 The second and probably greater challenge will be to make search methods less 
“fussy” and more “fuzzy”. For example, when designing a synthesis route for a 
compound, it may be that the compound has never been synthesized before, or that it 
has been synthesized, but via a rather inefficient route. Finding the synthesis route for 
similar compounds can help in both kinds of cases. However, despite Tanimoto 
coeffients and fingerprint calculations, it is unlikely that there is an universal measure 
of molecular similarity (similar molecular weight? Similar size? Similar melting point? 
Similar biological effects?). Domain experts and ideally data mining should be able to 
discover what the similarities are in compounds synthesized via the same route, for 
example, re-discovering that alcohols can be made out of available halo-alkanes using 
a Grignard-reaction, but also in which cases Grignard fails or is not used at all. This 
will be a complex piece of data mining where programmers and domain experts will 
have to work together, but having a system that can learn from existing data and adapt 
its knowledge when encountering new information would be extremely useful to build. 
 There are already several individuals and groups striving to improve data 
management in science from the 'let's do the same as always, only electronically' stage 
to transforming global scientific knowledge into a truly useful search engine, for 
example the Scientific Publishing Taskforce which is developing methods to make 
scientific publications computer-readable (http://esw.w3.org/topic/HCLS/Scientific 
PublishingTaskForce), attempts to unify data from many scientific sources into a single 
encyclopedia/wiki (http://www.wikipathways.org/index.php/WikiPathways) and a 
more fuzzy version of PubMed, eTBlast (http://invention.swmed.edu/etblast/ 
index.shtml). While the diversity of initiatives indicates that this field is far from ripe 
yet and standards need to be developed to unify the different projects, going into the 
direction of converting data into standardized formats and making search engines more 
intelligent will in my opinion greatly improve data availability and increase literature-







The paragraph on future applications of evolutionary algorithms focused on model 
development. Models, however, are not limited to linear regression models or neural 
network models or decision trees only. One of the most interesting directions that 
modeling is going is the simulation of cells, tissues and even of entire human bodies. 
Models for the heart are already available, as are models for blood flow and some 
cancers5. Evolutionary algorithms already help find good parameters for conventional 
models (such as neural networks), likewise they may help fine-tune simulations by 
supplying good values for missing parameters. All in all, though, evolutionary 
algorithms would only be a small part of the total work on simulations – many 
computational methods and algorithms are likely to be necessary, from logic 
programming and cellular automata for rough qualitative models to differential 
equations working on small simulated 'boxes' of cellular cytoplasm and cell membrane 
for the most advanced models. 
 While it may be difficult to create good simulations, it would be amazingly useful 
if we would have more reliable models for what happens in the various tissues in case 
of disease, and what the effects of various interventions would likely be. In contrast to 
biological experiments, it is very easy to knock a gene out in the computer or let a 
protein be deactivated fully without the need to discover a strong and selective protein 
antagonist first. Even better, good computer models could act as “living encyclopedias” 
of current biological knowledge, linking the many findings of biological research into 
one easily accessible and correctly interconnected whole, growing more and more 
accurate the more we learn about biology. Creating excellent simulations of biological 
systems may be one of the most difficult projects that could support drug design, but its 
huge advantages in both allowing us to test compounds reliably without endangering 
human volunteers and understanding the true mechanisms and complexities of disease 
will also probably make it the most useful of all possible software if we succeed. 
 
Interactivity 
On the surface, interactive evolution may look like nothing more than a speeding up of 
the usual process of the medicinal chemist stating the target and the constraints to the 
computational chemist, who programs these into the computer, which produces new 
molecules. It is indeed an advantage that interactive evolution can shorten and speed up 
this cycle, but the truly qualitative difference is that interactive evolution can use one 
resource which automated evolution can not take advantage of: the subconscious 
knowledge and expertise of the medicinal chemists. 
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As I stated in the introduction of this thesis, major progress could be made by letting 
people and computers work together more productively, complementing each other's 
strengths. While delegating simple tasks to computers has of course been done since 
the dawn of computing, for example by humans creating the formulas for the 
spreadsheet and the computer doing the calculations, only more recently computer 
programmers have deliberately started to try use human brain power. Interactive 
evolutionary algorithms are one example of this, another is the program C3vision 
which makes an EEG of the user's brain activity while (s)he is quickly browsing 
images, and can detect when the user sees something interesting much faster than the 
user him/herself realizes it, thereby speeding up scanning of images tenfold6. The 
human processing capabilities can also be tapped via games, for example 'fold-it' 
(http://fold.it) which lets humans predict protein folding quite successfully, as 
predictions by fold-it players won seven prizes at the protein structure prediction 
contest CASP8, outperforming purely computational methods, and in one case even 
outperforming professional scientists.  
 What will the future be of such interactivity between man and computer? For now, 
humans seem to excel in combinatorial problems (such as finding the right folding for 
a protein, where calculating the energy score is probably rather fast) and problems 
which require knowledge which is hard to make explicit ('hunches'). Docking could 
undoubtedly be performed similarly to fold-it, at least when the docking scoring 
functions have become more accurate. And perhaps humans could be trained to get 
toxicity “intuition” by showing different structures and making them guess whether a 
compound is mutagenic or not, perhaps recognizing patterns which may be difficult to 
find by computer.  
 It may be that human-computer interactivity will one day be surpassed by 
computers which either can process data in a human-like way or are so fast that they 
won't need the speedup provided by human knowledge anymore. But such advances 
are only likely to happen in the very far future, if at all. For now, the more we learn 
about computers and problems, the more we find that computers are not yet the answer 
to all our problems and that human experts are unexpectedly potent problem solvers. 
Making human-computer interaction work well is a field of research in itself, but the 
better we become at it, the more powerful our capabilities in science and drug research 








Computational drug design has come far since the first QSAR programs and molecule 
databases, and the Molecule Evoluator is certainly not the end point of its ongoing 
evolution. There have been quite some successes already (for example with virtual 
screening), but we can still do better. In my opinion, software developers should strive 
to make drug design software grow in three directions: deeper, wider, and closer. 
 Deeper software will be software that more elaborately uses core scientific 
knowledge such as quantum mechanics, molecular dynamics and thermodynamics to 
improve the accuracy of predicting ligand affinity, compound metabolism and other 
phenomena. The main challenges here are integrating the diverse formulas and 
principles of chemistry and physics (for example, ligand affinity prediction also needs 
accurate prediction of the energy of (de)solvation of the ligand), and speeding up the 
calculations so that accurate enough results are obtained in the computer time available. 
Wider software, which focuses on combining and comparing data, may be able to help 
us where calculations are yet too slow – by recognizing patterns in experiments we 
may in some cases be able to predict important properties from 'data-based' models 
where 'computation-based' models are as of yet too time-consuming. Software casting a 
wider net over our current scientific knowledge may also help us find connections 
between different subjects, by integrating the data on chemistry, biology and genetics 
into one organized whole. Finally, developing closer software means that we should 
strive to make software more accessible to 'lay' users, so it can be used more easily by 
scientists who are not experts in computer programming. For some software products, 
this would involve creating Windows versions, for almost all programmers it would 
mean focusing much more on user-friendliness and the user's goals. Consciously 
seeking to develop the most intelligent task division between computer and user will 
also greatly increase the user's power to tackle scientific and drug design problems.  
 Developing deeper, wider and closer software may never bring 'perfect' 
computational drug design as was perhaps once envisioned. It is quite likely that it will 
create computer programs which will be totally unexpected, and tackle problems we 
may not even know about yet. Only one thing is certain: by working steadfastly on 
finding new ideas and evolving our software, we will be able to increase our 
understanding of biology and drug design to a depth we would now deem incredible. 
May that understanding be used effectively for the progress of science, and for the 
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Designing drugs is hard. For many illnesses there are no effective drugs available (for 
example, for multiple sclerosis), in other cases existing drugs are not always effective 
enough (cancer). And even when effective treatment is available (for example for HIV), 
the drugs may have side effects that investigators and patients alike want to diminish. 
Chapter 1 introduces this thesis, and explains why it is so hard to design drugs. It also 
discusses how computers could help in the drug design process, as well as the 
advantages of effective collaboration between human drug designers and computers. 
Chapter 1 also explains some of the terms that are used throughout this thesis, such as 
data mining and docking, and it closes with an overview of the rest of the chapters. 
 Chapter 2 discusses one of the core methods used in our investigations: 
evolutionary algorithms. It describes the basic theory of evolutionary algorithms, and 
gives an overview of the different uses of evolutionary algorithms in drug design, 
varying from library design to QSAR and docking. It then compares these applications 
of evolutionary algorithms, and concludes with suggestions for future applications and 
further research. 
 The other main computational method we used, data mining, is discussed in 
Chapter 3. In data mining, one attempts to find patterns or rules in databases. In this 
chapter, we investigated a database of molecules, the NCI database, which, at the time 
of our investigation, contained 250,251 molecules. We were especially interested in 
how diverse this database was, since having a collection of diverse molecular structures 
leads to a greater chance of finding potential new drug molecules. We split all 
molecules in the NCI database into ring fragments and non-ring fragments, and 
determined the frequency of these fragments, as well as the frequency with which 
fragments occurred together in molecules. The molecules in the NCI database turned 
out to be remarkably undiverse: while there were over 10,000 different ring structures, 
the ten most frequent ring systems (<0,1% of the total ring diversity) accounted for 
62% of all the ring systems found in the molecules. On the other hand, thousands of 
ring systems occurred in only one or two molecules. We also found that many 
substructures occurred much more often with each other than would be expected by 
chance, forming 'superfragments', and, conversely, that there were also substructures 
which seemed to avoid each other. The data mining thus yielded lists of rare fragments 
and fragment combinations, which could be used to design new molecules. Such new 
molecules, when added to existing libraries, would increase its molecular diversity and 
thereby increase the chance of finding new drugs. 
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In Chapter 4 we return to evolutionary algorithms, in particular to the challenge of 
designing new drug molecules. When we started our study, there had been many 
investigations using evolutionary algorithms to design candidate drug molecules. 
However, all these approaches suffered from the problem that it is not yet possible to 
calculate a suitable fitness function, namely how good a certain molecule would be as a 
drug. This lack of quality fitness functions made optimization unreliable at best and 
meaningless at worst. Therefore, we decided to use a different approach, that of an 
interactive evolutionary algorithm. Interactive evolutionary algorithms use feedback 
from the user as fitness criterion; so in our case, chemists had to select the molecules 
they liked (which means, the molecules that seemed novel, drug-like and possible to 
synthesize without too many problems). In this way we could use the chemists' 
experience and chemical intuition, which would have been very difficult to 'extract' 
from their brains and program a computer with. We called the resulting interactive 
evolutionary algorithm the 'Molecule Evoluator'. Chapter 4 describes the design of the 
Molecule Evoluator, as well as the coding of the molecules, the different mutations, 
and the extra features that were needed to make the program usable for chemists and 
allow optimal use of their creativity. 
 One of the problems in the first versions of the Molecule Evoluator was that it 
created many molecules which either were unstable or would be difficult to synthesize. 
This annoyed chemists, leading them to abandon the optimization process prematurely. 
To increase the chance that molecules created by the Molecule Evoluator would be 
chemically sensible, we applied the technique discussed in Chapter 3, data mining. We 
mined the World Drug Index, a database that, at the time of our investigation, 
contained the structures of 32,000 drug molecules. In this collection of drug molecules, 
we determined the relative frequencies of small substructures containing one to four 
atoms, and used these data to adapt some of the Molecule Evoluator's mutations. We 
found that this indeed increased the chance that the Molecule Evoluator produced 
realistic molecules, while at the same time not forbidding substructures which actually 
occur in drugs. The exact procedures of the data mining, the adaptation of the mutation 
functions and the methods used to test whether the new mutations improved over the 
old ones are described in Chapter 5. 
 Our literature study for Chapter 2 encountered many evolutionary algorithms for 
designing drug molecules. However, it was difficult to compare the quality and 
effectiveness of these methods because they had not been compared to each other. This 
is unfortunate, since proper validation of molecules, either experimentally or by 
advanced computational methods, costs significant amounts of time and money. 
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Therefore it is important to make one's evolutionary algorithm as efficient as possible: 
an evolutionary algorithm which needs to evaluate only 1000 molecules to reach a 
certain improvement in biological activity would be much preferable over an 
evolutionary algorithm that needs 100,000 to reach a similar result. But what kind of 
evolutionary algorithm would be most efficient? Chapter 6 describes our investigation 
into the importance of one of the main factors in evolutionary algorithms for molecule 
design, namely whether evolution is atom-based (molecules are changed by adding, 
changing or removing single atoms), or fragment-based (where mutations add, change 
or remove multi-atom fragments). We evaluated the molecules by docking them into 
the reverse transcriptase enzyme of HIV. Docking was chosen as a fitness function here 
since it approximated the binding of molecules to a real protein with its irregular, three-
dimensional cavity. While the experiment did not show clear superiority of either 
atom-based evolution or fragment-based evolution, a closer study of the optimization 
processes yielded several insights on how we could improve our evolutionary 
algorithms. The details of the experiment, as well as the suggestions for future 
improvement of evolutionary algorithms for drug design, can be found in Chapter 6. 
 In theory, the Molecule Evoluator we described in Chapter 4 should be able to 
help chemists design new, biologically active molecules. However, does this also 
happen in practice? Chapter 7 describes an experiment in which we let the Molecule 
Evoluator generate 300 structures, of which chemists chose 34 for further investigation. 
By consulting chemical databases, we determined which of those molecules were novel. 
Subsequently, the chemists chose a number of the novel molecules and synthesized 
eight of them. These eight compounds were tested on 83 proteins, and four turned out 
to be biologically active in some way, amongst others on the α-adrenergic receptor. 
This result indicated that the collaboration between chemist and computer using the 
Molecule Evoluator can indeed create novel and biologically active compounds, which 
may be good leads for new drugs. Chapter 7 gives the detailed experimental protocol, 
the structures of the molecules synthesized, and the biological test results. 
 This thesis concludes with Chapter 8. The first part of this chapter contains the 
general conclusions of the investigations described in this thesis. The second part of 
Chapter 8 is dedicated to future perspectives: thoughts on the further development of 
the Molecule Evoluator and on the future role of evolutionary algorithms in drug 
design. It concludes with my vision on the directions that software for drug design 











Het ontwerpen van geneesmiddelen is moeilijk. Voor vele ziektes (zoals multiple 
sclerose) bestaan er nog geen geneesmiddelen, zijn de huidige geneesmiddelen 
onvoldoende om alle gevallen te genezen (kanker), of hebben bestaande 
geneesmiddelen bijwerkingen die we zouden willen verminderen (bijvoorbeeld bij de 
behandeling van HIV). Hoofdstuk 1 leidt dit proefschrift in en bespreekt waarom het 
moeilijk is geneesmiddelen te ontwerpen, hoe computers ons zouden kunnen helpen bij 
het ontwerp van geneesmiddelen, en het belang van goede samenwerking tussen 
computer en geneesmiddelonderzoeker. Ook bespreekt hoofstuk 1 enkele kern-
begrippen die in de rest van dit proefschrift terugkomen, zoals datamining en docking. 
Tenslotte bevat het een overzicht van de andere hoofdstukken. 
 De computermethode die we het meest gebruikt hebben, die van de evolutionaire 
algoritmen, wordt besproken in hoofdstuk 2. Hoofdstuk 2 geeft naast een inleiding van 
de theorie achter evolutionaire algoritmen een overzicht van de verschillende 
toepassingen van evolutionaire algoritmen in geneesmiddelontwerp. Deze toepassingen 
zijn onder te verdelen in het voorspellen van de eigenschappen van moleculen (zoals 
het afleiden van relaties tussen de structuur van een molecuul en zijn activiteit) en het 
ontwerpen van geheel nieuwe moleculen. De verschillende toepassingen die in de 
literatuur bekend zijn worden besproken en met elkaar vergeleken, alvorens mogelijke 
ontwikkelingen worden geschetst en suggesties worden gegeven voor verder onderzoek 
en mogelijke toekomstige toepassingen. 
 Hoofdstuk 3 beschrijft het onderzoek dat ik gedaan heb met een tweede 
computermethode, datamining ('data delven'). Bij datamining probeert men met behulp 
van een computer patronen te ontdekken in een grote database. Hoofdstuk 3 beschrijft 
het vinden en analyseren van patronen in de NCI database, een database van chemische 
verbindingen die ten tijde van ons onderzoek iets meer dan 250,000 moleculen bevatte. 
Van deze database wilden we de diversiteit bestuderen, omdat hoe diverser een set 
moleculen is, hoe groter de kans is dat het uittesten ervan een goed kandidaat-
geneesmiddel oplevert. We splitsten alle moleculen op in ringen en niet-ring-structuren, 
en ontdekten dat de database enigszins 'saai' was. Hoewel er duizenden verschillende 
ringstructuren en niet-ringstructuren in voorkwamen, vormden de tien meest 
voorkomende ringstructuren, die nog geen 0,1% van de totale ringdiversiteit 
vertegenwoordigden, 62% van alle ringen, terwijl er duizenden ringstructuren waren 
die maar in één of twee moleculen werden gebruikt. Ook bleek dat bepaalde structuren 
veel vaker dan statistisch verwacht samen voorkwamen en 'superfragmenten' vormden. 
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Aan de andere kant leken andere structuren elkaar te 'vermijden'. Dit dataminen leverde 
lijsten op met zeldzame fragmenten en ongebruikelijke fragmentcombinaties, die door 
chemici gebruikt zouden kunnen worden om nieuwe moleculen te ontwerpen. Zulke 
nieuwe moleculen, toegevoegd aan de bestaande molecuulbibliotheken, zouden de kans 
op het vinden van nieuwe geneesmiddelen een stuk groter kunnen maken. 
 In hoofdstuk 4 kom ik terug op de andere methode die we gebruikt hebben: 
evolutionaire algoritmen. Hoewel er al vele evolutionaire algoritmen bestonden om 
nieuwe moleculen te ontwerpen (hoofdstuk 2 geeft daarvan een overzicht), hadden al 
die methoden het probleem dat wetenschappers (nog) niet goed kunnen berekenen hoe 
'goed' een molecuul zou zijn als mogelijk geneesmiddel. Daarom besloten we de 
kwaliteit van de moleculen op een andere manier te bepalen, namelijk met een 
interactief evolutionair algoritme. Dat betekent dat de gemaakte moleculen niet door de 
computer worden beoordeeld, maar door chemici. Zo konden we de ervaring en 
chemische intuïtie van de chemici gebruiken, die anders moeilijk te achterhalen zijn. 
Het resulterende programma noemden we de “Molecule Evoluator”. Hoofdstuk 4 
bespreekt de details van hoe we de moleculen codeerden, de mutaties waarmee de 
moleculen veranderd werden, en de aanpassingen die we moesten doen om het 
interactieve evolutionaire algoritme bruikbaar te maken voor chemici, en de chemici in 
staat te stellen hun creativiteit optimaal te gebruiken.  
 Een van de problemen in de beginfase van de Molecule Evoluator was dat het 
programma nog te vaak moleculen produceerde die moeilijk te synthetiseren waren, of 
zo instabiel waren dat ze uit elkaar zouden vallen. Om dat op te lossen hebben we de 
hoofdmethode uit hoofdstuk 3, datamining, toegepast. We gebruikten allereerst 
datamining om te achterhalen hoe vaak bepaalde groepen van 1, 2, 3 en 4 atomen 
voorkwamen in de World Drug Index (een geneesmiddelendatabase die ten tijde van 
ons dataminen ongeveer 32000 verbindingen bevatte), en gebruikten die gegevens om 
de mutaties zó aan te passen dat bepaalde zeldzame substructuren (zoals O-F) veel 
minder vaak gemaakt werden. We testten de methode vervolgens uit op de fragmenten 
die we in de NCI hadden gevonden (hoofdstuk 3), en het bleek dat de door datamining 
aangepaste mutaties inderdaad vaker een ander bestaand fragment produceerden dan de 
oorspronkelijke mutaties. Hoofdstuk 5 geeft de gedetailleerde informatie over het 
dataminen, beschrijft hoe de mutaties precies werden aangepast, en bespreekt de 
precieze resultaten. 
 Een van de lacunes die naar voren kwam uit het literatuuronderzoek voor 
hoofdstuk 2 was dat evolutionaire algoritmen in geneesmiddelontwerp doorgaans niet 
met elkaar vergeleken werden. Zeker in ons veld, het ontwerp van nieuwe 
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geneesmiddelmoleculen, zijn er vele methodes, maar het was niet duidelijk welke 
methode de beste is, ofwel welke methode het effectiefst geneesmiddelmoleculen kan 
optimaliseren. Maar dat is wel een belangrijke vraag, omdat een goede evaluatie van 
een kandidaat-geneesmiddel veel tijd en geld kost, of dat nou gebeurt met een 
geavanceerd computermodel of met experimenten. Een evolutionair algoritme dat maar 
1000 moleculen hoeft te produceren voor een bepaalde verbetering, is daardoor veel 
nuttiger/economischer dan een algoritme dat voor dezelfde prestatie 10,000 moleculen 
nodig heeft. In hoofdstuk 6 onderzoeken we één van de belangrijkste kwesties bij 
evolutionaire algoritmen voor geneesmiddelontwerp: is evolutie die gedaan wordt met 
kleine stapjes (atoom voor atoom veranderen) effectiever dan evolutie die grote 
sprongen maakt (dus hele stukken molecuul ineens verplaatst of verandert)? De 
kwaliteit van elk molecuul evalueerden we met een docking-programma, dat het 
molecuul in het HIV-enzym reverse transcriptase paste en de interactie-energie 
berekende, om een benadering te krijgen van hoe de evolutie zich zou gedragen als we 
de moleculen echt zouden synthetiseren en testen. Atoom-gebaseerde en fragment-
gebaseerde evolutie leken het ongeveer even goed te doen, wel leerden we een aantal 
lessen waarmee we onze oorspronkelijke algoritmen kunnen verbeteren. Het verloop 
van het experiment staat samen met onze discussie en aanbevelingen in hoofdstuk 6. 
 Het door ons ontwikkelde evolutionaire algoritme zou samen met de resultaten 
van het dataminen in staat moeten zijn chemici te helpen bij het ontwerpen van nieuwe 
moleculen. Maar werkt het ook in de praktijk? Om dat uit te testen lieten we de 
Molecule Evoluator 300 moleculen genereren, die door chemici werden beoordeeld en 
aangepast. Uit dit proces kwamen 34 'interessante' moleculen, die we opzochten in de 
databases van Beilstein en de ACS om te kijken of deze moleculen of varianten erop al 
gemaakt waren. Van de moleculen die zowel nieuw waren als er 'geneesmiddelachtig' 
uitzagen, kozen de chemici een aantal uit om te synthetiseren. Uiteindelijk leverde dit 
acht kleine, geheel nieuwe moleculen op. Deze werden op 83 eiwitten uitgetest. Vier 
verbindingen bleken biologisch actief te zijn, onder andere op de α-adrenerge 
receptoren. Hoofdstuk 7 bespreekt dit experiment, inclusief de structuren en de 
syntheses. Het vinden van nieuwe, biologisch actieve verbindingen toonde aan dat onze 
methodes nuttig kunnen zijn voor het ontwerpen van nieuwe kandidaat-
geneesmiddelen: de Molecule Evoluator kan samen met de expertise van chemici 
geheel nieuwe en toch werkzame stoffen ontwerpen. 
 Dit proefschrift sluit af met hoofdstuk 8. Het eerste deel hiervan beschrijft de 
conclusies die ik uit het in dit proefschrift beschreven onderzoek getrokken heb. Het 
tweede deel van hoofdstuk 8 bevat mijn gedachten over de verdere uitbreidingen en 
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toepassingen voor de Molecule Evoluator en evolutionaire algoritmen in 
geneesmiddelontwerp, en een aantal mogelijkheden voor toekomstige software voor 
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